An investigation into the therapeutic utility of transcranial direct current stimulation in bulimia nervosa by Kekic, Maria
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 













Download date: 06. Nov. 2017
1 
 
An investigation into the therapeutic utility 





















Thesis submitted to King’s College London for the degree of  





Background: Recent neurobiological insights gained from functional neuroimaging 
studies suggest that bulimia nervosa (BN) is underpinned by dysregulated frontostriatal 
circuitry, which supports self-regulatory control and food reward processing capacities. 
Brain-directed interventions may therefore hold promise as treatments for the disorder. 
The overarching aim of this research was to investigate the therapeutic utility of 
transcranial direct current stimulation (tDCS; a form of non-invasive brain stimulation) 
in patients with BN.  
Methods: Four studies were conducted: (1) a systematic review of the clinical efficacy 
of tDCS across all psychiatric disorders; (2) a randomised controlled trial (RCT) of 
single-session tDCS applied to the dorsolateral prefrontal cortex (DLPFC) in healthy 
individuals with frequent food cravings; (3) a cross-sectional study of temporal 
discounting (a marker of poor self-regulatory control) in patients with BN and healthy 
controls; and (4) an RCT of single-session tDCS applied to the DLPFC in BN.  
Results: The main findings were as follows: (1) existing data indicate that tDCS 
interventions comprising multiple sessions can ameliorate symptoms of several major 
psychiatric disorders, both acutely and in the long-term; (2) a single session of sham-
controlled DLPFC tDCS transiently suppressed craving for sweet foods (i.e., altered 
food reward processing) among individuals with frequent food cravings; (3) patients 
with BN showed greater temporal discounting (i.e., poorer self-regulatory control) 
relative to healthy participants; and (4) a single session of sham-controlled DLPFC 
tDCS temporarily reduced symptoms, improved mood, and lowered temporal 
discounting (i.e., increased self-regulatory control) in individuals with BN.  
Conclusions: Taken together, the results provide preliminary support for the therapeutic 
utility of tDCS over the DLPFC in BN, and offer justification for multi-session trials in 
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LIST OF IMPORTANT ABBREVIATIONS1 
AN  anorexia nervosa 
AL/CR  anode left/cathode right 
AR/CL  anode right/cathode left 
BED   binge-eating disorder 
BMI   body mass index 
BN   bulimia nervosa 
DASS  Depression Anxiety and Stress Scales 
DF  discount factor 
DGI  Delaying Gratification Inventory 
DLPFC  dorsolateral prefrontal cortex 
DSM   Diagnostic and Statistical Manual of Mental Disorders 
ED  eating disorder 
EDDS  Eating Disorder Diagnostic Scale 
EDE-Q  Eating Disorder Examination-Questionnaire 
FCT  Food Challenge Task 
FCQ-(T/S)  Food Craving Questionnaire-(Trait/State) 
(f)MRI  (functional) magnetic resonance imaging 
HC  healthy control 
ICD International Statistical Classification of Diseases and Related 
Health Problems 
KCL  King’s College London 
LL  larger-later 
                                                 
1 As this is a thesis incorporating publications, and the body text of each publication has been left largely 
unchanged, acronyms are re-introduced in each chapter and some are chapter-specific.  
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M  mean 
MDD  major depressive disorder 
MEDCQ-R  Mize’s Eating Disorder Cognitions Questionnaire-Revised 
NHS  National Health Service (UK) 
NIBS   non-invasive brain stimulation 
NICE   National Institute for Health and Care Excellence (UK) 
NIMH   National Institute of Mental Health (US) 
PANAS  Positive and Negative Affect Schedule 
POMS   Profile of Mood States 
RCT  randomised controlled trial 
(r)TMS  (repetitive) transcranial magnetic stimulation 
SCID Structured Clinical Interview for Diagnostic and Statistical 
Manual Disorders 
SD  standard deviation 
SE  standard error 
SS  smaller-sooner 
SUD  substance use disorder 
TD   temporal discounting 
tDCS   transcranial direct current stimulation 
VAS  visual analogue scale  
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Advancing the understanding and treatment of eating disorders (EDs), including bulimia 
nervosa (BN), is an issue of immense public health importance and is recognised as an 
area of high priority by the US National Institute of Mental Health (NIMH) (Chavez & 
Insel, 2007). In recent years these psychiatric disorders, which were long thought to 
stem from purely psychological processes, have gained increasing recognition as 
physiological disorders of the brain (Chavez & Insel, 2007; Insel, 2010; Schmidt & 
Campbell, 2013; van Elburg & Treasure, 2013). One implication of this recognition is 
that the treatment of BN and other EDs can be approached with methods of modern 
neuroscience (Chavez & Insel, 2007). Indeed, the NIMH’s Research Domain Criteria 
project endorses the harnessing of neuroscience tools, such as neuromodulation, in the 
service of more effective therapeutic strategies (Cuthbert, 2014).  
 
This introductory chapter first describes the history, diagnostic criteria, epidemiology, 
course and outcome, pathogenesis, and treatment of BN. Following this, the 
neurobiology of the disorder is examined, including a brain-based developmental model 
of illness. Lastly, an overview of transcranial direct current stimulation (tDCS) – a 
neuromodulatory technique with potential clinical applications in neuropsychiatry – is 
presented.  
 
1.1 BULIMIA NERVOSA: AN OVERVIEW 
The Oxford English Dictionary defines BN as “an [ED] characterised by regular, 
usually secretive bouts of binge-eating followed by self-induced vomiting, purging, 
strict dieting, or extreme exercise, in association with persistent over-concern with body 





Scattered historical references to ancient practices of binge-eating and purging suggest 
that BN has existed since the Middle Ages; however, the ED was first named and 
described clinically as an “ominous variant of anorexia nervosa” (AN)2 in 1979 by the 
British professor and psychiatrist, Gerald Russell3 (Russell, 1979). Russell (1979) 
reported on a series of 30 patients whose illness resembled AN, but who did not 
necessarily reduce their food intake: these individuals were said to engage in frequent 
episodes of overeating, immediately followed by habitual self-induced vomiting and/or 
purging in an attempt to counteract the increased calorie intake. Based on prospective 
observations of this patient group over a six-and-a-half-year period, Russell (1979) 
specified a set of clear diagnostic criteria to enable other clinicians and researchers to 
identify the proposed condition:  
 (1) the patients suffer from powerful and intractable urges to overeat; 
(2) they seek to avoid the 'fattening' effects of food by inducing vomiting or 
abusing purgatives or both; 
(3) they have a morbid fear of becoming fat. 
 
One year after Russell’s clinical description of BN was published, the disorder was 
formally recognised by the international scientific world for the first time. Initially, 
‘bulimia’ was defined in the Diagnostic and Statistical Manual of Mental Disorders, 
Third Edition (DSM-III) (American Psychiatric Association, 1980) as a disorder that 
required the presence of binge-eating and little else (Palmer, 2004); however, this was 
                                                 
2 AN is an ED characterised by extremely low bodyweight and an irrational fear of weight gain (see 
section 1.1.2.2). 
3 The term ‘bulimia nervosa’ was suggested by Dr Patrick Campbell. 
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later replaced by BN in the DSM-III, Revised (American Psychiatric Association, 1987), 
with diagnostic criteria more closely resembling those proposed by Russell. In 1992, a 
similar entry was included in the first volume of the International Statistical 
Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) (World 
Health Organisation, 1992).  
 
1.1.2 Current diagnostic criteria 
Although there is an ongoing debate concerning the validity and usefulness of diagnosis 
in psychiatry (see section 6.6.6; Timimi, 2013), most clinicians and researchers regard 
categorical classification as having some value (Tyrer, 2014). This is because it 
facilitates effective communication of information relating to the clinical characteristics, 
pathogenesis, prognosis, and indicated treatment options associated with a disorder 
(Casey et al., 2013; Mellsop, Menkes, & El-Badri, 2007; Tyrer, 2014). At present, there 
are two widely established systems for classifying mental disorders, including BN: the 
‘Mental and Behavioural Disorders’ chapter of the ICD (currently in its 10th revision 
with a 2016 electronic update; World Health Organisation, 2016) and the DSM 
(currently in its 5th edition; American Psychiatric Association, 2013). While there is 
substantial convergence between the two classification systems, the DSM is generally 
considered more ‘accurate’ than the ICD, partly due to its use of operational criteria 
(Tyrer, 2014), and therefore tends to be the favoured diagnostic tool in research settings 
(Mezzich, 2002). Current diagnostic criteria for BN as well as for the other EDs are 
provided below. 
 
1.1.2.1 Bulimia nervosa 
The ICD-10 (World Health Organisation, 2016) classifies BN as an ED “characterised 
by repeated bouts of overeating and an excessive preoccupation with the control of body 
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weight, leading to a pattern of overeating followed by vomiting or use of purgatives”. 
The disorder is also acknowledged as sharing “many psychological features with AN, 
including an over-concern with body shape and weight”. Disorders that fulfil some but 
not all of the features of BN may be categorised as atypical BN.  
 
BN is listed in the ‘Feeding and Eating Disorders’ chapter of the DSM, Fifth Edition 
(DSM-5) (American Psychiatric Association, 2013). According to the manual, there are 
three essential features of the condition: 
(1) recurrent episodes of binge-eating (eating, in a discrete period of time, an 
amount of food that is larger than most individuals would eat in a similar period 
of time under similar circumstances, accompanied by a sense of lack of control); 
(2) recurrent inappropriate compensatory behaviours to prevent weight gain 
(e.g., self-induced vomiting, misuse of laxatives/diuretics, fasting, or excessive 
exercise); 
 (3) self-evaluation that is unduly influenced by body shape and weight. 
To qualify for the diagnosis, the binge-eating and inappropriate compensatory 
behaviours must both occur, on average, at least once a week for three months. 
Individuals who meet the criteria for BN but whose symptoms are of low frequency 
and/or limited duration may be diagnosed with a form of ‘other specified feeding or 
eating disorder’ (OSFED). It should be noted that the symptom frequency requirement 
for BN was reduced in the DSM-5 from a more stringent twice weekly in the DSM, 
Fourth Edition (DSM-IV; American Psychiatric Association, 2000) in an attempt to 
reduce the number of patients falling into this residual category (known previously as 
‘eating disorder not otherwise specified’ [EDNOS]). Individuals with BN are typically 
within the normal weight or overweight range (body mass index [BMI] ≥ 18.5 and < 30 




1.1.2.2 Other eating disorders 
Along with BN, a number of additional EDs are defined in the ICD-10 (World Health 
Organisation, 2016) and DSM-5 (American Psychiatric Association, 2013). Whilst a 
discussion of all of these is beyond the scope of this thesis, it is important to consider 
BN in the context of the other major EDs: AN and binge-eating disorder (BED). For 
brevity, and because BED is not currently included in the ICD-10 (World Health 
Organisation, 2016), only DSM-5 (American Psychiatric Association, 2013) diagnostic 
criteria are presented here. 
 
An individual will receive a DSM-5 (American Psychiatric Association, 2013) diagnosis 
of AN if they:  
(1) restrict their energy intake relative to requirements, leading to a significantly 
low body weight that is less than minimally normal or expected (BMI < 18.5 
in adults); 
(2) have an intense fear of gaining weight/becoming fat, or engage in persistent 
behaviour that interferes with weight gain;  
(3) display disturbances in the way their body weight/shape are experienced, 
assign undue influence of body weight/shape on their self-evaluation, or 
have a persistent lack of recognition of the seriousness of their current low 
body weight. 
Two subtypes of the disorder are described in the manual: restricting type, in which the 
patient does not engage in recurrent episodes of binge-eating or purging behaviour, and 




BED was officially recognised as a distinct ED diagnosis for the first time in the DSM-5 
(American Psychiatric Association, 2013). The essential feature of this condition is 
recurrent episodes of binge-eating (defined in section 1.1.2.1) that must occur, on 
average, at least once per week for three months. In contrast to that in BN, binge-eating 
in BED is not accompanied by extreme efforts to counteract it and, as such, individuals 
with the disorder are often overweight or obese (BMI ≥ 25 in adults).  
 
1.1.3 Epidemiology 
Epidemiology is the study of how often illnesses occur in different groups of people. 
Information gained from epidemiological studies is used to guide the development of 
intervention and prevention strategies; however, such investigations present multiple 
challenges in the field of EDs. For example, population base rates are low, which 
necessitates large samples in order to detect cases (Mitchison & Mond, 2015), and this 
problem is compounded by the tendency for individuals with EDs (males, in particular) 
to conceal their condition and avoid professional help (Hoek & van Hoeken, 2003). A 
further difficulty relates to the extensive use of DSM-IV classification criteria, which 
has resulted in an over-representation of the EDNOS diagnostic category (Mitchison & 
Mond, 2015) and an under-representation of people with BN (see section 1.1.2.1). 
Nevertheless, available data on the epidemiology of BN are summarised below.  
 
1.1.3.1 Incidence 
Incidence rate refers to the number of new cases of a disorder in a defined population 
over a specified period of time (usually one year). Limited incidence studies of BN have 
been conducted; however, in a review of those that have, Smink, van Hoeken, and Hoek 
(2012) reported overall primary-care incidence rates (per 100,000 persons per year) 
ranging from 6.1 in the Netherlands from 1995-1999 to 12.2 in the UK in 1993. In 
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community studies considering the group at highest risk (i.e., young females), and 
diagnoses in accordance with DSM-5 criteria, rates of up to 300 per 100,000 persons per 
year have been documented (Smink, van Hoeken, & Hoek, 2013). By contrast, 
incidence rates for males have been calculated at just 0.7-0.8 per 100,000 persons per 
year (Currin, Schmidt, Treasure, & Jick, 2005; Hoek & van Hoeken, 2003).  
 
Data concerning time trends in the incidence of BN are somewhat inconsistent; for 
example, a Danish nationwide psychiatric registry study found that rates increased from 
6.3 to 7.2 per 100,000 persons per year between 1995 and 2010 (Steinhausen & Jensen, 
2015), whilst the overall incidence rate of BN in Dutch primary-care has reportedly 
decreased significantly over the past three decades (Smink et al., 2016). In the UK, a 
threefold increase in the primary-care incidence of BN in 10-39-year-old women was 
observed between 1988 and 1993 (Turnbull, Ward, Treasure, Jick, & Derby, 1996), 
followed by a decrease between 1996 and 2000 (Currin et al., 2005), and a period of 
stability among males and females aged 10-49 during the first decade of the 2000s 
(Micali, Hagberg, Petersen, & Treasure, 2013).  
 
1.1.3.2 Prevalence 
Prevalence refers to the proportion of a population that has a disorder at a specific point 
or interval in time: at a certain date (point prevalence), in a certain year (one-year 
prevalence), or at any point in a life (lifetime prevalence). Prior to the reduction of the 
required minimum frequency of binge-eating and inappropriate compensatory 
behaviours in the DSM-5, the generally accepted prevalence rate for BN was 
approximately 1% among young females in Western countries (Hoek & van Hoeken, 
2003; Smink et al., 2012). Lifetime prevalence estimates for this group have since been 
calculated at 2.6% for full-syndrome BN and 4.4% for subthreshold BN (Stice, Marti, & 
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Rohde, 2013). Hudson, Hiripi, Pope, and Kessler (2007) reported a lifetime prevalence 
of 0.5% for DSM-IV BN among males in the US; however, comparable data in 
accordance with DSM-5 diagnostic criteria are currently unavailable.  
 
Studies investigating time trends have shown that the point prevalence of BN among 
university students in the US decreased from 4.2% in 1982 to 1.3% in 1992, but 
remained relatively stable from the 1990s to the early 2000s (Crowther, Armey, Luce, 
Dalton, & Leahey, 2008; Keel, Heatherton, Dorer, Joiner, & Zalta, 2006).  
 
1.1.3.3 Gender ratio 
Women are more affected by BN than men. Estimates of the female-male ratio are 
highly variable, ranging from 3:1 (Woodside et al., 2001) to 15:1 (Micali et al., 2013) 
and 20:1 (Steinhausen & Jensen, 2015).  
 
1.1.4 Course and outcome 
Course refers to the temporal pattern of an illness from onset to subsequent recovery, 
partial recovery, non-recovery, or death, while outcome describes the state of affected 
individuals at some specified time after the development of a disorder (Sullivan, 2005). 
ED course and outcome data can be used to inform patients and their families about 
prognosis, to help clinicians plan and balance their caseloads, and to aid our 
understanding of the classification of these conditions (Keel & Brown, 2010). However, 
as with epidemiological studies in EDs, those investigating course and outcome are 
associated with a number of complexities. For example, the field lacks unified 
definitions of stage of illness, remission, recovery, and relapse, and the resultant lack of 
consistency makes comparisons across studies very difficult (Berkman, Lohr, & Bulik, 
2007). A problem also exists in the heterogeneity of the diagnostic criteria used to 
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identify BN samples (Quadflieg & Fichter, 2003), which is primarily due to the major 
developments that have occurred in various editions of the DSM (see section 1.1.2.1). 
The following data should therefore be considered in this context.  
 
1.1.4.1 Age at onset 
BN usually begins in late adolescence or early adulthood. A recent study of 427 
outpatients with BN in Italy found that the group had a mean age at onset of 18.2 years 
(Volpe et al., 2016). This is consistent with previous research indicating that the median 
age at onset in a nationally representative US sample was 18.0 years (Hudson et al., 
2007), and that the peak age of incidence of BN among Finnish women was 16-20 years 
(Keski-Rahkonen et al., 2009). There is evidence to suggest that the age at onset of BN 
has decreased over the past three decades (Favaro, Caregaro, Tenconi, Bosello, & 
Santonastaso, 2009; van Son, van Hoeken, Bartelds, van Furth, & Hoek, 2006), 
although this may simply be a consequence of increased awareness of BN and thus 
earlier detection and diagnosis.  
 
1.1.4.2 Remission, recovery and relapse 
Keel and Brown (2010) reviewed studies describing ED course and outcome and found 
that remission rates in patients with BN increased with longer duration of follow-up – 
from 27% at 1-year follow-up (Bailer et al., 2004a) to 75% at 20-year follow-up (Keel, 
Gravener, Joiner, & Haedt, 2010), though most individuals achieved remission by 5 
years following intake. In their review of 79 studies covering data from 5,653 
individuals suffering from BN, Steinhausen and Weber (2009) found that, on average, 
45% of the patients showed a full recovery, 27% improved considerably, and 23% had a 




Estimates of relapse for BN vary considerably (from 17 to 63%) depending on the 
definition of relapse and the length of follow-up, with the first six months following 
remission constituting a peak period for the return of binge/purge symptoms (Olmsted, 
MacDonald, McFarlane, Trottier, & Colton, 2015; Quadflieg & Fichter, 2003). Many 
individuals who recover from BN have residual features of the disorder such as over 
concern about shape and weight, a tendency to restrict dietary intake, and low self-
esteem (Sullivan, 2005). This enduring psychopathology is one of the most commonly 
identified predictors of relapse in BN (Fairburn, Peveler, Jones, Hope, & Doll, 1993; 
Halmi, Agras, Mitchell, & et al., 2002; Keel, Dorer, Franko, Jackson, & Herzog, 2005).  
 
1.1.4.3 Psychiatric comorbidity 
Psychiatric comorbidity is the rule rather than the exception for patients with BN 
(Treasure, Claudino, & Zucker, 2010). The results of a large-scale nationally 
representative interview survey in the US showed that 88.0% of adolescents with BN 
and 94.5% of adults with BN met the criteria for at least 1 comorbid mental disorder 
(Hudson et al., 2007; Swanson, Crow, Le Grange, Swendsen, & Merikangas, 2011). 
Furthermore, BN was significantly associated with almost all of the core DSM-IV mood, 
anxiety, impulse-control, and substance use disorders (Hudson et al., 2007; Swanson et 
al., 2011). In an earlier review of ED comorbidity research, O'Brien and Vincent (2003) 
identified major depression as the most commonly diagnosed comorbid disorder in 
individuals with BN, while rates of obsessive-compulsive disorder, substance abuse, 
and borderline personality disorder were also consistently elevated.  
 
1.1.4.4 Physiological morbidity 
BN is associated with a number of serious medical complications. Most notably, fluid 
and electrolyte disturbances occur in approximately 50% of patients as a result of 
31 
 
excessive vomiting and/or laxative and diuretic misuse, and these can be life-threatening 
(Crow & Eckert, 2016; Westmoreland, Krantz, & Mehler, 2016). In addition, people 
with BN often have intermittent amenorrhea, enlarged salivary glands, and dental 
problems relating to the erosion of tooth enamel (Crow & Eckert, 2016).  
 
1.1.4.5 Mortality 
Data show that individuals with BN have an increased risk of both all-cause and suicide 
mortality; for example, Crow et al. (2009) conducted a longitudinal assessment of 906 
individuals with BN and found that 3.9% of the sample had died after the 8-25-year 
follow-up period (23% of these deaths were attributable to suicide). A similar result was 
obtained by Franko et al. (2013), who reported that 2 of 60 (3.3%) participants with BN 
died during a median follow-up period of 20 years, although no suicides were recorded. 
A recent meta-analysis of mortality rates in BN found them to be modestly elevated: the 
crude mortality rate (which can be understood in the same way as the incidence rate, 
when the event being measured is death) was 1.74 per 1000 persons per year (Arcelus, 
Mitchell, Wales, & Nielsen, 2011).  
 
1.1.5 Pathogenesis 
BN is a complex and multifaceted disorder associated with numerous determinants of 
risk and susceptibility. Factors contributing to disease pathogenesis span three broad 
categories – biological, psychological, and sociocultural – and can also be considered as 
predisposing, precipitating, or perpetuating (Watkins, 2011). Several comprehensive 
reviews have examined the aetiology of BN in detail (Jacobi, Hayward, de Zwaan, 
Kraemer, & Agras, 2004; Polivy & Herman, 2002; Treasure et al., 2010; Waller & 




1.1.5.1 Biological factors 
Disordered eating behaviour and associated psychopathology are increasingly 
conceptualised as biological phenomena. This is predominantly due to a rapidly 
growing literature substantiating the neurobiological basis of EDs (see section 1.24) and 
to evidence revealing significant genetic influences5 on the liability to these conditions. 
Studies have consistently reported a raised rate of BN among the relatives of individuals 
who have an ED, suggesting both familial aggregation and a shared transmissible 
vulnerability to BN (Watkins, 2011); for example, a large controlled family study 
showed that first-degree female relatives of probands with AN or BN had a fourfold 
increased risk of developing BN compared with relatives of unaffected controls 
(Strober, Freeman, Lampert, Diamond, & Kaye, 2000). Twin studies have confirmed 
that BN is familial whilst distinguishing genetic from environmental contributions, 
though heritability estimates have varied drastically from 28-83% (Hinney & Volckmar, 
2013), and it is unclear from such research whether there is a unique genetic risk for the 
development of EDs or whether the genetic vulnerability is shared with other 
psychiatric illnesses (Watkins, 2011).  
 
In addition to family and twin methodologies, modern advances in quantitative and 
molecular genetics have been applied to the study of EDs. Several candidate gene 
studies have reported significant associations between BN and polymorphisms in the 
serotonergic (Ricca et al., 2002), appetite (Miyasaka et al., 2006), oestrogen (Nilsson et 
al., 2004), and cannabinoid (Monteleone et al., 2009) systems, and variants of the brain-
                                                 
4 Due to their relevance and centrality to this thesis, neurobiological factors relating to the pathogenesis of 
BN are dealt with in detail in a discrete section.  
5 Genetic influences are regarded as distinct to neurobiological mechanisms in this thesis.  
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derived neurotrophic factor (BDNF; Ribases et al., 2004) and alpha-ketoglutarate-
dependent dioxygenase (FTO; Muller et al., 2012) genes have also been implicated. 
Nevertheless, contradictory findings are abundant and adequately powered genome-
wide association studies must be conducted in order to fully elucidate the genetic 
architecture of BN (Trace, Baker, Peñas-Lledó, & Bulik, 2013).  
 
1.1.5.2 Psychological factors 
Numerous psychological factors have been postulated as specific contributors to the 
development of BN. These include low self-esteem, body dissatisfaction, and affective 
disturbances (Polivy & Herman, 2002; Stice, 2002), as well as certain personality traits 
such as perfectionism (Bulik et al., 2003), obsessive-compulsiveness, impulsivity 
(Newton, Freeman, & Munro, 1993), sensation-seeking (Rossier, Bolognini, Plancherel, 
& Halfon, 2000), and narcissism (Steiger, Jabalpurwala, Champagne, & Stotland, 
1997), all of which have been shown to predict increases in bulimic symptoms. In 
addition, various interpersonal experiences – such as childhood sexual abuse, trauma, 
and teasing – have been associated with the disorder (Hastings & Kern, 1994; Kanakis 
& Thelen, 1995; Rorty & Yager, 1996).  
 
Many psychological theories have been proposed over the years in an attempt to 
combine such putative causal factors into a comprehensive whole (Polivy & Herman, 
2002). Most influential in terms of treatment have been cognitive behavioural models 
(Fairburn & Harrison, 2003), which posit that BN develops and is perpetuated as a 
result of a vicious feedback cycle of interrelated cognitions and behaviours associated 
with a dysfunctional system for evaluating self-worth, extreme concerns about shape 
and weight, strict dieting, a perceived lack of self-control, binge-eating, and 
inappropriate compensatory behaviours (Fairburn, Marcus, & Wilson, 1993). Additional 
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maintaining mechanisms acknowledged in extensions of the original theories are 
clinical perfectionism, core low self-esteem, mood intolerance, and interpersonal 
difficulties (Fairburn, Cooper, & Shafran, 2003). 
 
1.1.5.3 Sociocultural factors 
EDs do not occur uniformly in all cultures at all times (Polivy & Herman, 2002). 
Sociocultural theorists argue that, in Westernised societies, greater exposure and 
pressure to obtain the ‘thin-ideal’, internalisation of this thin-ideal, and thinness 
expectancies increase the risk for BN and other EDs in females (Culbert, Racine, & 
Klump, 2015). Considerable evidence supports this claim; for example, perceived 
pressure to be thin has been shown to predict the onset of binge-eating (Stice, Presnell, 
& Spangler, 2002) and purging behaviours (Field, Camargo, Taylor, Berkey, & Colditz, 
1999), and a prospective naturalistic study of Fijian schoolgirls found that bulimic 
pathology emerged following prolonged exposure to Western television (Becker, 
Burwell, Herzog, Hamburg, & Gilman, 2002). Furthermore, Keel and Klump (2003) 
evaluated the presence of EDs in non-Western countries and concluded that BN is a 
culture-bound syndrome.  
 
Although the contribution of sociocultural factors to the pathogenesis of BN is clearly 
relevant, a number of studies have not corroborated the association between Western 
values regarding thinness and features of EDs (Byely, Archibald, Graber, & Brooks-
Gunn, 2000; Cooley & Toray, 2001). In addition, much of the evidence is based on 
correlational analyses, which cannot rule out the possibility that individuals most 
dissatisfied with their bodies or wishing to be thinner may seek out particular types of 
media exposure (Tiggemann & Pickering, 1996). It should also be noted that ED cases 
have been reported throughout medical history, and although the idealisation of thinness 
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in women undeniably increased dramatically during the 20th century, data concerning 
time trends in the incidence of BN are inconclusive (see section 1.1.3.1).  
 
1.1.5.4 Integrative theories 
Although aetiological factors for BN can be categorised into distinct levels of analysis, 
they are not expected to operate in isolation. A complex interplay amongst the various 
contributors is likely (Culbert et al., 2015), and an integrated biopsychosocial 
understanding of the pathogenesis of BN is therefore favourable (Watkins, 2011). 
Culbert et al. (2015) propose a tentative model to describe the way in which biological, 
psychological, and sociocultural factors might intersect to increase the risk for EDs. In 
brief, they suggest that genetic and environmental influences, as well as neural and 
behavioural plasticity, determine an individual’s susceptibility to the ubiquitous 
messages regarding the importance of being thin (Culbert et al., 2015). The model also 
advocates that personality traits are partially rooted in one’s genes and neural circuitry, 
and that environmental experiences and biological vulnerabilities interact with and 
influence the expression of genetic risk (Culbert et al., 2015). 
 
1.1.6 Treatment 
Because BN is typically associated with marked feelings of guilt and shame regarding 
eating patterns, there is often a delay of many years before individuals with the disorder 
seek help (Fairburn & Harrison, 2003). Although the frequency of bulimic behaviours 
generally increases over time, most patients can be successfully treated with outpatient 
care, and inpatient admissions are rarely indicated (Crow & Eckert, 2016). Current 
National Institute for Health and Care Excellence (NICE) guidelines recommend 
evidence-based guided self-help programmes, cognitive behavioural therapy (CBT), and 
antidepressant drugs as possible first steps for treating BN (NICE, 2004). More than 40 
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randomised controlled trials (RCTs) have been conducted to assess treatment efficacy of 
psychological therapies, medications (primarily antidepressants), and combination 
treatments for BN (Crow & Eckert, 2016), and an overview of their findings is 
presented below. Nevertheless, whilst substantial evidence guides first-line treatments 
for BN, almost nothing is known about what approaches to try in patients who have not 
responded to, or been reluctant to engage in, such therapies.  
 
1.1.6.1 Psychological interventions 
CBT for BN (CBT-BN) is based on cognitive behavioural models of the disorder (see 
section 1.1.5.2), and is considered the best established treatment for adult sufferers 
(Murphy, Straebler, Cooper, & Fairburn, 2010). RCTs consistently demonstrate good 
outcomes, low relapse rates, and superiority to other psychological interventions; for 
example, the results of two meta-analyses showed that remission rates were 
significantly higher in patients who received CBT-BN than in both controls and those 
who received other forms of psychotherapy (Hay, Bacaltchuk, Stefano, & Kashyap, 
2009). A new transdiagnostic ‘enhanced’ version of the therapy is also available, which 
appears better suited to patients with marked additional psychopathology of the type 
targeted by the treatment (Fairburn et al., 2009). Efficacious therapeutic alternatives to 
CBT include interpersonal therapy and Emotional Social Mind Training, which yield 
comparable responses of BN symptom change to individual and group CBT treatment, 
respectively (Fairburn et al., 1991; Lavender et al., 2012).  
 
In recent years, successful psychological interventions for BN have been translated into 
guided and unguided self-help programmes delivered as bibliotherapy, CD-ROMs, or 
via the internet (Beintner, Jacobi, & Schmidt, 2014). These treatment options are 
appealing due to their cost-effectiveness (Watkins, 2011), and represent a robust means 
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of improving implementation and scalability of evidence-based treatment for EDs 
(Beintner et al., 2014). Examples of self-help programmes designed for patients with 
BN are Getting Better Bite by Bite (manual-based; Schmidt, Treasure, & Alexander, 
2015), Overcoming Bulimia (CD-ROM-based; Schmidt et al., 2008), and Overcoming 
Bulimia Online (internet-based; McClay, Waters, McHale, Schmidt, & Williams, 2013). 
A systematic review of 50 different trials of self-help interventions for BN and BED 
concluded that such tools can contribute to bridging the treatment gap for these 
disorders, especially if they are guided by mental health specialists, and if the features 
of their delivery and indications are considered carefully (Beintner et al., 2014).  
 
1.1.6.2 Pharmacological interventions 
Selective serotonin reuptake inhibitors (specifically fluoxetine at doses of 60mg per 
day) are the drugs of first choice for the treatment of BN in terms of acceptability, 
tolerability and reduction of symptoms (NICE, 2004). Evidence from pharmacological 
trials is encouraging; for example, a large collaborative study of 398 outpatients with 
BN found that, compared with placebo, fluoxetine treatment resulted in greater 
reductions in vomiting and binge-eating episodes per week as well as an improvement 
in other outcome measures (Goldstein, Wilson, Thompson, Potvin, & Rampey, 1995). A 
systematic review of the literature concluded that, overall, fluoxetine administered for 
8-16 weeks led to a significant reduction in binge-eating in the majority of studies 
(Shapiro et al., 2007), and data suggest that it may be a useful intervention for patients 
with BN who have not responded adequately to psychotherapy (Walsh et al., 2000). 
Nevertheless, evidence for long-term effects after treatment with medication in BN is 
scarce, and acceptability of pharmacotherapy is low when drugs are given alone 
(Treasure et al., 2010). It should be noted that fluoxetine’s efficacy in treating BN is not 
considered a consequence of its antidepressant properties, but rather a result of the 
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medication’s effects on satiety (Tortorella, Fabrazzo, Monteleone, Steardo, & 
Monteleone, 2014; Westmoreland et al., 2016).  
 
1.1.6.3 Combined treatments 
A number of studies have evaluated the efficacy of combined psychological and 
pharmacological interventions for individuals with BN. In a systematic review of these 
experiments, Hay, Claudino, and Kaio (2001) concluded that combination treatments 
were statistically superior to single psychotherapy but not to single antidepressants, 
though it was noted that the number of trials included may have been insufficient to 
show statistical significance in the latter comparison. Indeed, results of an earlier 
systematic review and meta-analysis suggested that the efficacy of combined treatments 
was superior to both single approaches (Bacaltchuk et al., 2000). Despite the apparent 
advantages of augmenting psychological interventions with pharmacological ones, data 
consistently show that BN patient acceptability of psychotherapy is significantly 
reduced with the addition of drugs (Bacaltchuk et al., 2000; Hay et al., 2001).  
 
1.2 NEUROBIOLOGY OF BULIMIA NERVOSA 
As mentioned previously, there is growing acknowledgement that neurobiological 
vulnerabilities make a substantial contribution to the pathogenesis of BN (Kaye, 2008). 
Since the human brain is often described as “the most complex structure in the universe 
– too complex for the human brain to understand” (Lask & Frampton, 2011), 
deciphering the neural mechanisms that might underpin BN has not been an easy task. 
Nevertheless, we now have a basic understanding of the various brain malfunctions that 
commonly occur in individuals with the disorder. A broad summary of the key findings 




1.2.1 Regulation of normal feeding behaviour 
Knowledge of the regulation of normal feeding behaviour is crucial to an understanding 
of neurobiological dysfunction in BN and other EDs (for a detailed review see Blundell, 
Halford, King, & Finlayson, 2016). Food intake in healthy individuals is a complex 
process which can be broadly conceptualised as a ‘feeding cascade’ comprising three 
stages: (1) an appetitive phase associated with the desire to approach food that might be 
triggered by hunger, thirst, or a memory that a certain food tastes pleasant; (2) the 
motivation to approach food (‘wanting’); and (3) an experience of pleasantness 
following ingestion (‘liking’) (Frank & Jappe, 2011). Based on the degree of ‘liking’, 
memories are formed that associate particular foods and environmental cues with 
reward, and thus initiate subsequent feeding (Frank & Jappe, 2011). The termination of 
eating and the prevention of further consumption are governed by a series of episodic 
signals that can be represented as a ‘satiety cascade’ (Blundell et al., 2016).  
 
Various neurotransmitters and neuropeptides contribute to individual hunger and satiety 
experiences; for example, dopamine and endogenous opioids have been linked to the 
concepts of ‘wanting’ and ‘liking’, respectively (Kelley, Baldo, Pratt, & Will, 2005), 
whereas serotonin (Voigt & Fink, 2015) and acetylcholine (Avena & Rada, 2012) have 
been implicated in the suppression of feeding. Neuropeptide-Y and peptide YY are 
brain chemicals thought to stimulate eating behaviour, while cholecystokinin (a peptide 
hormone of the gastrointestinal system) and leptin (a hormone made by adipose tissue) 
appear to mediate satiety (Frank & Jappe, 2011). Brain regions involved in the 
regulation of feeding behaviour include the thalamus, the hypothalamus, and the 




In addition to numerous biological mechanisms, emotional states have been shown to 
influence the regulation of non-pathological appetitive behaviour (Frank & Jappe, 
2011). Indeed, Macht and Simons (2000) demonstrated that healthy females reported 
stronger motivations to eat during periods of negative emotions in everyday life, and the 
psychophysiological stress response has been found to predict increased calorie intake 
in a non-clinical sample (Epel, Lapidus, McEwen, & Brownell, 2001). Cognitive factors 
also seem to play a role; for instance, data from neurologically intact individuals 
suggest that representation in memory of information about a recent eating episode may 
be factored into decisions about how much to consume at the next meal (Higgs, 2005). 
 
1.2.2 Neuropeptides and neuroendocrinology 
Neuropeptides are small proteinaceous substances, produced and released by neurons, 
which act on neural substrates (Peter & Burbach, 2011). Their role in the regulation of 
feeding behaviour is well-documented, thus it is unsurprising that many neuropeptides 
appear to be altered in BN. Specifically, the disorder has been associated with elevated 
concentrations of neuropeptide-Y (Baranowska, Wolinska-Witort, Wasilewska-
Dziubinska, Roguski, & Chmielowska, 2001), ghrelin (Monteleone, Martiadis, 
Fabrazzo, Serritella, & Maj, 2003), and peptide-YY (during early recovery; Kaye, 
Berrettini, Gwirtsman, & George, 1990), and with reduced levels of cholecystokinin 
(Hannon-Engel, 2012) and leptin (Jimerson, Mantzoros, Wolfe, & Metzger, 2000). 
Endogenous opioid levels are also low in normal-weight patients with BN (Frank & 
Jappe, 2011).  
 
In addition to mediating eating behaviour, a number of neuropeptides participate in the 
regulation of neuroendocrine pathways; therefore, studies have evaluated the possibility 
that neuropeptide alterations may contribute to hormone abnormalities in BN (Bailer & 
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Kaye, 2003). Indeed, there appears to be a role for dysregulation in both the 
hypothalamic-pituitary-gonadal and -adrenal axes in the acute stage of the illness 
(Hildebrandt, 2013). Nevertheless, it is important to note that most of the neuropeptide 
and neuroendocrine alterations apparent during symptomatic episodes of BN tend to 
normalise after recovery, suggesting that these disturbances may be secondary to 
pathological eating behaviours (Bailer & Kaye, 2003; Frank & Jappe, 2011).  
 
1.2.3 Neurotransmitters 
Attempts to explain altered mood and motivational states in individuals with BN have 
focused on the role of monoamine neurotransmitters: the serotonergic system has 
received the most research attention, with some interest in the dopaminergic system 
(Hildebrandt, 2013). A physiological study by Jimerson and colleagues (1992) revealed 
lower basal cerebrospinal fluid concentrations of serotonin and dopamine metabolites in 
participants with BN, when compared with healthy controls. Among patients, levels of 
both metabolites were inversely correlated with binge-eating frequency (Jimerson et al., 
1992); therefore, these neurobiological alterations may be specifically related to the core 
eating pathology that is characteristic of BN (Broft, Berner, Martinez, & Walsh, 2011). 
Reduced serotonin metabolite concentrations in cerebrospinal fluid have not only been 
observed in the acute symptomatic phase of illness, but also after long-term recovery 
from BN, suggesting that this abnormality is trait-related and contributes to the 
pathogenesis of the disorder (Kaye et al., 1998).  
 
Further evidence for serotonin dysfunction in BN comes from multiple RCTs of 
antidepressant medications used to treat the disorder (see section 1.1.6.2). Selective 
serotonin reuptake inhibitors work by increasing serotonin levels in the brain, and have 
been shown to effectively reduce (and sometimes eliminate) binge-eating and purging 
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behaviours, even in BN patients who are not depressed (Crow & Eckert, 2016; Kaye et 
al., 2005). In recent years, additional insights into the operation of the monoamine 
neurotransmitter systems in BN have been gained from neuroimaging receptor studies – 
the results of these are discussed in section 1.2.4.3. 
 
1.2.4 Neuroimaging 
The past two decades have seen the introduction of advanced neuroimaging tools that 
have allowed for the in vivo investigation of human brain structure and function in 
health and disease (Frank & Jappe, 2011; Van den Eynde et al., 2012). In the field of 
EDs, the information gathered using neuroimaging, from individuals in both ill and 
recovered states, has rapidly advanced our understanding of the neurobiological 
underpinnings of these conditions (Frank & Jappe, 2011). Based on the scanning 
technique employed, brain imaging studies in BN can be divided into several categories 
(Kaye, 2008), and data from each of these are summarised in turn below.  
 
1.2.4.1 Structural imaging 
One of the first techniques developed for structural brain imaging was computerised 
tomography (CT) (Fuglset & Frampton, 2011). In the study of EDs, this medical X-ray 
method has enabled the assessment of overall brain structure and total brain volume 
(Fuglset & Frampton, 2011). Cranial CT scans performed in patients with BN have 
revealed ventricular enlargement and sulcal widening, indicating an overall reduction in 
brain volume most likely attributable to endocrine and metabolic reactions to extreme 
dieting (Kiriike et al., 1990; Krieg, Lauer, & Pirke, 1989). Changes in brain tissue 
identified by CT do not appear to have severe consequences for the cognitive status of 




Magnetic resonance imaging (MRI) uses powerful magnetic fields to generate high-
resolution images of the structural characteristics of the brain; thus a major advantage of 
this neuroimaging modality over CT is that no radiation is used (Fuglset & Frampton, 
2011). MRI has the potential to detect pathological changes in the brain resulting in cell 
loss (Whitwell, 2009). Findings of decreased cortical mass in individuals with BN were 
confirmed in an early MRI study, in which patients with the disorder showed cerebral 
atrophy (but an absence of ventricular enlargement) relative to healthy controls 
(Hoffman et al., 1989). More recently, BN has been associated with increased regional 
grey matter volumes in the orbital frontal cortex and the ventral striatum (Schafer, Vaitl, 
& Schienle, 2010); however, whether such differences normalise with clinical recovery 
is somewhat unclear (Wagner et al., 2006). Van den Eynde et al. (2012) highlight the 
need for collaborative multicentre efforts across the diagnostic ED spectrum, and for the 
assessment of longitudinal changes in brain structure following the onset of illness.  
 
1.2.4.2 Perfusion and metabolic imaging 
Positron emission tomography (PET) and single photon emission computed tomography 
(SPECT) require the injection of a radioactive material and enable visualisation of brain 
function by measuring cerebral blood flow or metabolic rate (Fuglset & Frampton, 
2011). Nozoe et al. (1995) used SPECT to show that individuals with BN had 
significantly higher resting-state regional cerebral blood flow in the bilateral inferior 
frontal and left temporal regions, in comparison to those with AN and no ED. A 
subsequent study found that brain perfusion in the prefrontal and parietal cortices 
correlated positively with body dissatisfaction and ineffectiveness in a transdiagnostic 
sample of patients with AN and BN (Goethals et al., 2007). Cerebral blood flow 
disturbances in BN are likely a state-related phenomenon, since they differ between the 
binge-eating and restricting phases of illness (Hirano, Tomura, Okane, Watarai, & 
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Tashiro, 1999) and normalise after long-term recovery (Frank et al., 2007; Frank, Kaye, 
Greer, Meltzer, & Price, 2000).  
 
Data from PET imaging studies, using a radioactive isotope attached to a form of 
glucose, suggest that BN is associated with global and regional absolute hypo-
metabolism of glucose at rest, and with low resting-state relative values of glucose 
metabolism in the parietal cortex (Delvenne, Goldman, De Maertelaer, & Lotstra, 1999; 
Delvenne, Goldman, Simon, De Maertelaer, & Lotstra, 1997). Additionally, following 
engagement in a neuropsychological test, individuals with BN have shown significant 
loss of the normal right hemisphere glucose metabolic rate exceeding the left, 
particularly in the temporal lobe, basal ganglia, and medial frontal structures (Hagman 
et al., 1990; Wu et al., 1990). Lastly, in a study by Andreason et al. (1992), participants 
with BN displayed a correlation between lower left anterolateral prefrontal regional 
cerebral glucose metabolism and greater depressive symptoms.  
 
1.2.4.3 Receptor imaging 
PET scanning is not only used to evaluate cerebral glucose metabolism – it also allows 
for the exploration of how other brain chemicals are processed (Fuglset & Frampton, 
2011). This technology can therefore help to discover potential differences in 
neurotransmitter functioning between mentally ill patients and healthy controls (Fuglset 
& Frampton, 2011). In BN, receptor imaging studies using PET and a radioligand which 
binds to the serotonin 2A receptor (18F-altanserin) have found that recovered patients 
versus healthy controls display significantly reduced binding potential in several neural 
regions including the medial orbitofrontal cortex (Bailer et al., 2004b; Kaye et al., 
2001), which is implicated in inhibitory processes and in the representation of food-
related reward (Frank & Jappe, 2011). Serotonergic disturbances in BN are not limited 
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to the 2A receptor: symptomatic patients have shown reduced hypothalamic and 
thalamic serotonin transporter availability (Tauscher et al., 2001) as well as increased 
serotonin 1A receptor binding, primarily in the angular gyrus, medial prefrontal cortex, 
and posterior cingulate cortex (Tiihonen et al., 2004).  
 
Alterations within other neurotransmitter systems have also been reported; for example, 
relative to a control group, individuals with BN were found to display decreased 
dopamine type 2 receptor binding in two striatal sub-regions (Broft et al., 2012). In 
addition, BN was associated with low striatal dopamine release in the putamen (Broft et 
al., 2012) and with reduced μ-opioid receptor binding in the insula, which is the primary 
gustatory cortex (Bencherif et al., 2005). These abnormalities were negatively 
correlated with the frequency of binge-eating and fasting, respectively (Bencherif et al., 
2005; Broft et al., 2012), suggesting that dysregulated neurotransmitter activity may 
contribute to the maladaptive feeding behaviours that characterise BN (Frank & Jappe, 
2011).   
 
1.2.4.4 Functional task-activation imaging 
As well as generating high-resolution images depicting brain anatomy, MRI can be used 
to measure and map neural activity by detecting associated changes in blood 
oxygenation, typically in response to some form of stimulus exposure and/or 
neuropsychological task (Fuglset & Frampton, 2011). Known specifically as functional 
MRI (fMRI), this imaging technique provides a means of assessing brain dysfunction in 
psychiatric disorders. Results from fMRI studies in BN have been used to formulate 
neurocircuit-based models of illness, and are therefore discussed within this context in 





The brain’s overall function is the result of a complicated interaction between different 
anatomical regions and their interconnections; thus, the diverse symptoms of BN are 
likely to be mediated by widespread pathological neurocircuitry. This is a view 
championed by the NIMH (Insel et al., 2010; Insel, 2010; Insel & Wang, 2010), and is 
loosely supported by neuroimaging studies in which patients with the disorder have 
demonstrated disturbances in blood flow, metabolic rate, and neurotransmitter 
functioning across numerous brain areas (see sections 1.2.4.2 and 1.2.4.3). Attempts to 
identify the neurocircuitry of BN have focused on systems which regulate behaviours, 
cognitive functions, or biological drives that are disrupted among individuals with the 
disorder, and evidence surrounding three major neurocircuit models of BN is considered 
below (key brain areas implicated are shown in Figure 1.1). 
 
1.2.5.1 Self-regulation 
Self-regulation refers to the modulation of thoughts, feelings, and actions involving 
deliberate as well as automated mechanisms (Karoly, 1993). It encompasses the ability 
to regulate emotional responses and to inhibit temptations for immediate gratification in 
pursuit of larger but delayed rewards (Berner & Marsh, 2014). From a clinical 
perspective, individuals with BN demonstrate pervasive deficits in self-regulation: a 
sense of ‘loss-of-control’ is a core feature of binge-eating (Wolfe, Baker, Smith, & 
Kelly-Weeder, 2009), which typically co-occurs with a host of other risky or impulsive 
behaviours such as substance misuse, self-harm, unprotected sex, compulsive buying, 
and reckless driving (Pearson et al., 2016). Furthermore, though not always consistent, 
neurocognitive data indicate that the condition is associated with impaired decision-
making under circumstances of uncertainty, poor inhibitory control (the ability to 
withhold inappropriate or unwanted behaviour; Van den Eynde et al., 2011), increased 
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temporal discounting (the tendency to devalue delayed rewards; see chapter 4), and 
emotion dysregulation across multiple dimensions (Lavender et al., 2015).  
 
The administration of neuropsychological tests in the brain scanning environment has 
permitted the characterisation of frontostriatal circuits that connect frontal lobe regions 
with the striatum and subserve the capacity for self-regulation (Berner & Marsh, 2014). 
These circuits comprise a portion of the broader cortico-striato-thalamo-cortical loops, 
which relay information from the cerebral cortex to targets in the subcortex, and then 
back to the original territory via direct or indirect pathways (Berner & Marsh, 2014; 
Marsh, Maia, & Peterson, 2009a). At least five parallel loops have been defined, 
initiating from and projecting back to the: (1) supplementary motor area; (2) frontal eye 
fields; (3) dorsolateral prefrontal cortex (DLPFC); (4) lateral orbitofrontal cortex; and 
(5) anterior cingulate cortex (Marsh et al., 2009a). The first three of these loops pass 
through the dorsal striatum and the last two pass through the ventromedial striatum, 
including the nucleus accumbens (Marsh et al., 2009a). Whereas the dorsal (cognitive) 
circuits support self-regulatory abilities, the ventral (limbic) circuits are involved in 
reward processing functions (Berner & Marsh, 2014; see section 1.2.5.2). 
 
Emerging evidence from fMRI studies suggests that functional disturbances within 
frontostriatal networks may differentiate BN patients from healthy controls and 
underscore their impairments in behavioural self-regulation (i.e., their binge-eating and 
apparent impulsivity; Marsh et al., 2009a). Indeed, Marsh et al. (2009b) reported that, 
during the Simon Spatial Incompatibility task (which requires inhibiting a more 
automatic response in favour of a task-relevant one), women with BN responded more 
impulsively than healthy controls whilst failing to engage their frontostriatal circuitry 
appropriately (in the left inferolateral prefrontal cortex, bilateral inferior frontal gyrus, 
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lenticular and caudate nuclei, and anterior cingulate cortex). Reduced activation in 
frontostriatal systems was subsequently recorded in a similar study of bulimic 
adolescents, despite the finding that patients and control participants performed equally 
well on the task (Marsh et al., 2011).  
 
An additional study using a Go/No-Go task to examine inhibitory motor control among 
female adolescents with BN or the binge-eating/purging subtype of AN also recorded 
abnormal frontostriatal responses in patients versus controls (e.g., in the right DLPFC 
and anterior cingulate cortex) in the absence of any performance disparities (Lock, 
Garrett, Beenhakker, & Reiss, 2011). Interestingly, however, BN was associated with 
increased as opposed to decreased frontostriatal activation in this instance (Lock et al., 
2011). Notwithstanding this directional inconsistency, which may relate to differences 
in the study sample and/or neurocognitive task employed (Lock et al., 2011), taken 
together preliminary fMRI data implicate a role for deficient self-regulatory control 
circuitry in the pathophysiology of BN.  
 
1.2.5.2 Appetite regulation and food reward processing 
Since BN is predominantly characterised by aberrant feeding behaviour, and individuals 
with the disorder self-report an increased preference for sweet foods (Drewnowski, 
Bellisle, Aimez, & Remy, 1987), scientists have explored the possibility that the 
condition is associated with dysregulation in the neural circuitry that underpins appetite 
regulation and food reward processing. Brain imaging experiments have interrogated 
these circuits using sweet taste stimuli, and have shown that the taste pathway begins 
peripherally with chemoreceptors on the tongue (Kaye, Wagner, Fudge, & Paulus, 
2011; Oberndorfer et al., 2013). From here, signals are transmitted through the 
brainstem and thalamus to the primary gustatory cortex, which includes the anterior 
49 
 
insula – a vital component of the ventral limbic circuitry, which supports food reward 
processing (Oberndorfer et al., 2013; see section 1.2.5.1). The anterior insula and 
associated gustatory cortex are therefore thought to respond not only to the taste and 
physical properties of food, but also to its rewarding value (Kaye et al., 2011). 
However, reward from food intake is not only experienced post-consumption; a 
dissociable ‘mesolimbic’ pathway (connecting the ventral tegmental area to the nucleus 
accumbens) is activated during the anticipation of palatable food rewards (Friederich, 
Wu, Simon, & Herzog, 2013). For this reason, the literature makes an important 
distinction between appetitive and consummatory reward, or wanting versus liking 
(Berridge, 1996).  
 
Considerable efforts have been made to determine whether patients with BN display 
abnormal neural activation in response to food intake or anticipated food intake (i.e., 
craving), which is generally provoked by exposing participants to food-related cues 
(Friederich et al., 2013). In a recent systematic review of fMRI studies employing visual 
food stimuli, García-García et al. (2013) noted that patients with BN versus healthy 
controls displayed hypo-activation in the temporal lobe, inferior parietal lobule, 
postcentral gyrus, and visual cortex, as well as increased responses in the lateral 
prefrontal cortex and anterior insula. Regarding the anterior cingulate cortex, both 
hyper- and hypo-activation have been observed in participants with this ED (García-
García et al., 2013). The authors concluded that, in BN and other EDs, images of food 
elicit abnormal patterns of activation in two brain circuits: (1) prefrontal areas 
supporting cognitive control processes; and (2) limbic and paralimbic areas associated 




Consummatory food reward has been assessed using taste experiments in bulimic 
patients (Friederich et al., 2013); for example, Bohon and Stice (2011) reported that 
women ill with BN showed trends for less activation than healthy controls in the left 
middle frontal gyrus, right posterior insula, right precentral gyrus, and right mid dorsal 
insula during receipt of a chocolate milkshake (versus tasteless solution). Furthermore, 
in response to simple sugars (glucose and sucrose), women recovered from BN have 
displayed reduced activity in the right anterior cingulate cortex and left cuneus (Frank et 
al., 2006), but elevated hemodynamic responses in the right anterior insula (Oberndorfer 
et al., 2013). High-fat taste has been associated with increased ventral striatum 
activation in women recovered from BN relative to those with no history of the disorder 
(Radeloff et al., 2014).  
 
Evidence that BN is underpinned by dysfunction within the neural circuits that regulate 
appetite and food reward processing has also been obtained from neurochemical studies 
of humans (see section 1.2.4.3) and animal models of the disorder. Regarding the latter, 
findings suggest that alterations in dopamine, acetylcholine, and opioid systems in 
reward-related brain areas occur in response to binge-eating of palatable foods (Avena 
& Bocarsly, 2012). Despite the direction-of-activation discrepancies, which mirror 
those present in self-regulation research, the prevailing hypothesis is that individuals 
with BN have hypo-responsive reward circuitry, which may be compensated for by 
binge-eating (Friederich et al., 2013). Compared to people without an ED, patients with 
BN may have to eat a larger amount of appetitive food to stimulate their reward system 




1.2.5.3 Body-image perception 
Body image disturbance is a complex concept, which includes several 
psychopathological components such as overestimation of body size, body 
dissatisfaction, over-concern with shape and weight, and extreme reward experience 
when weight loss is obtained (Zanetti, Santonastaso, Sgaravatti, Degortes, & Favaro, 
2013). It is influenced by perceptual and visuospatial abilities and by cognitive and 
affective factors relating to one's own body experience (Zanetti et al., 2013). Since 
distorted body image perception is a core and persisting feature of EDs, including BN, a 
number of fMRI studies have probed the neural correlates of this puzzling 
multidimensional symptom by exposing patients to body-related stimuli inside the 
scanner.  
 
Interestingly, Van den Eynde et al. (2013) found that brain activation patterns in 
response to food cues did not differ between women with and without BN; however, 
when evaluating themselves against images of slim women, BN patients versus healthy 
controls engaged the insula more and the fusiform gyrus less, suggesting increased self-
focus among individuals with BN whilst comparing themselves to a thin-ideal. Relative 
to healthy comparison participants, patients with the disorder have also demonstrated 
reduced activity in the inferior parietal lobule when viewing photographs of their own 
body (Vocks et al., 2010), increased medial prefrontal cortex response to images of 
overweight bodies (Spangler & Allen, 2012), and a reduced activation of the precuneus 
and middle frontal gyrus during two body image tasks (Mohr et al., 2011).  
 
Intrinsic functional connectivity MRI has emerged as a powerful neuroimaging tool for 
assessing regional interactions and mapping large-scale networks in the human brain 
(Buckner, Krienen, & Yeo, 2013). Using this technique, Lee and colleagues (2014) 
52 
 
found that women with BN versus age matched healthy controls showed stronger 
resting-state synchrony between the dorsal anterior cingulate cortex and precuneus, 
which correlated with higher body shape preoccupation. Greater synchronous activity 
between the dorsal anterior cingulate cortex and medial orbitofrontal cortex was also 
observed (Lee et al., 2014). In a similar study, Lavagnino et al. (2014) reported that, 
relative to healthy comparison participants, those with BN had an alteration in the 
resting-state functional connectivity of the somatosensory cortex – a brain area 
implicated in body processing. Whilst available evidence indicates that body image 
disturbances in BN are represented at a neural level, the precise neurocircuitry involved 
has yet to be defined.  
 
 




1.2.6 Comparison to other eating disorders 
Individuals with EDs are currently diagnosed and treated according to readily 
observable symptoms, and these categorisations have dominated the research field. 
Although the conditions are associated with distinct clinical features (see section 1.1.2), 
they are all characterised by a dangerously maladaptive approach to food and, perhaps 
unsurprisingly, appear to be underpinned by shared neurobiological mechanisms. Most 
notably, there is substantial evidence that dopaminergic taste-reward pathways play a 
central role in the pathophysiology of all three major EDs, and alterations of the neural 
circuitry underlying aspects of self-regulation are also not exclusive to BN (for reviews 
see Avena & Bocarsly, 2012; Frank, 2015; Friederich et al., 2013; Wierenga et al., 
2014). These observations have contributed to the view that EDs should be considered 
within a transdiagnostic framework (Brooks, Rask-Andersen, Benedict, & Schiöth, 
2012; Wade, Bergin, Martin, Gillespie, & Fairburn, 2006; Waller, 2008).  
 
1.2.7 Comparison to substance use disorders 
The clinical features of BN bear significant similarities to those of drug addiction. In 
fact, characteristic symptoms of the ED mirror some of the DSM-5 criteria for substance 
use disorder (American Psychiatric Association, 2013): people with BN report 
experiencing intense food cravings; food is often consumed in larger amounts than was 
intended; unsuccessful efforts to cut down or control one’s binge-eating are 
commonplace; and dysregulated eating is continued despite knowledge of having a 
physical or psychological problem that is likely to have been caused by this behaviour. 
Comorbidity data are also suggestive of a strong relationship between the disorders, 
with the range and occurrence of substance use problems in people with BN far 
exceeding those in individuals with other EDs and in the general population (Woodside, 
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2008). Given the clinical evidence linking BN to substance use disorders, there has been 
extensive speculation that the conditions may share common mechanisms of neural 
dysfunction.  
 
Indeed, a considerable literature shows that hyper-palatable, energy-dense foods (which 
are typically consumed during binge-eating episodes in BN; Rosen, Leitenberg, Fisher, 
& Khazam, 1986) and traditional drugs of abuse have similar effects on the human 
brain: they both activate dopamine and opioid neural circuitry, trigger artificially 
elevated levels of reward, and alter neurobiological systems (Gearhardt, Davis, 
Kuschner, & Brownell, 2011). Furthermore, recent experimental research in laboratory 
rats has revealed that sweet substances can be even more desirable than addictive drugs, 
and that the neural substrates of sugar may be more robust than those of cocaine 
(Ahmed, Guillem, & Vandaele, 2013).  
 
Additional evidence for a shared neurobiology for BN and drug addiction comes from 
functional neuroimaging studies, which have demonstrated parallels across several 
domains; for example, there are relatively consistent findings that, like individuals with 
BN (see sections 1.2.4.3, 1.2.5.2, and 1.2.5.3), those with substance use disorders 
display reduced dopamine type 2 receptor binding in striatal regions, as well as 
increased prefrontal cortex activity when presented with disorder-salient stimuli (Hadad 
& Knackstedt, 2014). Moreover, the dorsal cognitive and ventral limbic neural circuits 
that appear to be disrupted in BN and other EDs are also proposed to function as key 
neural mechanisms underlying the altered behavioural regulation, reward processing, 
and cognition found in addictions (Kaye et al., 2013). Nevertheless, despite convincing 
support for an ‘addiction model’ of BN, controversy remains about whether the ED 




1.2.8 Neurobiological models 
Given the breadth and complexity of brain-based aberrations that reportedly influence 
the pathogenesis of BN, formulating a coherent neurobiological model of illness is a 
challenging endeavour. Recent attempts have focused largely on the neurocircuitry of 
the disorder and have sought to integrate findings relating to dysfunctional self-
regulatory and food reward systems (see sections 1.2.5.1 and 1.2.5.2). For example, 
Wierenga et al. (2014) posit that eating pathology in BN and other EDs emerges from 
an altered balance between inhibitory control and reward processing that is driven by 
changes in the dorsal and ventral neural circuitry supporting these constructs.  
 
Similarly, Berner and Marsh (2014) contend that functional disturbances in 
frontostriatal circuits arise early in adolescence and contribute to an impaired capacity 
for self-regulatory control, which interacts with hunger to release eating behaviour from 
regulatory control. Aesthetic ideals of thinness then promote compensatory behaviours, 
which are intended to counteract weight gain (Berner & Marsh, 2014). Dysregulated 
frontostriatal circuits are also hypothesised to promote abnormal reward-based learning 
functions, which alter the processing of food rewards and allow binge-eating behaviours 
to solidify as ‘habits’ (Berner & Marsh, 2014). The authors point out that negative 
affect may be involved in BN pathophysiology; indeed, negative mood has been shown 
to diminish self-regulatory control processes (Heatherton & Wagner, 2011) and to alter 
the reward value of food (Bohon & Stice, 2012; Wagner, Boswell, Kelley, & 
Heatherton, 2012). A schematic representation of this neurobiological model, adapted 





Figure 1.2 Neurobiological model of bulimia nervosa (BN), adapted from Berner and 
Marsh (2014).  
Dysregulated overlapping dorsal cognitive and ventral limbic frontostriatal 
neurocircuits contribute to impaired self-regulatory control and food reward 
processing, respectively. The combination of these behavioural maladies leads to binge-
eating, which is made more likely by negative affect. Compensatory behaviours, 
intended to prevent weight gain, ensue due to an over-concern with body weight and 
shape. This cycle is repeated and maintained as a result of altered habit learning 
processes caused by disturbances in frontostriatal circuitry, ultimately contributing to 




Viewing disordered eating from this perspective provides a foundation for developing 
more specific and effective interventions for BN (Wierenga et al., 2014). Indeed, Berner 
and Marsh (2014) conclude that non-invasive brain stimulation techniques, such as 
tDCS and transcranial magnetic stimulation (TMS), capable of enhancing frontostriatal 
function may hold promise as treatments for the disorder.  
 
1.3 TRANSCRANIAL DIRECT CURRENT STIMULATION 
tDCS is a form of non-invasive neuromodulation with wide ranging potential 
applications in restoring impaired neural function (prosthetics), as a novel form of 
medical treatment (therapy), and as a tool for investigating neurons and neural function 
(research) (Luan, Williams, Nikolic, & Constandinou, 2014). Here, an overview of the 
technique is provided in relation to its role as an emerging therapeutic tool in 
psychiatry. The results of studies investigating the clinical efficacy of tDCS in patients 
with mental disorders are reviewed in chapter 2.  
 
1.3.1 History 
The effects of uncontrolled electrical stimulation on the brain have been reported since 
the distant past: as early as the first century, Romans used strong electric currents from 
live torpedo fish to treat headaches and, in the 11th century, electric catfish were 
suggested for the treatment of epilepsy (Brunoni et al., 2012; Williams & Fregni, 2009). 
With the introduction of the voltaic pile in the 1700s (the first electrical battery that 
could continuously provide an electric current to a circuit), it became possible to 
evaluate the effects of transcranial stimulation experimentally and, during the following 
two centuries, many researchers used galvanic current in an attempt to treat melancholia 
and various mental disorders (Brunoni et al., 2012). In the 1960s, data from animal 
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experiments showed that weak electrical currents can produce changes in spontaneous 
neural activity which persist for hours after the end of stimulation (Bindman, Lippold, 
& Redfearn, 1964; Purpura & McMurtry, 1965); nevertheless, interest in the field 
subsequently diminished due to the increasing popularity of electroconvulsive therapy 
and psychopharmacologic drugs (Brunoni et al., 2012).  
 
A reappraisal of tDCS took place at the turn of the 21st century (Brunoni et al., 2012), 
when researchers learnt that the application of weak direct currents through the intact 
scalp could effectively influence the human brain, and that the strength, duration, and 
direction of changes in cortical excitability could be controlled by altering the 
stimulation parameters (Nitsche & Paulus, 2000; Priori, Berardelli, Rona, Accornero, & 
Manfredi, 1998). This discovery led to a rapidly growing literature on the therapeutic 
potential of tDCS in individuals with psychiatric disorders (see chapter 2).  
 
1.3.2 Operation 
tDCS uses a weak continuous electric current applied through scalp electrodes to inject 
currents into the brain and modulate spontaneous neuronal activity in a painless manner 
(Williams & Fregni, 2009). Two electrodes are typically placed over two different brain 
regions, though one can be positioned extracephalically, and connected to a battery 
source (Figure 1.3). The current enters the brain from the anode (the positively charged 
electrode), travels through the intervening tissue, and exits via the cathode (the 
negatively charged electrode; George & Aston-Jones, 2010).6 In monkeys, 
                                                 
6 Conflicting information has been published regarding the direction of current flow during tDCS, with 
some papers reporting that the current flows in the opposite direction – from the cathode to the anode 
(Nitsche et al., 2008; Williams & Fregni, 2009). 
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approximately 50% of the transcranially applied current successfully passes through the 
skull (Rush & Driscoll, 1968), and this estimate has been confirmed in humans 
(Dymond, Coger, & Serafetinides, 1975). Most studies use surface conductive rubber 
electrodes sized between 25 and 35cm2, placed in saline-soaked cotton or sponge (Stagg 
& Nitsche, 2011). Currents vary between 1 and 2mA in intensity (resulting in charge 
densities of 343-960 C/m2) and are commonly applied for durations of 10-20 minutes 
(Stagg & Nitsche, 2011). 
 
 
Figure 1.3 Illustration showing transcranial direct current stimulation application.  
Note: the yellow arrows indicate the direction of current flow. 
 
1.3.3 Physiological effects and mechanism of action 
The precise physiological mechanisms that underlie the observed clinical responses to 
tDCS in psychiatric disorders (see chapter 2) are not fully understood; however, a 
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number of human, animal, and cell-culture studies have sought to elucidate the 
processes involved. Evidence shows that, at cellular level, tDCS induces focal, polarity-
specific shifts in resting membrane potentials and consequent alterations in spontaneous 
cerebral excitability and activity via the regulation of ion channels (e.g., sodium and 
calcium; Nitsche et al., 2003a). It is generally accepted that anodal stimulation causes 
tonic depolarisation, enhanced excitability, and increased firing rates, whilst cathodal 
tDCS has the reverse effect, though the direction of cortical modulation depends strictly 
on the spatial orientation of axons and dendrites in the induced electrical field and on 
the intensity of the current applied (Zaghi, Acar, Hultgren, Boggio, & Fregni, 2010).  
 
Changes in neuronal membrane potentials are thought to account primarily for the intra-
stimulation and short-term effects of tDCS; however, a single session can elicit 
prolonged effects which outlast the period of stimulation for up to 2 hours (Alonzo, 
Brassil, Taylor, Martin, & Loo, 2012) and cannot be attributed to polarisation 
mechanisms. Evidence suggests that these after-effects are associated with synaptic 
modulation and share some features with NMDA receptor-dependent long-term 
potentiation and depression (Nitsche et al., 2003a), which are well-characterised 
phenomena of neuroplasticity. A non-synaptic mechanism of action has also been 
proposed: this involves alterations in neuronal membrane function caused by either 
transmembrane protein migration or by changes in intracellular pH (Ardolino, Bossi, 
Barbieri, & Priori, 2005).  
 
The physiological effects of tDCS are not confined to the area of the brain beneath the 
electrodes; sustained and widespread changes to cerebral activity in remote cortical and 
subcortical structures and alterations in functional connectivity between these regions 
have also been observed (DaSilva et al., 2012; Mangia, Pirini, & Cappello, 2014; 
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Polania, Paulus, Antal, & Nitsche, 2011; Polania, Paulus, & Nitsche, 2012). These 
network consequences of stimulation are likely to be key mechanistic contributors to the 
therapeutic effects of tDCS in psychiatry (see chapter 2), since disturbed interactions 
among brain regions are associated with most mental disorders (Sporns, 2013). 
Nevertheless, little is known about the specific physiological effects of tDCS applied to 
clinically relevant anatomical sites (e.g., the DLPFC), because studies investigating the 
neurobiological effects of stimulation have predominantly targeted the motor cortex.  
 
1.3.4 Safety 
When administered at intensities of up to 2mA for durations of approximately 20 
minutes, tDCS is considered a safe neuromodulatory technique (Utz, Dimova, 
Oppenländer, & Kerkhoff, 2010). Indeed, the charge density typically applied in 
humans is two orders of magnitude lower than the experimentally determined threshold 
estimate in rats (Liebetanz et al., 2009), and pathological consequences in human 
participants have been ruled out by electroencephalography (Iyer et al., 2005), skin 
temperature measurements (Nitsche & Paulus, 2000), oedemasensitive magnetic 
resonance tomography scanning (Nitsche et al., 2004), and normal neuron specific 
enolase values (Nitsche et al., 2003b).  
 
tDCS is generally well-tolerated and is associated with relatively minor, benign, and 
transient side effects. Although seizure is a potential risk of stimulation, no such 
incidences have been recounted to date (Bikson et al., 2016) and, while tDCS 
application has led to skin burns on rare occasions (Palm et al., 2009), this appears to 
occur only when standard procedures are not followed (Fregni et al., 2015). Poreisz and 
colleagues (2007) summarised the partially adverse effects of 567 tDCS sessions and 
found that a mild tingling sensation was the most commonly reported experience (noted 
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by 70.6% of participants). Other side effects included moderate fatigue (35.3%), a light 
itching sensation under the electrodes (30.4%), a headache (11.8%), and nausea (2.9%) 
(Poreisz et al., 2007). Nevertheless, such data should be interpreted with caution since 
there is evidence of selective reporting of adverse treatment effects in a large number of 
tDCS studies (Brunoni et al., 2011).  
 
Whilst there is general consensus regarding the safety of particular tDCS parameters, 
and specific exclusion criteria are ordinarily applied to studies involving human 
participants (e.g., pregnancy, history of epilepsy7, medications which decreased seizure 
threshold), there remains a lack of any clarity on international regulatory pathways and 
clear guidelines about the standard tDCS application protocols are still needed (Fregni 
et al., 2015).  
 
1.3.5 Comparison to other neuromodulation modalities 
tDCS is one of several neuromodulation modalities capable of influencing neural 
activity without the need for any invasive surgical procedures. Of these techniques, 
tDCS and TMS are the most commonly employed. During TMS, a figure-of-eight coil 
placed on the scalp generates an electrical field in the underlying cortex via 
electromagnetic induction (McClelland, Bozhilova, Campbell, & Schmidt, 2013), which 
depolarises neurons and triggers action potentials (Di Lazzaro et al., 2004). Pulses of 
TMS can be applied at varying intensities and in single pulses or in repetitive trains 
(rTMS) of high or low frequency: the choice of stimulation parameters defines whether 
the effects are excitatory or inhibitory (O'Shea & Walsh, 2007). Other non-invasive 
                                                 
7 With the exception of studies of tDCS in epilepsy.   
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neuromodulation modalities, which have gained interest in recent years, are transcranial 
alternating current stimulation and transcranial random noise stimulation.  
 
tDCS presents several practical advantages over TMS, such as the small size of the 
apparatus – allowing portability – and the possibility of simultaneously increasing and 
decreasing neuronal activity in two different areas of the cortex (Williams & Fregni, 
2009). It is also easier to administer and significantly less expensive due to the 
simplicity of the device: a stimulator can cost less than £75 if manufactured locally 
(Fregni, Boggio, Nitsche, & Pascual-Leone, 2005). Lastly, in clinical trials the effects of 
tDCS can be controlled for by a sham (placebo) method that participants cannot 
distinguish from real stimulation (Kekic et al., 2014).  
 
1.3.6 Importance as a clinical tool 
Significant research efforts have been devoted to determining the therapeutic potential 
of tDCS in humans (Fregni et al., 2015). Although its efficacy in the treatment of BN 
has not been explored prior to the research presented in this thesis, data from numerous 
studies by international teams have repeatedly shown that tDCS interventions 
comprising multiple sessions can provide clinical benefits for several psychiatric 
disorders (see chapter 2). If further studies confirm the encouraging results, tDCS might 
be useful: (1) in patients who have not responded to prevailing therapies; (2) to 
potentiate medications or psychological treatments; or (3) as an alternative to 





BN is a complex disorder characterised by the concurrent presence of binge-eating and 
inappropriate compensatory behaviours. It most commonly begins during adolescence 
in females and is frequently a chronic and disabling condition associated with 
substantial psychological and physiological morbidity (Kaye, 2008). Although 
empirically supported psychological and pharmacological treatments exist for BN, 
recovery rates remain inadequate. During recent years, significant efforts have been 
made to understand the neurobiological basis of BN, and evidence suggests that it is 
underpinned by dysfunctional dorsal cognitive and ventral limbic frontostriatal 
neurocircuits, which support self-regulatory control and food reward processing 
capacities, respectively (Berner & Marsh, 2014; Friederich et al., 2013; Wierenga et al., 
2014). tDCS is a non-invasive neuromodulatory tool capable of influencing cortical 
excitability and functional connectivity in the human brain, which may have clinical 
potential in the treatment of a variety of neuropsychiatric disorders, including BN.  
 
1.5 AIMS AND HYPOTHESES 
The overarching aim of this research was to investigate the therapeutic utility of tDCS 
in BN. Specifically, four major hypotheses were tested (additional hypotheses are 
detailed in the introductory sections of chapters 3-5): 
(1) Existing literature demonstrates that tDCS induces beneficial clinical effects 
in several psychiatric disorders, and may therefore have therapeutic potential 
in BN (chapter 2). 
(2) A single session of real versus sham tDCS applied to the bilateral DLPFC 
will temporarily reduce food craving and temporal discounting (a marker of 
low self-regulatory control denoting a preference towards more immediate 
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rewards) in healthy women with frequent food cravings – again, suggesting 
tDCS may have therapeutic potential in BN (chapter 3).  
(3) Individuals with BN will display increased temporal discounting (i.e., poor 
self-regulatory control) relative to healthy comparison participants (chapter 
4). 
(4) A single session of real versus sham tDCS applied to the bilateral DLPFC 
will temporarily reduce symptoms, improve mood, alter food wanting/liking, 
and decrease temporal discounting (i.e., improve self-regulatory control) in 
individuals with BN (chapter 5). 
 
1.6 THESIS MAP 
This thesis consists of six chapters, inclusive of the present chapter. All results are 
presented within publications, which is reflected in the structure of the relative chapters 
(2-5) – each one includes an introduction explaining the background and rationale for 
the research, a material and methods section, an account of the results, and a discussion 
of the findings and their implications. Whilst the formatting of each publication has 
been amended to ensure stylistic consistency throughout the thesis, the body text 
remains unchanged8. PDF versions of the published articles are included in Appendix 
A.  
 
Chapter 1: General introduction 
This chapter provides detailed background information about the research topic. An 
overview of BN is presented, as well as a discussion of the neurobiological basis of the 
disorder, and an introduction to tDCS.  
                                                 




Chapter 2: A systematic review of the clinical efficacy of transcranial direct 
current stimulation in psychiatric disorders 
As a first step towards investigating the therapeutic utility of tDCS in BN, this 
systematic review evaluates the clinical efficacy of the neuromodulatory technique 
across all mental disorders. Specifically, an up-to-date and comprehensive synthesis of 
the full evidence base is presented, which is inclusive of all study designs, and which 
uses a standardised quality assessment. The discussion contains a critical appraisal of 
the literature and an overview of the ethical issues surrounding the use of tDCS in 
psychiatry.  
 
Chapter 3: The effects of prefrontal cortex transcranial direct current stimulation 
on food craving and temporal discounting in women with frequent food cravings 
This chapter describes an RCT investigating the effects of a single-session of tDCS 
applied to the bilateral DLPFC on food craving, temporal discounting9, and actual food 
consumption in healthy women with frequent food cravings. Findings relating to the 
potential moderating role of individual differences in temporal discounting, the success 
of the blinding procedure, and the tolerability/safety of tDCS are also reported. This 
preliminary RCT was conducted to inform the design of, and provide support for, the 
larger study presented in chapter 5. The sample was chosen because food craving is a 
prominent feature of BN (see section 1.2.7) that can be regarded as a manifestation of 
altered anticipatory food reward processing.  
 
Chapter 4: Increased temporal discounting in bulimia nervosa 
                                                 
9 In this chapter, temporal discounting is discussed in relation to high impulsivity (a deficiency in the self-
regulation process) as opposed to low self-regulatory control. 
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A cross-sectional study assessing temporal discounting among individuals with BN and 
healthy controls is reported in this chapter. This research was conducted because the 
study presented in chapter 5 draws on the premise that individuals with BN have 
impaired self-regulatory control, and that manipulation of the neurocircuits that 
subserve this capacity will therefore induce therapeutic effects in this patient population.  
 
Chapter 5: Transcranial direct current stimulation improves symptoms, mood, 
and self-regulatory control in bulimia nervosa: A randomised controlled trial 
This chapter reports on the core study of the thesis: an RCT examining the effects of a 
single-session of tDCS applied to the bilateral DLPFC on symptoms, the wanting/liking 
of food (i.e., food reward processing), mood, and temporal discounting in patients with 
BN. Data concerning the role of electrode polarity, the effectiveness of the blinding 
procedure, and the safety, tolerability, and acceptability of tDCS are also presented. 
 
Chapter 6: General discussion 
In this final chapter, the key findings from the studies conducted for this thesis are 
summarised, and their implications discussed. Strengths and limitations associated with 
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Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation 
technique, which can be used to selectively disrupt patterns of neural activity that are 
associated with symptoms of mental illness. tDCS has been implemented in numerous 
therapeutic trials across a range of patient populations, with a rapidly increasing number 
of studies being published each year. This systematic review aimed to evaluate the 
efficacy of tDCS in the treatment of psychiatric disorders. Four electronic databases 
were searched from inception until December 2015 by two independent reviewers, and 
66 eligible studies were identified. Depression was the most extensively researched 
condition, followed by schizophrenia and substance use disorders. Data on obsessive 
compulsive disorder, generalised anxiety disorder, and anorexia nervosa were also 
obtained. The quality of included studies was appraised using a standardised assessment 
framework, which yielded a median score corresponding to “weak” on the three-point 
scale. This improved to “moderate” when case reports/series were excluded from the 
analysis. Overall, data suggested that tDCS interventions comprising multiple sessions 
can ameliorate symptoms of several major psychiatric disorders, both acutely and in the 
long-term. Nevertheless, the tDCS field is still in its infancy, and several 
methodological and ethical issues must be addressed before clinical efficacy can truly 
be determined. Studies probing the mechanisms of action of tDCS and those facilitating 
the definition of optimised stimulation protocols are warranted. Furthermore, evidence 
from large-scale, multi-centre randomised controlled trials is required if the transition of 





Mental disorders constitute a major public health issue, directly accounting for 7.4% of 
disease burden worldwide (Murray et al., 2012) and 17.8% in the European Union 
(Wittchen et al., 2011). They are the leading cause of years lived with disability globally 
(Whiteford et al., 2013), impacting personal well-being, social relationships and work 
productivity, and are associated with substantial loss of quality of life (Alonso et al., 
2004). Despite an increase in the rate of treatment, psychiatric morbidity has remained 
relatively stable over the past two decades (Kessler et al., 2005; Wittchen et al., 2011), 
thus there is a need to develop novel therapeutic strategies to improve clinical outcomes. 
 
Recent advances in functional neuroimaging have facilitated an improved understanding 
of the disturbances in neural circuitry that underlie mental disorders (Frangou, 2014; 
Price & Drevets, 2013). Consequently, there has been increased interest in 
neuromodulation methods which can be used to selectively disrupt patterns of neural 
activity that are associated with symptoms of illness, with the objective of improving 
behavioural outcomes whilst generating information about disease mechanisms. These 
emerging brain-directed interventions adhere to an experimental therapeutics approach, 
which is now widely regarded as the gold-standard strategy for treatment-focused 
psychiatric research (Insel, 2014; Insel & Gogtay, 2014; Medical Research Council, 
2010). 
 
Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation 
technique which delivers low-amplitude direct currents to the brain via two surface 
sponge electrodes (anode and cathode) attached to distinct areas of the scalp with a 
rubber headband (Wagner, Valero-Cabre, & Pascual-Leone, 2007). The current 
penetrates the skull and enters the brain from the anode, travels through the tissue, and 
99 
 
exits via the cathode (George & Aston-Jones, 2010). tDCS presents several practical 
advantages over alternative neuromodulation modalities – it has a favourable safety-
feasibility profile, offers a convincing placebo, can be applied bilaterally, and is 
portable and inexpensive.  
 
During the past decade, tDCS has been implemented in numerous trials across a range 
of patient populations and psychiatric conditions, with a rapidly increasing number of 
studies being published each year (Figure 2.1). This systematic review critically 
evaluates the clinical efficacy of tDCS in people with mental illness, and is warranted 
given the limited efficacy of existing therapies, the evidence that psychiatric disorders 
are neural circuit-based disorders that could benefit from brain-directed interventions, 
and the appealing characteristics of tDCS in comparison to other forms of 
neuromodulation. Although several reviews and meta-analyses have previously 
addressed this topic, the majority have either studied major depression (Berlim, Van den 
Eynde, & Daskalakis, 2013; Brunoni, Ferrucci, Fregni, Boggio, & Priori, 2012a; Kalu, 
Sexton, Loo, & Ebmeier, 2012; Meron, Hedger, Garner, & Baldwin, 2015; Shiozawa et 
al., 2014b) or schizophrenia alone (Mondino et al., 2015a), or used unsystematic search 
procedures (Brunoni et al., 2012b; Kuo, Paulus, & Nitsche, 2014; Tortella et al., 2015) 
which promote a number of biases (Schmidt & Gotzsche, 2005). To our knowledge, one 
prior publication has systematically reviewed the therapeutic effects of tDCS across all 
psychiatric disorders (Mondino et al., 2014). Given the high growth rate of publication 
in the field, we have provided an up-to-date and comprehensive synthesis of the full 
evidence base, which is inclusive of all psychiatric conditions and study designs, and 





Figure 2.1 Number of publications included in this review by year between 2006 and 
2015. 
Note: databases were searched for papers published online or in print until 3rd December 2015.  
 
2.3 MATERIAL AND METHODS 
2.3.1 Selection criteria 
Studies in English of any design that investigated the clinical efficacy of tDCS in 
individuals with psychiatric disorders were eligible for inclusion. Studies of participants 
with neurological conditions were excluded, as were those that did not report any 
symptom outcome variables. Publications were not restricted based on whether details 
of a Diagnostic and Statistical Manual of Mental Disorders/International Classification 
of Diseases diagnosis were given, and those involving co-interventions were eligible for 



























2.3.2 Search strategy  
Four electronic databases (MEDLINE, Embase, PsycINFO, and CINAHL) were 
searched (via OvidSP and EBSCOhost) from inception until 3rd December 2015 using 
the following Medical Subject Headings and keywords: transcranial direct current 
stimulation, tDCS, and transcranial DC stimulation, in combination with mental 
disorder, mental illness, psychiatric disorder, psychiatric disease, addict*, anorexi*, 
anxiety disorder, auditory verbal hallucinations, bipolar disorder, bulimi*, catatonia, 
craving, dependence, depersonali?ation, depressi*, eating disorder, mania, obsessive 
compulsive disorder, OCD, panic disorder, personality disorder, phobi*, posttraumatic 
stress disorder, psychosis, PTSD, and schizophrenia. These searches were supplemented 
by internet searches and hand-searches of reference lists of relevant papers and reviews. 
Citation tracking in Web of Science was also performed.  
 
Titles and abstracts of retrieved publications were imported into EndNote, duplicates 
were removed, and papers that were deemed highly unlikely to be relevant were 
disregarded. Full-text versions of the remaining articles were then obtained and 
screened according to the pre-specified eligibility criteria. All papers that did not meet 
the inclusion criteria were excluded, with the reasons documented (Figure 2.2). The 
entire search process was conducted independently by two reviewers (M.K. and E.B.) 





Figure 2.2 Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flow diagram. 
 
2.3.3 Quality assessment and data extraction 
The quality of included studies was appraised using a standardised evaluation 
framework – the Effective Public Health Practice Project (EPHPP) Quality Assessment 
Tool for Quantitative Studies (Thomas, Ciliska, Dobbins, & Micucci, 2004) – which is 
suitable for use with multiple study designs. The instrument assesses six methodological 
domains: selection bias, study design, confounders, blinding, data collection methods, 
and withdrawals and dropouts. Each component is rated as strong, moderate, or weak on 
a three-point scale and these scores are averaged to provide a global rating. The quality 
Records identified through 
database searching 
n = 1642 
 
- MEDLINE  n = 300 
- Embase  n = 998 
- PsycINFO  n = 310 
- CINAHL  n = 34 
 
Additional records identified 
through other sources 
n = 5 
Records after duplicates 
removed 
n = 1088 
Records screened 
n = 1088 
Records excluded 
n = 963 
Full-text articles assessed for 
eligibility 
n = 125 
Full-text articles excluded, with 
reasons n = 58 
 
- No clinically relevant outcome 
variables  n = 27 
- Uses data from included study 
and reports no additional 
relevant information  n = 13 
- No clinical sample  n = 9 
- tDCS administered as a co-
intervention  n = 8 
- Comorbid neurological 
disorder  n = 1 
Studies included in the 
qualitative synthesis 
n = 66 
(Reported in 67 publications) 
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assessment was performed independently by two reviewers (M.K. and E.B.) and 
discrepancies were discussed until an agreement was reached.   
 
The principal reviewer (M.K.) extracted data from all included studies into an electronic 
summary table which was then checked by another reviewer (E.B.). Information 
collected related to patient population, sample size, study design, stimulation protocol, 
measurement of clinical efficacy, and relevant findings. Due to the methodological 
diversity of the included studies, a narrative synthesis is presented.  
 
2.4 RESULTS 
2.4.1 Characteristics of included studies  
We identified 66 studies (reported in 67 publications, including data from 1021 
participants) that met the inclusion criteria for this review (Figure 2.2). The majority (30 
studies) evaluated the efficacy of tDCS for the treatment of major depression in patients 
with major depressive disorder (MDD) or bipolar disorder (BP). The remaining studies 
were of patients with schizophrenia (23 studies), substance use disorders (SUDs; 7 
studies), obsessive compulsive disorder (OCD; 4 studies), generalised anxiety disorder 
(GAD; 1 study), and anorexia nervosa (AN; 1 study). There were 23 randomised 
controlled trials (RCTs) and 41 open-label studies (2 had blind-raters) including 24 case 
reports/series. In addition, there was one double-blind, sham-controlled case report and 
one study with a hybrid design involving both double-blind, sham-controlled and open-
label conditions. All studies had adult-only samples which differed substantially in size, 




All but four of the studies had stimulation protocols comprising multiple sessions; 
however, the duration, number, and frequency of these sessions, as well as the tDCS 
parameters employed, varied considerably across trials (Tables 2.2-2.5). The unilateral 
or bilateral dorsolateral prefrontal cortex (DLPFC) was targeted in 59 of the 66 studies. 
Other hypothesis-driven sites of stimulation were the temporoparietal junction (TPJ), 
cerebellum, occipital lobe, orbitofrontal cortex (OFC), frontotemporal region, pre-
supplementary and supplementary motor areas (pre-SMA/SMA), and Wernicke’s area.  
 
2.4.2 Quality of included studies 
The median global rating derived from the EPHPP Quality Assessment Tool for 
Quantitative Studies was 3 (weak). Overall, the weakest scores were obtained for the 
selection bias component of the tool because 38% of studies were case reports/series 
and a further 26% did not adequately describe the participant selection process. A high 
number of weak ratings were also assigned for the blinding component because 62% of 
the studies were open-label. The strongest-scoring dimension was data collection 
methods because 63 of the 66 studies used at least one standardised outcome measure 
with known reliability and validity. Where relevant, withdrawals and dropouts were 
generally addressed and reported accurately, and only 5 studies had a retention rate 
lower than 80% at the final stage of data collection. Of the 18 studies that involved 2 or 
more independent experimental groups, 16 reported no baseline between-group 
differences with respect to important variables, 1 noted that the active group had more 
severe symptoms pre-tDCS, and 1 study did not provide this information. A numerical 
summary of the component ratings is provided in Table 2.1. Since the high proportion 
of case reports/series notably impacted the results of the quality assessment, average 




Table 2.1 Median and mean component ratings from the EPHPP Quality Assessment 
Tool for Quantitative Studies. 
Component 
Ratings 
All included studies 
(N = 66) 
Excluding case reports/series 
(n = 41) 
Median Mean Median Mean 
Selection Bias 3 2.65 2 2.44 
Study Design 2 2.05 1 1.44 
Confounders 1 1.21 1 1.21 
Blinding 3 2.24 1 1.83 
Data Collection Methods 1 1.08 1 1.12 
Withdrawals and Dropouts 1 1.23 1 1.23 
Global Rating 3 2.35 2 1.93 
 
2.4.3 Study findings 
2.4.3.1 Major depression 
A number of studies have provided evidence that unilateral DLPFC stimulation (anodal 
tDCS to the left DLPFC [l-DLPFC], cathodal tDCS to a contralateral intra- or extra-
cephalic region) can ameliorate symptoms of major depression (Table 2.2). The earliest 
of these were conducted by Fregni and colleagues (Fregni et al., 2006a; Fregni, Boggio, 
Nitsche, Rigonatti, & Pascual-Leone, 2006b) who found that five sessions of sham-
controlled tDCS induced significant improvements in mood (indexed by the Hamilton 
Rating Scale for Depression [HRSD] and the Beck Depression Inventory [BDI]) in two 
small samples of MDD patients (N = 10, N = 18). Their findings were later extended by 
Boggio et al. (2008a) who demonstrated that, in 40 MDD patients, 10 sessions of anodal 
tDCS to the l-DLPFC led to persisting reductions in HRSD and BDI scores when 
compared with both sham tDCS and an active control (anodal tDCS to the occipital 
cortex). Lasting improvements in depressive symptoms following 10 sessions of anodal 
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l-DLPFC tDCS were also recorded in 8 HIV-MDD co-diagnosed individuals (Knotkova 
et al., 2012) and one 92-year-old MDD patient (Shiozawa et al., 2014a).  
 
Other studies of anodal tDCS to the l-DLPFC in major depression have yielded less 
encouraging results. For example, Palm et al. (2009) reported that 16 sessions of tDCS 
did not exert a meaningful therapeutic effect in a patient with treatment-resistant MDD, 
and Wolkenstein and Plewnia (2013) recorded no tDCS-related changes in positive or 
negative affect (indexed by the Positive and Negative Affect Schedule [PANAS]) in 22 
MDD patients following real versus sham tDCS (though a single session protocol was 
used). More ambiguous findings have also been documented: a 2-week course of sham-
controlled tDCS had no effect on clinical depression ratings (HRSD, BDI) but increased 
subjectively-rated positive emotions (according to the PANAS) in 22 participants with 
refractory MDD (n = 20) or BP (n = 2) (Palm et al., 2012). Similarly, whilst 10 sessions 
of sham-controlled twice-daily tDCS did not alleviate symptoms in 23 patients with 
treatment-resistant MDD (indexed by the HRSD, BDI, and Montgomery-Åsberg 
Depression Rating Scale [MADRS]), more participants in the active tDCS group met 
the response and remission criteria immediately, 12 days, and 30 days after treatment 
(Bennabi et al., 2015).  
 
In a parallel group RCT conducted by Loo et al. (2010), comparable reductions in 
depression severity (HRSD, MADRS) occurred following 5 sessions of real and sham 
anodal l-DLPFC tDCS in 35 patients with MDD. Although the authors later recorded a 
reduction in MADRS scores in 58 MDD/BP patients following 15 sessions of sham-
controlled tDCS, this result was clinically modest, the differences did not reach 
significance on any other mood outcome measures, and an equal number of participants 
in the active and sham groups met the response and remission criteria (Loo et al., 2012). 
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Nevertheless, a between-group difference in the proportion of responders became 
apparent after participants (n = 52) received an additional 15 sessions of open-label 
active tDCS: at 1-week and 1-month follow-ups, responder rates were superior in the 
group that had received active treatment throughout (Loo et al., 2012). Interestingly, 11 
participants who showed an inadequate response to, or relapsed following, 3 weeks of 
active tDCS treatment in this study (Loo et al., 2012) subsequently displayed moderate 
clinical improvements after 20 further sessions of open-label tDCS in which the cathode 
was placed extracephalically (over the right upper arm) instead of over the right lateral 
orbit (Martin et al., 2011). Those who met the criterion for response (n = 7), and 19 
responders from the original study (Loo et al., 2012), then received 6 months of 
weekly/fortnightly continuation tDCS and data indicated that the cumulative probability 
of surviving without relapse was 84% at 3 months and 51% at 6 months (Martin et al., 
2013).  
 
In contrast to those described above, a number of studies investigating the effects of 
tDCS in major depression have used bilateral DLPFC modulation (anodal left/cathodal 
right). For example, Ferrucci et al. (2009b) administered 10 sessions of twice-daily 
open-label tDCS to 14 patients with severe, drug-resistant MDD and observed mood 
improvements (HRSD, BDI, self-report visual analogue scales [VASs]) which persisted 
for at least 1 month after the end of treatment. Similarly, Dell'Osso et al. (2012) 
delivered tDCS at the same parameters to 23 poor-responder depressed patients (MDD 
= 15, BP = 8) and noted a clinical benefit that was maintained for at least 3 months in 
half of the sample (Dell'Osso et al., 2014). This protocol (10 sessions of twice-daily 
open-label tDCS) was adopted by three further studies which explored the comparative 
benefits of tDCS in patients with differing clinical profiles (Brunoni et al., 2013a; 
Brunoni et al., 2011b; Ferrucci et al., 2009a). Robust and persisting improvements in 
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depressive symptoms were recorded across a total of 145 individuals with MDD (n = 
112) or BP (n = 33) (Brunoni et al., 2013a; Brunoni et al., 2011b; Ferrucci et al., 
2009a), and whilst the treatment appeared to be equally effective for patients regardless 
of their diagnosis (Brunoni et al., 2013a; Brunoni et al., 2011b), a better response was 
seen in participants with severe MDD than in those with mild/moderate MDD (Ferrucci 
et al., 2009a). Interactions between tDCS and drug therapy were also reported: whereas 
benzodiazepine use was associated with a worse outcome, antidepressants generally 
increased the beneficial effects of tDCS (Brunoni et al., 2013a).   
 
Evidence from a multi-phase trial by Brunoni et al. (2013b) supports the finding that 
bilateral DLPFC tDCS has greater efficacy when administered with antidepressants. 
During phase I, 120 patients with MDD were assigned to 1 of 4 groups: sham 
tDCS/placebo pill (placebo), sham tDCS/sertraline (sertraline-only), active 
tDCS/placebo pill (tDCS-only), or active tDCS/sertraline (combined treatment) (the 
tDCS intervention consisted of 10 consecutive weekday sessions followed by 2 extra 
sessions every other week) (Brunoni et al., 2013b). On the basis of MADRS scores, 
tDCS-only was more effective than placebo, but the combined treatment was superior to 
all other groups (Brunoni et al., 2013b). In phase II of the trial, willing non-responders 
who received sham tDCS in phase I (n = 23) underwent 10 sessions of active tDCS and 
moderate improvements in depressive symptomology were observed (Valiengo et al., 
2013). During phase III, active tDCS responders from phase I and II (n = 42) received 
24 weeks of maintenance treatment and continued to respond for an average of 11.7 
weeks (Valiengo et al., 2013).  
 
Less promising results were obtained by Blumberger, Tran, Fitzgerald, Hoy, and 
Daskalakis (2012), who found that 15 sessions of sham-controlled bilateral DLPFC 
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tDCS did not lower HRSD scores in 24 patients with treatment-resistant MDD. 
Additionally, Shiozawa, da Silva, and Cordeiro (2015) described a patient – with 
inferred right hemispheric dominance – whose depressive symptoms intensified 
(according to HRSD scores) following five sessions of anodal left/cathodal right 
DLPFC tDCS. Brunoni et al. (2014a) showed that in 37 MDD patients, active tDCS (10 
sessions) combined with cognitive control therapy (CCT) was not superior to sham 
tDCS combined with CCT. This is in contrast to a study by Segrave, Arnold, Hoy, and 
Fitzgerald (2014), in which concurrent CCT potentiated antidepressant outcomes 
(MADRS, BDI) from anodal l-DLPFC tDCS (the cathode was placed over the right 
lateral orbit). D'Urso, Mantovani, Micillo, Priori, and Muscettola (2013) also described 
the effects of adjunctive tDCS and cognitive therapy: in a patient with refractory MDD, 
the therapeutic response to 10 sessions of bilateral DLPFC tDCS (indexed by the 
HRSD) was substantially more enduring when the treatment was coupled with weekly 
cognitive behavioural therapy (CBT).  
 
To date, two studies using tDCS to treat major depression have targeted an alternative 
site to the DLPFC. In these open-label trials, improvements in symptoms (indexed by 
the MADRS) were observed following modulation of the fronto-occipital (Ho et al., 




Table 2.2 Studies in patients with major depression (in chronological order). 
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No mention of 
DSM/ICD diagnosis.  
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   Design Stimulation protocol for experimental condition(s)    




















Loo et al. 
(2012) 
[Phase I] 




























only) after active 
versus sham tDCS, 
but an equal number 
of participants in 
each group met the 
criterion for 
response and no 






   Design Stimulation protocol for experimental condition(s)    




















Loo et al. 
(2012) 
[Phase II] 
























27 participants met 
the criterion for 
response post-tDCS. 
There were 22 and 
20 responders at 1-





active or sham tDCS 
in phase I of the trial 
(Loo et al., 2012). The 
group who received 
active tDCS in phase I 
had better responder 
rates after phase II. 
Palm et al. 
(2012) 
























No improvement in 
clinical depression 




after active versus 




   Design Stimulation protocol for experimental condition(s)    


























64 MDD and 
BP 
Exploratory analysis of 
Loo et al. (2012) 
No tDCS performed MADRS Improvement in 
dysphoria and 
retardation after 
active versus sham 
tDCS. 
















2 35 20 mins, 10 
sessions (2 
per day for 5 
consecutive 
days) 
HRSD, BDI Improvement in 
depressive 
symptoms post-
tDCS. Use of 
benzodiazepines 
was associated with 




   Design Stimulation protocol for experimental condition(s)    




















































weeks then 1 















maintained for at 




   Design Stimulation protocol for experimental condition(s)    




















D'Urso et al. 
(2013) 













weeks) x 2 
HRSD Improvement in 
depressive 
symptoms post-
tDCS, only partially 







of symptoms at 12-
month follow-up.  





following 6 months. 
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   Design Stimulation protocol for experimental condition(s)    




















Martin et al. 
(2013) 










2 35 (100 for 
extracephalic 
electrode) 
20 mins (1 per 
week for 3 
consecutive 







After tDCS, half the 
sample survived for 
at least 24 weeks 
without relapse. 
Participants were 
from Loo et al. (2012) 
or Martin et al. 
(2011). Three 
participants 
commenced a new 
antidepressant 







23 MDD Open-label, 
uncontrolled 
















received sham tDCS 
in phase I of 
SELECT-TDCS 




   Design Stimulation protocol for experimental condition(s)    

























42 MDD Open-label, 
uncontrolled 




2 25 30 mins, 9 
sessions (1 
per week for 6 
alternative 
weeks then 1 





After tDCS, half the 
sample survived for 
at least 24 weeks 
without relapse. The 
mean response 




received active tDCS 
in phase I or phase II 
of SELECT-TDCS 
(Brunoni et al., 

















1 35 20 mins, 1 
session 
PANAS No change in 
subjective mood 
state after active 
versus sham tDCS. 
 
Brunoni et 
al. (2014a)  






























   Design Stimulation protocol for experimental condition(s)    




















not superior to sham 
tDCS + CCT. 
Brunoni et 
al. (2014b) 
120 MDD Exploratory analysis of 
Brunoni et al. (2013b) 






after active versus 
sham tDCS. 




23 MDD and 
BP 
Follow-up of Dell'Osso et 
al. (2012), blind-rater 






for at least 3 months 
in half the sample. 
Participants were 




   Design Stimulation protocol for experimental condition(s)    




















Ho et al. 
(2014) 
















2 35 (100/50 
for cathodes) 












Player et al. 
(2014) 








(n = 12) 
(i) tDCS; 
(ii) sham 
















MADRS Improvement in 
depressive 
symptoms after 
sham tDCS, but 
greater 
improvement after 
active tDCS.  
Participants were 
from several different 
trials which varied in 
study design/tDCS 
parameters. Clinical 
results from one 
subject were also 




   Design Stimulation protocol for experimental condition(s)    






































2 35 24 mins, 5 
sessions (1 









maintained for at 
least 3 weeks (BDI-
II scores only). 
Combined 
tDCS/CCT 
treatment was most 
effective but had a 




1 MDD Open-label, 
uncontrolled 














for at least 3 weeks. 




   Design Stimulation protocol for experimental condition(s)    



































2 35 30 mins, 10 
sessions (2 






No improvement in 
depressive 
symptoms after 
active versus sham 
tDCS, but more 
participants in the 




days, and 30 days 
after treatment. 
 
Ho et al. 
(2015) 
4 MDD Open-label, 
uncontrolled 













MADRS Improvement in 
depressive 
symptoms after 
tDCS. At the end of 
treatment, two 
participants met the 
criteria for response 
and one met the 
Participants had 
previously received 
multiple courses of 
tDCS (Chan et al., 
2013; Loo et al., 





   Design Stimulation protocol for experimental condition(s)    
























1 MDD Open-label, 
uncontrolled 




2 35 20 mins, 5 
sessions (1 
per day for 5 
consecutive 
days) 




No mention of 
DSM/ICD diagnosis. 
Patient had right 
hemispheric 
dominance (he was 





BDI, Beck Depression Inventory; BDI-II, Beck Depression Inventory-II; BP, bipolar disorder; BP-II, bipolar II disorder; BP-NOS, bipolar disorder not otherwise specified; BPRS, 
Brief Psychiatric Rating Scale; CCT, cognitive control training; CGI, Clinical Global Impression; CGI-S, Clinical Global Impression - Severity scale; DLPFC, dorsolateral prefrontal 
cortex; DSM, Diagnostic and Statistical Manual of Mental Disorders; HRSD, Hamilton Rating Scale for Depression; ICD, International Classification of Diseases; IDS, Inventory of 
Depressive Symptomatology; MADRS, Montgomery–Åsberg Depression Rating Scale; MADRS-SR, Montgomery–Åsberg Depression Rating Scale - Self-Report; MDD, major 
depressive disorder; PANAS, Positive and Negative Affect Schedule; PGI-I, Patient Global Impression of Improvement; QIDS-C, Quick Inventory of Depressive Symptomatology - 
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Clinician Rating; QIDS-SR, Quick Inventory of Depressive Symptomatology - Self-Report; SELECT-TDCS, The sertraline versus electrical current therapy for treating depression 
clinical study; tDCS, transcranial direct current stimulation; VAS, visual analogue scale.  




Studies examining the clinical effects of tDCS in schizophrenia have mostly employed 
an electrode montage in which the anode is placed over the l-DLPFC and the cathode is 
positioned over the left temporoparietal junction (l-TPJ). This set-up appears to have 
been consistently successful in ameliorating symptoms of the illness; for example, 
Brunelin et al. (2012a) demonstrated that in 30 patients, 10 sessions of twice-daily 
sham-controlled tDCS robustly reduced auditory verbal hallucinations (AVHs; indexed 
by the Auditory Hallucination Rating Scale [AHRS]) acutely and at 3-month follow-up. 
Improvements in other schizophrenic symptoms, according to the total Positive and 
Negative Syndrome Scale (PANSS) score, were also recorded (Brunelin et al., 2012a). 
Mondino, Haesebaert, Poulet, Suaud-Chagny, and Brunelin (2015c) administered the 
same treatment protocol to a group of 28 patients, 15 of whom had previously taken part 
in the aforementioned study (Brunelin et al., 2012a), and also observed a large decrease 
in treatment-resistant AVH frequency in the active versus sham tDCS group.  
 
Additional evidence of efficacy for this tDCS montage and protocol (10 twice-daily 
sessions, anode l-DLPFC/cathode l-TPJ) comes from three further open-label trials in 
which a total of 60 schizophrenic patients with persistent auditory hallucinations (AHs) 
presented significant reductions in Psychotic Symptoms Rating Scales 
(PSYRATS)/AHRS scores following treatment (Bose et al., 2014; Brunelin, Hasan, 
Haesebaert, Nitsche, & Poulet, 2015; Shivakumar et al., 2015). While all participants 
experienced improvements, being a non-smoker (Brunelin et al., 2015) and carrying a 
particular variant of a neuroplasticity-related gene (catechol-O-methyltransferase 
[COMT]) (Shivakumar et al., 2015) were both associated with having a greater 
therapeutic response. A number of case reports/series describing patients with refractory 
schizophrenia have also offered support (Brunelin et al., 2012b; Jacks, Kalivas, 
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Mittendorf, Kindt, & Short, 2014; Narayanaswamy et al., 2014; Nawani et al., 2014a; 
Nawani et al., 2014b; Rakesh et al., 2013; Shenoy et al., 2015; Shivakumar et al., 2014). 
For instance, Shenoy et al. (2015) recorded near-total improvement of the exacerbation 
of AVHs during pregnancy, Narayanaswamy et al. (2014) noted a delayed but persistent 
improvement in negative symptoms, and Rakesh et al. (2013) observed complete 
cessation of AVHs immediately after the first two tDCS sessions and at post-
intervention re-assessment. Shivakumar et al. (2014) also witnessed a tDCS-induced 
termination of AVHs, and subsequently found that application of intermittent booster 
tDCS (6 sessions) resulted in sustained improvements for a period of one year.  
 
Less positive results were obtained in one case report of a patient presenting with 
severe, treatment-resistant symptoms who received a higher acute dose of tDCS (20 
twice-daily sessions, anode l-DLPFC/cathode l-TPJ) but did not show any clinical gains 
(Shiozawa et al., 2014d). In addition, although Praharaj, Behere, and Sharma (2015) did 
observe a reduction of AHs in a patient with treatment-resistant schizophrenia following 
10 sessions of tDCS, PSYRATS scores returned to baseline levels six days later. 
Interestingly, Bose et al. (2015) documented a lack of clinical response to 18 twice-
daily sessions of anode l-DLPFC/cathode l-TPJ tDCS in a patient with treatment 
resistant AVHs; however, significant improvements in symptoms (indexed by the 
PSYRATS) were subsequently recorded after an additional 20 sessions in which the 
electrodes were placed at homologous sites on the right side of the brain.  
 
Shiozawa, da Silva, Cordeiro, Fregni, and Brunoni (2013b) conducted a case study of 
tDCS in patients with long-term, refractory schizophrenia, opting for a unique protocol 
targeted at the selective improvement of visual hallucinations (VHs) and AHs. Twenty 
sessions of tDCS were performed in two blocks with a 5-day interval between: for the 
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first 10 sessions, the cathode was placed over the occipital area (to hypothetically 
inhibit VHs) and for the remaining 10 sessions over the l-TPJ (to hypothetically inhibit 
AHs) (Shiozawa et al., 2013b). The anode was positioned over the l-DLPFC throughout 
(Shiozawa et al., 2013b). Although a transitory increase in hallucinations was observed 
during the period of stimulation, this was followed by a reduction in VHs and AHs 
(assessed with the Launay Slade Hallucination Scale [LSHS] and the AHRS, 
respectively), as well as marked improvements in other positive, negative, and general 
symptoms (indexed by the PANSS) (Shiozawa et al., 2013b).  
 
A number of other electrode montages have also been trialled for the treatment of 
schizophrenia, and findings have been mixed. For example, Palm et al. (2013) observed 
considerable improvement in positive and negative symptoms (using several clinical 
assessment tools) following a 2-week course of anodal tDCS to the l-DLPFC (the 
cathode was placed over the right supraorbital area) in a patient with refractory 
schizophrenia. In contrast, 29 patients who received 5 sessions of sham-controlled tDCS 
at the same parameters experienced no clinical benefits (indexed by the PANSS and the 
PSYRATS) (Smith et al., 2015). Shiozawa, da Silva, Cordeiro, Fregni, and Brunoni 
(2013a) described a treatment-resistant patient who achieved complete remission from 
catatonic symptoms (indexed by the Bush–Francis catatonic scale) in response to 10 
sessions of tDCS over the bilateral DLPFC (anodal left/cathodal right). Gomes et al. 
(2015) later replicated this protocol in an RCT of 15 participants and correspondingly 
found a reduction in negative symptoms (according to the PANSS) after active versus 
sham tDCS. Although no effects were reported for positive symptoms, the real tDCS 
group had higher scores on the positive subscale of the PANSS at baseline. An 
improvement in negative but not positive symptoms was also demonstrated by 9 further 
patients following 10 sessions of anodal l-DLPFC tDCS (with the cathode placed 
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extracephalically) (Kurimori, Shiozawa, Bikson, Aboseria, & Cordeiro, 2015). Finally, 
Homan et al. (2011) showed that 10 sessions of cathodal stimulation over Wernicke’s 
area (the anode was positioned over the right supraorbital area) led to persisting 
reductions in AVHs and other symptoms (indexed by the Hallucination Change Scale, 
PANSS, and the PSYRATS) in a patient with treatment-resistant schizophrenia.  
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Table 2.3 Studies in patients with schizophrenia (in chronological order). 
    Design Stimulation protocol for experimental condition(s)       





























1 35 15 mins, 10 
sessions (1 per 






Reduction in AVH and 
improvement in other 
schizophrenic 
symptoms post-tDCS, 
maintained for at least 
6 weeks. 
No mention of 
DSM/ICD diagnosis. 




(i) tDCS Left 
DLPFC 
Left TPJ 2 - 20 mins, 10 
sessions (2 per 





Reduction in AH and 
improvement in other 
schizophrenic 
symptoms post-tDCS, 
maintained for at least 
3 months. 
 











Left TPJ 2 35 20 mins, 10 
sessions (2 per 





Reduction in AVH 
(maintained for at least 
3 months) and 
improvement in other 
schizophrenic 
symptoms after active 




    Design Stimulation protocol for experimental condition(s)       





























2 - 20 mins, 10 
sessions (1 per 















(i) tDCS Left 
DLPFC 
Left TPJ 2 35 20 mins, 10 
sessions (2 per 
day for 5 
consecutive 
days) 
AHRS Complete cessation of 
AVH post-tDCS. 
 









2 - 20 mins, 20 
sessions (1 per 
day for 10 
consecutive 
days, 5 day 
break, then 1 






during tDCS, followed 
by reduction post-
tDCS, in AH and VH, 
maintained for at least 
2 months, and 
improvement in other 
schizophrenic 
symptoms after tDCS. 




    Design Stimulation protocol for experimental condition(s)       




























2 35 20 mins, 10 
sessions (1 per 
day for 10 
consecutive 
days) 
BFCRS Improvement in 
catatonic symptoms 
during tDCS treatment 
course. Patient was 
asymptomatic at 4-
month follow-up. 
No mention of 
DSM/ICD diagnosis. 




(i) tDCS Left 
DLPFC 
Left TPJ 2 35 20 mins, 10 
sessions (2 per 





Reduction in AH post-
tDCS. 
 




(i) tDCS Left 
DLPFC 
Left TPJ 2 - 20 mins, 10 
sessions (2 per 
day for 5 
consecutive 
days) 
PANSS Improvement in 






tDCS, but no change in 
positive or negative 
Participant received an 
acute course of ECT 
plus weekly 
maintenance sessions 
for several months prior 




    Design Stimulation protocol for experimental condition(s)       























et al. (2014) 
1 Open-label, 
uncontrolled 
(i) tDCS Left 
DLPFC 
Left TPJ 2 - 20 mins, 10 
sessions (2 per 






in negative symptoms 
and small reduction in 
AVH, maintained for at 
least 6 months.  
 




(i) tDCS Left 
DLPFC 
Left TPJ 2 - 20 mins, 10 
sessions (2 per 
day for 5 
consecutive 
days) 
AHRS Reduction in AVH 
post-tDCS. 
 




(i) tDCS Left 
DLPFC 
Left TPJ 2 - 20 mins, 10 
sessions (2 per 
day for 5 
consecutive 
days) 





    Design Stimulation protocol for experimental condition(s)       
























(i) tDCS Left TPJ Right TPJ 2 35 20 mins, 10 
sessions (1 per 
day for 10 
consecutive 
days) 
PANSS No improvement in 
schizophrenic 
symptoms post-tDCS. 






(i) tDCS Left 
DLPFC 
Left TPJ 2 - 20 mins, 10 
sessions (2 per 
day for 5 
consecutive 









Complete cessation of 
AVH after acute course 
of tDCS, maintained 
for 3 months. Booster 
tDCS sessions 
controlled 3 subsequent 
relapses over 1 year. 
Participant was free of 





    Design Stimulation protocol for experimental condition(s)       



































2 35 (i) 20 mins, 18 
sessions (2 per 
day for 9 
consecutive 
days); (ii) 20 
mins, 20 
sessions (2 per 





No improvement in 
schizophrenic 
symptoms after left-
sided tDCS, but 
reduction in AH after 
right-sided tDCS. 
Electrode positioning 
was modified due to 
lack of clinical 
response.  




(i) tDCS Left 
DLPFC 




AHRS Reduction in AH post-
tDCS. 
Patients with a 
comorbid tobacco use 
disorder (n = 10) were 
less responsive to 
tDCS. 













2 - 20 mins, 10 
sessions (1 per 
weekday for 2 
consecutive 
weeks) 
PANSS Improvement in 
negative but not 
positive symptoms 
after active versus 
sham tDCS. 
At baseline, the tDCS 
group had higher 
PANSS scores for the 
positive scale relative to 
the sham tDCS group. 
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    Design Stimulation protocol for experimental condition(s)       




























2 - 20 mins, 10 
sessions (1 per 
weekday for 2 
consecutive 
weeks) 
PANSS Improvement in 
negative but not 
positive symptoms 
post-tDCS. 
No mention of 
DSM/ICD diagnosis. 











Left TPJ 2 35 20 mins, 10 
sessions (2 per 





Reduction in AVH 
after active versus 
sham tDCS. 
No mention of 
DSM/ICD diagnosis. 15 
participants were from 
Brunelin et al. (2012a). 
AVH frequency method 
of assessment not 
stated.  




(i) tDCS Left 
DLPFC 
Left TPJ 2 25 20 mins, 5 
sessions (1 per 





Reduction in AH post-
tDCS, but symptoms 
returned to baseline 
levels 6 days after 
treatment. 




    Design Stimulation protocol for experimental condition(s)       
























(i) tDCS Left 
DLPFC 
Left TPJ 2 - 20 mins, 10 
sessions (2 per 
day for 5 
consecutive 
days) 
AHRS Reduction in AVH 
post-tDCS, with further 
improvement for at 
least 1 month.  
Participant was 
pregnant, and received 
tDCS treatment 
previously (reference 






(i) tDCS Left 
DLPFC 
Left TPJ 2 35 20 mins, 10 
sessions (2 per 





Reduction in AH post-
tDCS. 
Allelic variations in the 
COMT gene influenced 
the clinical efficacy of 
tDCS. 














2 5.08 20 mins, 5 
sessions (1 per 
day for 5 
consecutive 




No improvement in 
schizophrenic 
symptoms after active 
versus sham tDCS. 
  
 
AH, auditory hallucinations; AHRS, Auditory Hallucination Rating Scale; AHS, Auditory Hallucinations Subscale; AVH, auditory verbal hallucinations; BFCRS, Bush-Francis 
Catatonia Rating Scale; CDSS, Calgary Depression Scale for Schizophrenia; COMT, Catechol-O-methyltransferase; DLPFC, dorsolateral prefrontal cortex; DSM, Diagnostic and 
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Statistical Manual of Mental Disorders; ECT, electroconvulsive therapy; HCS, Hallucination Change Scale; ICD, International Classification of Diseases; LHS, Launay Slade 
Hallucination Scale; PANSS, Positive And Negative Syndrome Scale; PSYRATS, Psychotic Symptom Rating Scales; SANS, Scale for the Assessment of Negative Symptoms; 
tDCS, transcranial direct current stimulation; TPJ, temporo-parietal junction; VH, visual hallucinations.  
a N refers to the number of participants whose data was included at the final stage of analysis.
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2.4.3.3 Substance use disorders 
The literature on the clinical utility of tDCS for treating SUDs consists of a small 
number of RCTs which have generated mixed results. Boggio et al. (2008b) were the 
first to publish data here: in a group of 13 participants with alcohol dependence, one 
session of tDCS to the bilateral DLPFC (either anodal left/cathodal right or anodal 
right/cathodal left) was shown to decrease alcohol craving (indexed by the Alcohol 
Urge Questionnaire [AUQ]) relative to sham stimulation. Interestingly, Klauss et al. 
(2014) found that a higher dose of bilateral DLPFC tDCS (10 twice-daily sessions) did 
not diminish craving (assessed with the Obsessive Compulsive Drinking Scale [OCDS]) 
but reduced relapse probability in 33 alcohol dependent individuals (Klauss et al., 
2014). A dissociation between levels of craving and the likelihood of relapse to alcohol 
use was also reported by da Silva et al. (2013): 13 alcoholics received 5 weekly sessions 
of sham-controlled unilateral DLPFC stimulation (anode over the l-DLPFC, cathode 
over the right supradeltoid area) and, although the treatment suppressed cravings 
(indexed by the OCDS), there was an unexpected trend for more relapses in the active 
versus sham tDCS group. The same electrode montage was adopted in a single-session 
trial involving 49 alcohol-dependent patients in which no anti-craving effects were 
observed (Nakamura-Palacios et al., 2012).  
 
Three studies examining the therapeutic potential of tDCS in individuals addicted to 
substances other than alcohol have been conducted. In the first, Shahbabaie et al. (2014) 
provided evidence suggesting that tDCS has a state-dependent effect on craving in 
methamphetamine (mAMP) users. Thirty patients underwent one session of sham-
controlled anodal tDCS over the right DLPFC (r-DLPFC) (the cathode was placed over 
the left supraorbital area) and, while active tDCS acutely reduced craving at rest, it 
increased craving during mAMP-related cue exposure. In the second, Conti, Moscon, 
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Fregni, Nitsche, and Nakamura-Palacios (2014) administered 5 sessions of real or sham 
bilateral DLPFC stimulation (anodal right/cathode left) to 13 crack-cocaine addicted 
individuals and observed a higher percentage of abstinence at 3-month follow-up in 
those assigned to the real tDCS group. This study was later replicated using a larger 
group of patients (n = 36), whose crack-cocaine cravings were suppressed for at least 




Table 2.4 Studies in patients with substance use disorders. 
      Design Stimulation protocol for experimental condition(s)       













































2 35 20 mins, 1 
session 
AUQ Reduction in alcohol 
craving after anode 
left/cathode right tDCS 
and anode 
right/cathode left tDCS 
versus sham tDCS. 
Alcohol craving could 
not be increased by 
alcohol cues after 




















1 35 10 mins, 1 
session 
OCDS No reduction in alcohol 
craving after active 
versus sham tDCS. 
Alcohol 





      Design Stimulation protocol for experimental condition(s)       




































2 35 20 mins, 5 
sessions (1 per 







Reduction in alcohol 
craving after active 
versus sham tDCS, but 
trend for relapse during 
treatment in active 
tDCS group. 
 















2 35 13 mins, 10 
sessions (2 per 









No reduction in alcohol 
craving after active 
versus sham tDCS, but 
patients in the active 
tDCS group were more 
likely to survive for at 
least 6 months without 
relapse. 
Alcohol 



























Reduction in mAMP 
craving at rest, but 
increase in cue-induced 
craving, during active 
versus sham tDCS.  





      Design Stimulation protocol for experimental condition(s)       




































2 35 20 mins, 5 
sessions (1 per 






differences in relapse 
rates during the 
treatment period. At 3-
month follow-up, more 
participants in the real 




Only 50% of 
participants in 





86% in the real 
group).  
















2 35 20 mins, 5 
sessions (1 per 











cocaine craving after 
active versus sham 
tDCS, maintained for at 




AUQ, Alcohol Urge Questionnaire; CICT, Computerised Cue-Induced Craving Assessment Task; DLPFC, dorsolateral prefrontal cortex; mAMP, methamphetamine; OCDS, 
Obsessive Compulsive Drinking Scale; tDCS, transcranial direct current stimulation; VAS, visual analogue scale.  
a N refers to the number of participants whose data was included at the final stage of analysis.
147 
 
2.4.3.4 Other psychiatric disorders 
Limited data exist on the clinical efficacy of tDCS in other psychiatric disorders; 
however, some promising results have been reported. For example, Shiozawa et al. 
(2014c) described the case of a patient with treatment-resistant GAD who underwent a 
three-week course of cathodal r-DLPFC tDCS (the anode was placed over the left 
deltoid) and was asymptomatic both acutely and at one-month follow-up. Additionally, 
Khedr, Elfetoh, Ali, and Noamany (2014) showed that 10 sessions of anodal stimulation 
over the l-DLPFC (the cathode was positioned over the right arm) relieved eating 
disorder symptoms in 5 of 7 AN patients and, furthermore, 4 participants maintained 
these improvements for at least 1 month after the end of treatment.  
 
Mondino, Haesebaert, Poulet, Saoud, and Brunelin (2015b) demonstrated that 10 
sessions of twice-daily cathodal tDCS over the left OFC (the anode was positioned over 
the right occipital cortex) induced delayed but lasting reductions in Yale-Brown 
Obsessive Compulsive Scale (Y-BOCS) scores in a patient with treatment-resistant 
OCD. Sustained symptom improvements were also recorded in two patients with drug-
resistant OCD, following 20 sessions of twice-daily anodal tDCS over the left pre-
SMA/SMA (the cathode was placed over the right supraorbital area) (Narayanaswamy 
et al., 2015). Interestingly, D'Urso et al. (2015) found that a two-week course of anodal 
tDCS over the same region (with the cathode placed extracephalically) exacerbated a 
patient’s OCD symptoms. The electrodes were then inverted for a further 10 sessions, 
which reduced Y-BOC scores (beyond baseline levels) for at least 3 months post-
treatment (D'Urso et al., 2015). Lastly, Volpato et al. (2013) administered 10 sessions of 
cathodal l-DLPFC tDCS (with the anode placed over the posterior neck base) to a 
patient with severe and enduring OCD and, although the intervention had no effect on 
OCD-specific symptoms (indexed by the Y-BOCS), it improved the patient’s comorbid 
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anxiety and depression (assessed with the Hamilton Rating Scale for Anxiety [HRSA] 
and the HRSD, respectively). 
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Table 2.5 Studies of patients with other psychiatric disorders (obsessive compulsive disorder, generalised anxiety disorder, and anorexia nervosa). 
   Design Stimulation protocol for experimental condition(s)    






































2 35 20 mins, 10 
sessions (1 per 






No improvement in 
OCD symptoms, but 
improvement in 
depression and 
anxiety, after real 
versus sham tDCS.  
  
Shiozawa et al. 
(2014c) 
1 GAD Open-label, 
uncontrolled 
(i) tDCS Left deltoid Right 
DLPFC 
2 25 30 mins, 15 
sessions (1 per 











tDCS and at 1-month 
follow-up. 





   Design Stimulation protocol for experimental condition(s)    




















Khedr et al. 
(2014) 
7 AN Open-label, 
uncontrolled 
(i) tDCS Left 
DLPFC 
Right arm 2 24 (100 for 
extracephalic 
electrode) 
25 mins, 10 
sessions (1 per 
weekday for 2 
consecutive 
weeks) 
EAT, EDI Improvement in 
eating disorder 
symptoms post-
tDCS, maintained for 
at least 1 month. 
Large variability in 
responses.  
 
D'Urso et al. 
(2015) 














2 25 20 mins, 20 
sessions (1 per 
weekday for 4 
consecutive 
weeks) 
Y-BOCS Worsening and 
improvement of OCD 
symptoms after 
anodal and cathodal 
tDCS, respectively. 
Overall reduction in 
symptoms at the end 
of treatment, 
maintained for at 
least 3 months. 









   Design Stimulation protocol for experimental condition(s)    
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day for 10 
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AN, anorexia nervosa; BAI, Beck Anxiety Inventory; DLPFC, dorsolateral prefrontal cortex; DSM, Diagnostic and Statistical Manual of Mental Disorders; EAT, Eating Attitudes 
Test; EDI, Eating Disorder Inventory; GAD, generalised anxiety disorder; GAD-7, Generalised Anxiety Disorder 7-item scale; HRSA, Hamilton Rating Scale for Anxiety; HRSD, 
Hamilton Rating Scale for Depression; ICD, International Classification of Diseases; MDD, major depressive disorder; OCD, obsessive compulsive disorder; OFC, orbitofrontal 
cortex; rTMS, repetitive transcranial magnetic stimulation; SMA, supplementary motor area; tDCS, transcranial direct current stimulation; Y-BOCS, Yale-Brown Obsessive 
Compulsive Scale. 




2.5.1 Clinical efficacy 
This review provides evidence that tDCS has the potential to ameliorate symptoms 
associated with several major psychiatric disorders. Most notably, data from a number 
of RCTs suggest that tDCS interventions comprised of multiple sessions can induce 
enduring therapeutic effects in patients with depressive disorders and schizophrenia. 
Further indication of clinical utility in these conditions has come from numerous open-
label trials and case reports, often involving patients who have experienced dramatic 
improvements and, in some instances, achieved full remission following treatment with 
tDCS. Although research in other mental disorders is somewhat limited, several RCTs 
support the prospective application of tDCS in SUDs, and emerging data from a small 
number of patients indicate that tDCS can induce significant clinical gains in people 
with OCD, GAD, and AN.  
 
Despite evidence that tDCS offers exciting possibilities for treatment development in 
psychiatry, symptom improvements have been modest or absent in a considerable 
number of studies. Furthermore, a small number of publications have reported a tDCS-
induced exacerbation of symptoms. Multiple factors are likely to contribute to the 
variability of response in tDCS studies, and these are discussed in turn below.  
 
2.5.1.1 Patient characteristics 
A number of inter- and intra-individual biological, psychological, and lifestyle factors 
appear to influence the clinical efficacy of tDCS. First, differences in genotype have 
been linked to altered tDCS responding, possibly via impact on anatomical and 
neurophysiological states. Shivakumar et al. (2015), for example, showed that a 
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polymorphism at the neuroplasticity-related COMT gene moderated the therapeutic 
effects of tDCS in a group of patients with schizophrenia. Second, the psychological 
state of participants at the time of stimulation seems to play a role: in SUD, prefrontal 
tDCS has been found to intensify cravings if those receiving it are in the presence of 
drug-related cues (Shahbabaie et al., 2014). Third, nicotine smoking has been associated 
with reduced clinically efficacy of tDCS in patients with schizophrenia (Brunelin et al., 
2015). This may explain the negative results reported by Smith et al. (2015), since all 
participants in this study were regular smokers. Fourth, illness severity has been 
identified as a predictor of response to tDCS: Ferrucci et al. (2009a) observed a greater 
therapeutic effect for severe MDD than for mild/moderate MDD.  
 
It has been proposed that degree of treatment-resistance may also influence clinical 
outcomes of tDCS (Brunoni & Fregni, 2011; Mondino et al., 2014), although this factor 
has not been explicitly investigated and studies of patients with treatment-resistant 
disorders have produced both negative (e.g., Bennabi et al., 2015; Blumberger et al., 
2012; Palm et al., 2012) and positive (e.g., Dell'Osso et al., 2012; Ferrucci et al., 2009b; 
Palm et al., 2013) results. Nevertheless, close attention must be paid to the definition of 
treatment-resistance because, in some instances, studies with negative results 
(Blumberger et al., 2012; Palm et al., 2012) have used more stringent refractoriness 
criteria than those with positive ones (Dell'Osso et al., 2012). 
 
2.5.1.2 Concomitant therapy 
The medication status of patients varied significantly both within and between studies 
included in this review. In some cases, tDCS was administered as an “add-on” therapy 
to a stable dose of medication (e.g., Bose et al., 2014), while other studies excluded 
participants taking any neuropsychotropic drugs (e.g., Boggio et al., 2008b), included a 
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mix of medicated and non-medicated patients (e.g., Loo et al., 2010), or failed to 
address concomitant pharmacotherapy at all (e.g., da Silva et al., 2013). Evidence 
indicates that particular psychoactive substances can interact with the effects of tDCS; 
specifically, benzodiazepines have been reported to hinder therapeutic effects, whereas 
antidepressants have been associated with enhanced outcomes (Brunoni et al., 2013a; 
Brunoni et al., 2013b). Crucially, three studies which found tDCS to be clinically 
ineffective permitted benzodiazepine use during the trial (26-33% of patients were 
taking benzodiazepines) (Bennabi et al., 2015; Blumberger et al., 2012; Brunoni et al., 
2014a), and one study which found tDCS to be effective tolerated antidepressant but not 
benzodiazepine use (52% of patients were taking antidepressants) (Segrave et al., 2014). 
Nonetheless, Boggio et al. (2008a) used opposing eligibility criteria – allowing 
benzodiazepine but not antidepressant use – and still observed positive effects. 
Cognitive-based therapies can also influence clinical outcomes from tDCS (D'Urso et 
al., 2013; Segrave et al., 2014); however, information regarding the use of concurrent 
non-pharmacological treatments was seldom provided.  
 
2.5.1.3 Parameters of stimulation 
tDCS interventions varied extensively between the reviewed studies according to a 
range of parameters, such as electrode size and positioning, current amplitude, duration 
of stimulation, and number and frequency of sessions (see Tables 2.2-2.5). Considerable 
heterogeneity was even present among studies attempting to treat the same psychiatric 
disorder. Unsurprisingly, results from several investigations suggested that the number 
of sessions administered, the placement of the reference electrode, and the 
anode/cathode polarity moderate the therapeutic effects of tDCS (Bose et al., 2015; 
D'Urso et al., 2015; Loo et al., 2012; Loo et al., 2010; Martin et al., 2011). Most 
notably, D'Urso et al. (2015) demonstrated that 10 sessions of anodal tDCS applied to 
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the pre-SMA led to an exacerbation of symptoms in a patient with OCD; however, 
when the polarity of the electrodes was inverted (for a further 10 sessions of tDCS), 
significant and persisting improvements beyond baseline levels were observed.  
 
2.5.1.4 Study design 
This review incorporated studies of varying design. Interestingly, the majority of studies 
with negative results were RCTs (e.g., Blumberger et al., 2012; Klauss et al., 2014; Loo 
et al., 2012; Nakamura-Palacios et al., 2012; Palm et al., 2012; Smith et al., 2015), 
which raises the possibility of a placebo effect. Indeed, sham tDCS frequently exerts 
some degree of influence over outcomes; however, the improvements observed in open-
label investigations are unlikely to be the result of placebo mechanisms alone since 
many of the patients involved in these studies were treatment-resistant, and 
refractoriness is associated with lower placebo responding (Brunoni, Lopes, Kaptchuk, 
& Fregni, 2009). It should also be noted that publication bias – in which research with 
unfavourable results has a lower probability of being published – is more likely to affect 
open-label, uncontrolled studies than RCTs (Easterbrook, Gopalan, Berlin, & Matthews, 
1991). Thus, the higher proportion of RCTs with negative results may be, at least in 
part, an artefact of such bias.  
 
2.5.2 Safety issues and ethical considerations 
Administration of tDCS interventions that comply with recommended safety regulations 
(current: < 2.5 mA, duration: 20-60 min per session, frequency: ≤ twice per day, 
application: with electrodes that minimise skin burns) (Fregni et al., 2015) has presented 
minimal risk across a wide range of participants. Only mild and transient side-effects – 
such as itching, tingling, and headache – have been reported (Brunoni et al., 2011a), 
leading to the conclusion that tDCS is a relatively safe procedure. However, the absence 
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of serious adverse events is not irrefutable evidence that the technique is unequivocally 
benign, and a number of ethical and safety issues remain (Fitz & Reiner, 2015; Kadosh, 
Levy, O'Shea, Shea, & Savulescu, 2012; Widdows & Davis, 2014).  
 
Firstly, Brunoni et al. (2011a) argue that adverse events are being neglected in tDCS 
research, possibly due to a subjective belief that the technique raises negligible safety 
concerns. In their systematic review of 209 tDCS clinical trials, 92 studies did not report 
the presence and/or absence of adverse effects, which the authors interpret as evidence 
of selective reporting bias (Brunoni et al., 2011a). Secondly, despite knowledge that 
stimulation of one particular cortical site can alter activation and connectivity in regions 
distal to the electrodes, the nature of the functional networks associated with the target 
brain areas seems to have little influence in the design of tDCS experiments (Wokke, 
Talsma, & Vissers, 2014). Data suggest that cognitive enhancement mediated by tDCS 
can occur at the expense of other cognitive functions (Iuculano & Cohen Kadosh, 
2013), yet the potential for collateral behavioural impairments arising from the use of 
tDCS in psychiatric research has been largely overlooked. Our incomplete 
understanding of the neural bases of mental disorders and the resultant lack of any 
standardised stimulation guidelines pose risks for the occurrence of unintended and 
undesirable effects. Thirdly, Widdows and Davis (2014) point out that qualitative 
differences in anatomy are sometimes seen in people with mental illness compared to 
healthy controls; for example, patients with eating disorders have shown low levels of 
subcutaneous adipose tissue around the head and altered cortical folding. These factors 
are likely to have an impact on the effects of tDCS-induced electrical currents, therefore 
extra caution ought to be exercised in such patient groups (Widdows & Davis, 2014). 
Lastly, tDCS has recently garnered considerable ‘neurohype’ in the media as a portable, 
painless, inexpensive, and safe therapeutic device. This positive portrayal has the 
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potential to shape the public’s risk-benefit perceptions, promote a therapeutic 
misconception, and have an impact on the uptake of this technology (Dubljević, Saigle, 
& Racine, 2014). Without some degree of ‘neuromodesty’ (Morse, 2012), desperate and 
vulnerable mentally ill patients may overestimate the benefits and underestimate the 
risks of tDCS.  
 
2.5.3 Conclusions and future directions 
Research into the clinical efficacy of tDCS in psychiatric disorders has grown 
exponentially over the past decade. We have systematically reviewed the literature and 
have provided an objective and analytical account of its current state. Overall, data from 
studies appraised in this review suggest that tDCS has the potential to induce clinically 
relevant behavioural changes in often difficult-to-treat patient populations, and could 
thus represent a valuable tool for intervention in a range of mental disorders. 
Nevertheless, the use of tDCS for treating psychiatric disorders is still in its infancy, and 
further evidence of its efficacy from large-scale, multi-centred RCTs is required if the 
transition of this therapy from the laboratory to the clinic is to be considered. Indeed, 
the approval of repetitive transcranial magnetic stimulation (a related non-invasive 
neuromodulation technique) as a second-line treatment for major depression in several 
countries was preceded by extensive sham-controlled investigations (Dell’Osso & 
Altamura, 2014). It is also essential that steps are taken to resolve the discrepancies in 
clinical findings; for example, sample variability should be controlled and reproducible 
stimulation parameters should be defined in terms of optimising therapeutic response 
for different clinical applications. A better understanding of the neural responses to 
tDCS will accelerate progress here, and is likely to arise through combined tDCS-
neuroimaging experiments (Venkatakrishnan & Sandrini, 2012) and computational 
neurostimulation approaches (de Berker, Bikson, & Bestmann, 2013). Finally, all 
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investigators conducting research with tDCS should be mindful of the various safety 
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Obesity and eating disorders, such as bulimia nervosa (BN) and binge-eating disorder 
(BED), can be conceptualised as forms of addiction. Food cravings are thought to 
precipitate the compulsive overeating that is seen in these conditions. Transcranial 
direct current stimulation (tDCS) has been used to suppress food cravings, but there is 
insufficient evidence to support its application in clinical practice. Furthermore, the 
potential moderating role of impulsivity has not been considered. This study employed a 
randomised within-subjects crossover design to examine whether a 20-minute session of 
placebo-controlled bilateral tDCS to the dorsolateral prefrontal cortex (DLPFC) (anode 
right/cathode left) would transiently modify food cravings and temporal discounting 
(TD; a measure of choice impulsivity) in 17 healthy women with frequent food 
cravings. Whether the effects of tDCS on food cravings were moderated by individual 
differences in TD behaviour was also explored. Participants were exposed to real food 
and to a film of people eating, and food cravings and TD were assessed before and after 
active and sham stimulation. Craving for sweet but not savoury foods was reduced 
following real tDCS. In addition, participants who exhibited more reflective choice 
behaviour were more susceptible to the anti-craving effects of tDCS than those who 
displayed more impulsive choice behaviour. No differences were seen in TD or actual 
food consumption after real versus sham tDCS. These findings support the efficacy of 
tDCS interventions in temporarily lowering food cravings and identify the moderating 





It has been proposed that certain foods – particularly those high in sugar – are addictive, 
and that obesity and eating disorders, such as bulimia nervosa (BN) and binge-eating 
disorder (BED), can be conceptualised as forms of addiction (Avena et al., 2009). Food 
cravings (intense urges to consume particular foods) are thought to precipitate the 
compulsive overeating that characterises these conditions, and have been positively 
associated with binge-eating (Ng & Davis, 2013), daily calorie intake (Lafay et al., 
2000), BMI (Franken & Muris, 2005), daytime sleep (Landis et al., 2009), and dieting 
failure (Meule et al., 2011). There is also evidence that excessive craving for sweet 
foods is associated with drug and alcohol abuse (for a review see Pelchat, 2002).  
 
Extensive behavioural and neurobiological data indicate many commonalities between 
food craving and drug craving (for a review see Pelchat, 2009). For instance, both lead 
to foraging and ingestion habits that persist and strengthen despite the threat of negative 
health and social consequences (Volkow & Wise, 2005) and, furthermore, cravings can 
predict both relapse to drug taking in abstinent substance users (Rosenberg, 2009) and 
weight regain after bariatric surgery in obese patients (Odom et al., 2010). The 
neurotransmitter systems implicated in food craving overlap substantively with those 
involved in drug craving; for example, exposure to both food and drug craving-
provoking stimuli is associated with increased levels of reward circuitry dopaminergic 
activation in the brain (Blum et al., 2011). Food craving and drug craving are also 
mediated by shared functional neuroanatomy. Several brain regions appear to be 
involved (for a review see Tang et al., 2012), but most data suggest that the left, right, 
or bilateral dorsolateral prefrontal cortex (DLPFC; an area in the prefrontal cortex 
important for executive functioning) is activated in response to cues that induce both 
food (Siep et al., 2009; Gearhardt et al., 2011) and drug cravings (Maas et al., 1998; 
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Bonson et al., 2002; Hayashi et al., 2013). The level of cue-elicited prefrontal activation 
can predict prospective food intake (Cornier et al., 2010) and drug use (Grüsser et al., 
2004), and appears to be altered in compulsive overeaters (Schienie et al., 2009) and 
drug-addicted individuals (Wexler et al., 2001; Yalachkov et al., 2009) compared with 
healthy controls. A deficiency in the prefrontal cortical inhibitory networks might 
therefore contribute to the pathophysiology of disordered eating and substance use 
disorders.  
 
A growing number of studies have sought to directly manipulate DLPFC activation as a 
means of reducing cravings. Two non-invasive brain stimulation (NIBS) methods have 
been used, both of which are well-tolerated, have minimal side effects, and do not 
require surgical procedures. Repetitive transcranial magnetic stimulation (rTMS) 
employs an electromagnetic field generated by a figure-eight coil to suppress (low-
frequency) or enhance (high-frequency) cortical excitability in a localised area of the 
brain (McClelland et al., 2013a). Alternatively, transcranial direct current stimulation 
(tDCS) involves the delivery of a weak electrical current via two surface electrodes; 
anodal and cathodal tDCS cause excitatory and inhibitory effects on underlying cortical 
neurons, respectively (McClelland et al., 2013a).  
 
Research has consistently shown that NIBS can reduce drug craving in laboratory 
settings; cue-provoked cravings for cocaine, alcohol, and nicotine have been transiently 
lowered with a single session of rTMS or tDCS to the left or right DLPFC (Camprodon 
et al., 2007; Boggio et al., 2008; Fregni et al., 2008b; Mishra et al., 2010; Li et al., 
2013). Emerging evidence indicates that NIBS can also temporarily lower cravings for 
foods (for reviews see Jansen et al., 2013; McClelland et al., 2013a). In the earliest of 
these studies, Uher and colleagues (2005) showed that a single session of high-
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frequency rTMS to the left DLPFC suppressed cravings in healthy women with frequent 
food cravings. This finding was later replicated by two studies using bilateral DLPFC 
tDCS (anode right/cathode left), the former also showing a reduction in calories 
ingested following active versus sham stimulation (Fregni et al., 2008a; Goldman et al., 
2011). The effects of prefrontal cortex modulation have also been investigated in a 
clinical sample; Van den Eynde et al. (2010) found that high-frequency rTMS to the left 
DLPFC lowered cue-induced food cravings in patients with a bulimic disorder.  
 
Although the anti-craving effects recorded in these experiments were temporary (the 
effects of a single session of rTMS or tDCS are expected to last for up to two hours, 
depending on the parameters used; Nitsche et al., 2001; Hoogendam et al., 2010), it is 
possible that NIBS delivered over extended periods of time could induce longer-lasting 
behavioural responses through changes in neuroplasticity. Indeed, interventions 
comprising multiple sessions of NIBS have shown therapeutic potential for a range of 
conditions including BN (Downar et al., 2012), anorexia nervosa (McClelland et al., 
2013b), and substance use disorder (Politi et al., 2008). Moreover, rTMS is an approved 
second-line treatment for major depressive disorder in many countries including the UK 
and US. Given that food cravings play a central role in obesity and some eating 
disorders, the potential for NIBS to enduringly suppress these cravings represents an 
exciting prospect.  
 
Whilst the tendency to overeat or binge-eat can be influenced by food cravings, Davis et 
al. (2004) point out that “human overeating is not just a passive response to...powerful 
physiological drives; it is also about making choices” (p. 929). It is well-established that 
drug addicts have maladaptive decision-making capabilities (for a review see Dom et 
al., 2005), and the same applies to compulsive overeaters. Specifically, obese people 
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and patients with BED show steeper rates of temporal discounting (TD; Weller et al., 
2008; Davis et al., 2010) – an experimental proxy of aspects of impulsivity such as 
temporal foresight and delay of gratification. In the context of eating, these individuals 
struggle to defer food gratification in the interest of future health or aesthetics. Evidence 
shows that the capacity for self-control in reward-related decision-making tasks – 
including TD – depends crucially on DLPFC activity levels (Clark et al., 2003; Hare et 
al., 2009; Christakou et al., 2011). Furthermore, reduced prefrontal reactivity during a 
TD task has been found to predict a greater rate of weight gain in obesity (Kishinevsky 
et al., 2012). It is possible that NIBS could reduce overeating behaviours by 
simultaneously suppressing food cravings and improving intertemporal decision-
making. Indeed, Figner et al. (2010) showed that low-frequency rTMS delivered to the 
left DLPFC altered the discounting of delayed rewards in healthy adults. Nevertheless, 
to our knowledge the relationship between the DLPFC, food craving, and TD behaviour 
is yet to be explored.   
 
This study investigated whether bilateral manipulation of the DLPFC with tDCS 
modulates food craving-related thoughts and behaviours in healthy women who 
experience frequent food cravings. tDCS was chosen because of its practical advantages 
over rTMS (e.g., it is simpler, safer, and less expensive; Poreisz et al., 2007; Priori et 
al., 2009), and because its efficacy in lowering food cravings has been demonstrated in 
two non-clinical samples comparable to our own (Fregni et al., 2008a; Goldman et al., 
2011). Unlike these studies, however, we also included a measure of choice impulsivity. 
The main aims were to establish whether: (1) one session of sham-controlled tDCS 
(anode over the right DLPFC and cathode over the left DLPFC) would temporarily 
reduce food cravings; (2) this session of tDCS would transiently alter TD behaviours; 
and (3) the effects of tDCS on food cravings are moderated by individual differences in 
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intertemporal decision-making abilities. Based on Fregni et al.’s (2008a) finding, we 
also speculated that actual food consumption in a free-eating task might decrease 
following active versus sham stimulation. 
 
3.3 MATERIALS AND METHODS 
3.3.1 Participants 
Healthy female volunteers who self-identified as having frequent food cravings (≥ 1 per 
day, assessed by self-report questionnaire) aged 18-60 were recruited from the King’s 
College London (KCL) recruitment webpage. Respondents were screened by phone and 
were excluded if they: (a) smoked > 10 cigarettes per day; (b) drank > the recommended 
daily alcohol intake (3-4 units for men and 2-3 units for women; National Health 
Service [NHS], 2013); (c) used illicit drugs; (d) had a current major psychiatric 
disorder; (e) had a current or past history of an eating disorder; (f) had any significant 
health problems in the previous 6 months; (g) had a personal or family history of 
seizures; (h) had a history of stroke; (i) had a history of head injury or neurosurgery; (j) 
had any implanted metal devices; (k) suffered from frequent or severe headaches; (l) 
were taking any medications associated with lowered seizure threshold; (m) were 
pregnant or sexually active and not using contraception; (n) were allergic to any of the 
foods presented in the study; or (o) gave any threshold answers in the Structured 
Clinical Interview for Diagnostic and Statistical Manual (DSM) Axis I Disorders 
(SCID-I; First et al., 2002). 
 
Twenty-eight women completed the telephone screen and 25 fulfilled all 
inclusion/exclusion criteria. Of these, 20 completed both study sessions – 4 withdrew 
before the first visit and 1 experienced skin irritation so did not return for the second 
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appointment. The data of three participants were excluded due to their responses in 
baseline assessments completed in the laboratory – two had clinically significant global 
scores (≥ 4; Rø et al., 2012) on the Eating Disorder Examination Questionnaire (EDE-
Q; Fairburn & Beglin, 1994) and one had moderate scores on all three dimensions of the 
Depression Anxiety and Stress Scale (DASS-21; Lovibond & Lovibond, 1995). The 
final sample included in the analyses consisted of 17 females aged 19-55 (M = 26.41, 
SD = 8.30) who were predominantly Caucasian (70.6%). Participants reported 
experiencing an average of 3.15 (SD = 1.41, range = 1-5.5) food cravings per day and 
the majority (82.4%) primarily craved sweet foods. The mean BMI was 23.81 (SD = 
2.60, range = 19.85-29.28); 70.6% of participants were in the healthy range (18.5-24.9) 
and 29.4% were overweight (25-25.9) (NHS, 2012). All participants were educated to 
A-level standard or higher. See Table 3.1 for more participant characteristics.  
 
The study was carried out at the Institute of Psychiatry, KCL (London, UK). Ethical 
approval was obtained from the KCL Psychiatry, Nursing and Midwifery Research 
Ethics Subcommittee. All participants provided written informed consent and were 




Table 3.1 Baseline characteristics of participants. 
Characteristic Mean SD Range 
Age 26.41 8.31 19.00 - 55.00 
BMI 23.81 2.60 19.90 - 29.30 
DASS-21 depression 3.88 4.33 0.00 - 14.00 
DASS-21 anxiety 2.12 2.40 0.00 - 8.00 
DASS-21 stress 7.18 4.53 0.00 - 18.00 
Global EDE-Q 1.46 0.98 0.49 - 3.88 
Global FCQ-T 118.47 18.46 91.00 - 151.00 
Cravings per daya 3.15 1.36 1.00 - 5.50 
Baseline k-value 8.05 9.86 0.91 - 39.92 
 
SD, standard deviation; BMI, body mass index; DASS-21, 21-item Depression, Anxiety and Stress Scale; 
EDE-Q, Eating Disorders Examination Questionnaire; FCQ-T, Food Craving Questionnaire-Trait. 
a Assessed with self-report demographic questionnaire (“How many food cravings do you experience per 
day?”) 
 
3.3.2 Design and procedure 
This study employed a double-blind sham-controlled within-subjects crossover design 
in which all participants received real and sham tDCS. Order of stimulation was 
randomised and counterbalanced across participants using STATA® software (to allow 
for experimenter blinding, real and sham stimulation were encoded with five-digit 
numbers which were assigned to each session by a third party). An intersession interval 
(≥ 48 hours) was used to avoid any carryover effects due to stimulation and, where 
possible, both sessions were held at the same time of day (difference between time of 
day of real and sham session: M = 61 minutes, SD = 121 minutes).  
 
Upon arrival to the first appointment only, participants completed a battery of baseline 
assessments (demographic questionnaire, EDE-Q, DASS-21, Food Craving 
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Questionnaire-Trait [FCQ-T; Cepeda-Benito et al., 2000]). A 10cm continuous visual 
analogue scale (VAS) measuring baseline hunger was administered at the start of both 
sessions, followed by several pre-tDCS measures in the following order: (1) Food 
Challenge Task (FCT); (2) Food Craving Questionnaire-State (FCQ-S); (3) saliva 
sample; and (4) TD task. Participants then received a 20-minute tDCS session (real or 
sham). Immediately after this (post-tDCS), they repeated the pre-tDCS measures in the 
following order: (1) TD task; (2) FCT; (3) FCQ-S; and (4) saliva sample. Participants 
then engaged in a free-eating task. At the end of the second appointment only, we 
evaluated the tolerability of the intervention and the success of the blinding procedure. 
All instruments used in the protocol have sound psychometric properties.  
 
3.3.3 Food Challenge Task 
This is a behavioural measure – used to induce and assess food cravings – which was 
developed and administered previously in our laboratory (Uher et al., 2005; Van den 
Eynde et al., 2010, 2013), and adapted for use in the current study. Two short films (< 3 
minutes each) of adults eating energy-dense foods (chocolates, crisps, nuts, and 
biscuits) were shown to participants consecutively, and the same foods were present in 
the room. After the films, participants rated their attitude towards food intake and their 
emotional state on a series of 10cm continuous VASs measuring appearance, smell, 
taste, and urge to eat for each food separately, as well as hunger, general urge to eat, 
general urge to binge, stress, anxiety, tension, and mood. The primary outcome variable 
in the analyses (global FCT score) was computed by totalling the ratings on all VASs 
relating to food intake except for hunger. This is because food cravings tend to be 
hedonically driven and are unrelated to an individual’s physiological needs (Pelchat et 




3.3.4 Food Craving Questionnaire-State 
This is a self-report inventory used to assess food craving as a psychological state in 
response to specific situations, which was developed for use among average-weight 
adults (Cepeda-Benito et al., 2000). The instrument contains 15 items organised into 5 
subscales. Responses are made on a 5-point Likert scale ranging from 1 (strongly 
disagree) to 5 (strongly agree), yielding a global score and a score for each dimension.  
 
3.3.5 Hormonal stress response (saliva sample) 
To assess whether tDCS had an effect on the hypothalamus-pituitary-adrenal (HPA) 
axis stress response we collected salivary cortisol samples. Participants chewed on a 
3x1cm inert polymer oral swab (Salivette®) for 1 minute, which was then placed into a 
capped centrifuge tube. Samples were stored at -20°C – where they remain stable for up 
to 3 months (Garde & Hansen, 2005) – and were analysed for cortisol using competitive 
immunoassays (Salimetrics® salivary ELISA kits). Data indicate that cortisol 
measurement with Salivettes® is a reliable prediction method of total and calculated free 
serum cortisol levels (Poll et al., 2007). 
 
3.3.6 Temporal discounting task 
Choice impulsivity was assessed with a computerised hypothetical monetary TD task, 
which measures the degree to which a reward is subjectively discounted in relation to its 
temporal delay (Rubia et al., 2009). A monetary task was used because food TD tasks 
present several difficulties (e.g., the reinforcing value of food is not linear and food 
preferences are highly variable) and because compulsive overeaters appear to have a 
general tendency to make impulsive choices, which is not specific to choices about 
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food10 (Manwaring et al. 2011). Participants chose between a smaller amount of money 
(between £0 and £100) available immediately, and a larger amount (always £100) 
available after 1 week, 1 month, 1 year, or 2 years (25 trials for each delay). The value 
of the immediate reward was adjusted in an algorithm based on previous choices; this 
narrowed the range of the immediate values offered until an amount was reached that 
the participant judged as equivalent to the fixed delayed reward (Richards et al., 1999). 
This point of subjective equality is referred to as the indifference point. A hyperbolic 
decay function was fitted to the indifference point for each delay to describe the 
relationship between the subjective value of a reward as a function of the delay to its 
presentation. The mathematical expression of this relationship is V = A/(1 + kD), where 
V is the subjective value of a reward of amount A, D is the delay to reward presentation, 
and k is a constant characterising the individual’s rate of discounting (Rachlin et al., 
1991). The value of k is frequently used as the main dependent variable in the TD 
paradigm, and is considered an experimental proxy of aspects of impulsivity such as 
temporal foresight and delay of gratification. Participants with larger k-values show 
greater TD – for them rewards given after a delay lose more subjective value.  
 
3.3.7 Real transcranial direct current stimulation 
A single 20-minute session of tDCS was delivered using a neuroConn® DC-
STIMULATOR device at a constant current of 2 mA (with a 10-second fade in/out) 
using two 25 cm2 surface sponge electrodes soaked in a sterile saline solution (0.9% 
sodium chloride). At least 50% of this transcranially applied current is expected to enter 
the brain through the skull (Nitsche et al., 2008). The anode and cathode were placed 
                                                 
10 Women with BED discounted both monetary and directly consumable rewards (food, massage time, 
preferred sedentary activity) more steeply than obese and control groups.  
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over the right (F4) and left (F3) DLPFC, respectively. The sites of interest were located 
using the International EEG 10-20 system. The tDCS parameters used have been shown 
to be safe in healthy individuals (Iyer et al., 2005) and the charge density was two 
magnitudes lower than the experimentally determined threshold estimate in rats 
(Liebetanz et al., 2009). tDCS is generally well-tolerated and is associated with 
relatively minor side effects; a mild tingling sensation is the most commonly reported 
adverse effect (Poreisz et al., 2007). We assessed tolerability via salivary cortisol and a 
10cm continuous VAS measuring discomfort during the procedure. 
 
3.3.8 Sham transcranial direct current stimulation 
The electrode placement for sham tDCS was the same as for active tDCS; however, the 
stimulation automatically turned off after 30 seconds. Participants therefore experienced 
the initial itching sensation but received no current for the rest of the 20-minute session. 
Research shows that this method for sham tDCS is reliable and cannot easily be 
distinguished from real tDCS by participants or investigators (Gandiga et al., 2006). The 
validity of the sham treatment was assessed by asking participants to guess which 
session they thought was a placebo, and to rate their confidence in this guess on a 10cm 
continuous VAS.  
 
3.3.9 Free-eating task 
To measure actual food consumption after real and sham tDCS, weights of foods 
presented in the FCT were recorded before and after each laboratory session. After the 
final post-tDCS measure, the experimenter left the room for 3 minutes and invited the 
participant to help themselves to any of the foods while they were gone. The percentage 





Statistical analyses were performed using IBM® SPSS® software (Version 20). For 
variables with normally distributed data, the effects of active versus sham tDCS were 
evaluated using two-way 2 (stimulation: real vs. sham) x 2 (timepoint: pre-tDCS vs. 
post-tDCS) repeated measures ANOVAs, whereby a significant stimulation x timepoint 
interaction indicated a difference in the effect that real and sham tDCS had on pre-tDCS 
scores. Where data were not normally distributed, non-parametric alternatives were 
employed. All statistical tests were two-tailed and the level of significance was set at α 
= 0.05.  
 
3.4.1 Food cravings and transcranial direct current stimulation 
When compared to sham stimulation, real stimulation did not alter global FCT scores 
[F(1, 16) = 0.74, ns]. There was a significant stimulation x timepoint interaction for 
global FCQ-S score [F(1, 16) = 5.02, p < .05] in the opposite direction to that expected; 
pre-tDCS scores were lowered more by sham (M = -11.32%, SD = 21.12%) than by real 
stimulation (M = -1.94%, SD = 21.36%). However, this finding is largely attributable to 
scores on FCQ-S subscale 5 (craving as a physiological state) as the global FCQ-S 
interaction term was not significant when this subscale was excluded from the analysis 
[F(1, 16) = 3.19, ns]. 
 
3.4.2 Food cravings for specific food groups and transcranial direct 
current stimulation 
To examine the effect of tDCS on cravings for specific food groups, we analysed FCT 
ratings (appearance, smell, taste, urge to eat) for sweet (chocolate and biscuits) and 
189 
 
savoury (crisps and nuts) foods separately. A significant stimulation x timepoint 
interaction was observed for sweet [F(1, 16) = 4.59, p < .05] but not savoury foods [F(1, 
16) = 2.20, ns]. Cravings for sweet foods were reduced more by real (M = -13.31%, SD 
= 34.73%) than by sham tDCS (M = -6.06%, SD = 29.86%), whilst cravings for savoury 
foods were lowered by comparable amounts in both conditions (real: M = -9.29%, SD = 
36.84%, sham: M = -10.30%, SD = 30.46%) (Figure 3.1).  
 
 
Figure 3.1 Mean percentage change in Food Challenge Task scores (appearance, smell, 
taste, urge to eat) for sweet and savoury foods in real and sham transcranial direct 
current stimulation conditions.  
FCT, Food Challenge Task; tDCS, transcranial direct current stimulation. 
Note: Error bars represent ± SE. 
 
3.4.3 Temporal discounting and transcranial direct current stimulation 
Since k-values on the TD task were not normally distributed, the effect of tDCS on 



































rank tests. Post-tDCS k-values did not differ significantly from pre-tDCS k-values 
following real [z = -0.45, ns] or sham stimulation [z = -0.31, ns].  
 
3.4.4 Interaction between temporal discounting, food cravings, and 
transcranial direct current stimulation 
To establish whether the effects of tDCS on food cravings were moderated by 
individual differences in intertemporal decision-making abilities, we performed the 
analyses with baseline k-value (calculated as the mean of the two pre-tDCS k-values) as 
a covariate. Results showed a significant stimulation x timepoint interaction for global 
FCT score [F(1, 15) = 4.82, p < .05]; after controlling for baseline k-value there was a 
sharper decrease in global FCT scores following real tDCS than following sham tDCS. 
In addition, the stimulation x timepoint interaction for global FCQ-S score was no 
longer significant [F(1, 15) = 0.18, ns].  
 
There was also a significant stimulation x timepoint x baseline k-value interaction for 
global FCT score [F(1, 15) = 5.12, p < .05] and global FCQ-S score [F(1, 15) = 5.60, p 
< .05]. Participants with lower baseline k-values – and greater intertemporal decision-
making abilities – were more susceptible to the anti-craving effects of active tDCS. 
Conversely, baseline k-value did not moderate the effects that sham tDCS had on food 
cravings. To illustrate this graphically, we divided participants into two groups 
according to their baseline k-value; participants with baseline k-values in the first or 
second quartiles (n = 9) were classified as showing low TD (more reflective choice 
behaviour) whilst those with baseline k-values in the third or fourth quartiles (n = 8) 





Figure 3.2 Mean pre- and post- transcranial direct current stimulation (tDCS) global 
Food Challenge Task scores for participants showing high and low temporal 
discounting in real and sham tDCS conditions. 










































3.4.5 Actual food consumption and transcranial direct current 
stimulation 
Values for the amount of food consumed during the free-eating task were not normally 
distributed, and were therefore analysed using paired-samples Wilcoxon signed-rank 
tests. Results showed no significant difference in the proportion of chocolate, crisps, 
nuts, biscuits, or total food ingested after real versus sham tDCS [zs < -1.04, ps > .30]. 
These results were not confounded by baseline hunger which was stable across the two 
conditions [t(16) = -0.67, ns]. 
 
3.4.6 Success of blinding procedure 
Participants were not able to distinguish real stimulation from sham stimulation at a rate 
better than chance [X2(1) = 2.88, ns]. Furthermore, the mean confidence rating for this 
guess on a 10cm continuous VAS was 5.04 (SD = 3.12, range = 0.0-9.7), indicating that 
participants were not particularly certain that their guess was accurate. The order in 
which participants received real and sham stimulation did not affect their ability to 
identify the placebo session [p = .29; Fisher’s exact test]. 
 
3.4.7 Tolerability and safety of transcranial direct current stimulation 
One participant withdrew from the study after the first appointment due to skin irritation 
at the site of stimulation. Another participant reported developing a slight headache 
following active tDCS which subsided without treatment. Overall, the intervention was 
well-tolerated and participants reported experiencing minimal discomfort (10cm VAS: 
M = 2.64, SD = 2.51, range = 0-7.7). When compared to sham tDCS, real tDCS did not 
have any adverse effects on the HPA axis stress response [F(1, 15) = 0.29, ns] and did 




3.4.8 Order effects 
There was evidence of an order effect whereby, following real stimulation, participants 
allocated to the real/sham condition displayed a sharp decrease in global FCT scores 
whereas those in the sham/real condition showed a marginal increase in scores [F(1, 15) 
= 7.17, p < .05]. Participants who received real tDCS first (n = 8) did not differ 
significantly from those who received sham tDCS first (n = 9) in any baseline measures 
[Fs < 3.89, ps > .08].  
 
3.5 DISCUSSION 
The present study investigated the effects of a single session of sham-controlled tDCS 
(anode over the right DLPFC, cathode over the left DLPFC) on food cravings, 
intertemporal choice behaviour, and actual food consumption in healthy women with 
frequent food cravings. The key findings were that tDCS reduced cravings for sweet but 
not savoury foods, and that participants who exhibited more reflective choice behaviour 
were more susceptible to the anti-craving effects of tDCS than those who displayed 
more impulsive choice behaviour. 
 
The observed decrease in craving for sweet foods is consistent with numerous accounts 
of prefrontal cortex tDCS transiently lowering food and drug cravings (Boggio et al., 
2008; Fregni et al., 2008a; Fregni et al., 2008b; Goldman et al., 2011), and provides 
evidence that food craving is associated with DLPFC activity. This brain region is 
thought to regulate cravings by integrating information relating to cues, cravings, 
motivation, and expectancy (McBride et al., 2006). By combining rTMS with functional 
magnetic resonance imaging (fMRI), Hayashi et al. (2013) formulated a two-stage 
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model of cue-reactivity whereby the medial orbitofrontal cortex (mOFC) encodes the 
subjective value of the drug (or food) and the DLPFC incorporates intertemporal 
availability and cue information to modulate the presumed mOFC value signal.  
 
The mechanisms by which DLPFC stimulation lowers cravings are unknown, although 
data suggest that reduced function in the right prefrontal cortex may lead to overeating 
(Alonso-Alonso & Pascual-Leone, 2007). Interestingly, however, NIBS appears to 
suppress cravings even when the right DLPFC is inhibited and/or the left DLPFC is 
excited (Uher et al., 2005; Boggio et al., 2008; Fregni et al., 2008a; Fregni et al., 2008b; 
Van den Eynde et al., 2010). It has therefore been proposed that state craving depends 
on a bilateral balance between left and right DLPFC activity, and that any disruption to 
this balance will cause cravings to subside (Boggio et al., 2008). DLPFC modulation 
might also lead to craving inhibition by indirectly altering the activity level of the 
mOFC.  
 
That tDCS suppressed cravings for sweet but not savoury foods is in approximate 
agreement with Goldman et al.’s (2011) findings, and provides an explanation as to why 
global FCQ-S and global FCT scores were not reduced by tDCS. It is possible that the 
mechanisms underlying cravings for sweet and savoury foods are different; several lines 
of evidence support this interpretation. Firstly, the concept of sweet food addiction is 
frequently likened to drug addiction (e.g., Avena et al., 2008), whereas parallels have 
not been drawn between drug addiction and addiction to savoury foods. Secondly, 
chocolate contains several biologically active constituents – which are not found in 
savoury foods – that can cause psychological sensations comparable to those of other 
addictive substances (Bruinsma & Taren, 1999). Thirdly, sweet foods generally contain 
higher sugar concentrations than savoury foods, and sugar is known to have addictive 
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potential because it releases opioids and dopamine (Avena et al., 2008). Finally, ample 
data – including that in this study – indicate that cravings for sweet foods are stronger 
and more prevalent than cravings for savoury foods (Yanovski, 2003; Hill, 2007).  
 
The present study demonstrates that inter-individual differences in intertemporal 
decision-making abilities moderate the anti-craving effects of prefrontal cortex tDCS. 
Specifically, participants who exhibited more impulsive choice behaviours showed a 
smaller reduction in cravings following active stimulation than those who displayed 
more reflective choice behaviours. This is unsurprising since individuals with a strong 
tendency to devalue delayed rewards are expected to hold particularly disinhibited 
attitudes towards food intake (Davis et al., 2010), and dimensions of impulsivity have 
also been found to negatively predict outcomes of existing treatments for binge eating 
(Manasse et al., 2016). Unlike Figner et al. (2010), we did not observe significant 
changes in TD following DLPFC modulation. It may be that an individual’s ability to 
delay gratification cannot be easily modified with NIBS; indeed, only one study has 
demonstrated otherwise and, moreover, the capacity for adaptive intertemporal 
decision-making is not a capricious psychological state but rather a stable personality 
trait (Davis et al., 2010). Alternatively, the TD task employed may have lacked 
sensitivity since all trials used ‘Accelerate’ framing (i.e., when the value of the delayed 
reward is fixed), which is associated with decreased discounting relative to ‘Delay’ 
framing (i.e., when the value of the immediate reward is fixed; Steinglass et al., 2012).  
 
In our study, real versus sham tDCS did not affect the amount of food consumed in the 
free-eating task. Although Fregni et al. (2008a) reported reduced caloric ingestion 
following active stimulation, Goldman et al. (2011) did not replicate this result. It is 
possible that the observed reduction in self-reported craving did not translate into an 
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equipollent reduction in food consumption because the free-eating session lacked 
ecological validity; eating behaviours displayed in this task are unlikely to mirror those 
engaged in on a daily basis, particularly if participants suspected that their food 
consumption was being recorded. Goldman et al. (2011) suggested instead performing 
“a natural observation of food consumption during a mealtime later in the day or the 
following day” (p. 745); however, the tDCS parameters used are not expected to have 
such a lasting effect. It might therefore prove more beneficial to revise the experimental 
free-eating task to improve its generalisability; for example, it could take place in a 
more natural setting and its length could be increased.  
 
This study has some limitations; for example, we observed an order effect whereby real 
tDCS only reduced food cravings for participants who received real stimulation during 
their first session. One explanation for this draws on the finding that cue-induced 
craving for cigarettes was dramatically increased when people were told they could 
smoke immediately after testing (Hayashi et al., 2013). In our study, participants were 
not informed prior to testing that they would be given ad libitum access to a selection of 
foods; therefore, they would have only anticipated the free-eating task during their 
second visit, once they were familiarised with the experimental procedure. This 
anticipation might have potentiated cravings in the second session, making them less 
susceptible to modulation by tDCS. We did not ask participants to fast prior to their 
scheduled sessions. Although hunger is not a necessary prerequisite for food craving 
(Pelchat et al., 2004), similar studies have required that participants refrain from eating 
and drinking (except water) for several hours before testing (Uher et al., 2005; Van den 
Eynde et al., 2010; Goldman et al., 2011). Nevertheless, our results showed that 
baseline hunger was stable across conditions. We also did not collect data on menstrual 
phase despite evidence that it influences food craving (Davidsen et al., 2007); however, 
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not all studies of NIBS and food craving have addressed this issue (Fregni et al., 2008; 
Van den Eynde et al., 2010). In addition, we did not measure IQ or income which may 
influence TD of monetary rewards (Green et al., 1996; de Wit et al., 2007), though this 
is unlikely to have impacted the results since each participant served as their own 
control. A final limitation is that we did not include an anode left/cathode right tDCS 
condition, which would have helped to clarify whether there is a hemispheric laterality 
for food craving.  
 
The present research has some important implications. Although the anti-craving effects 
observed here were presumably only temporary, it is possible that NIBS delivered over 
longer periods of time could elicit more sustained reductions in food craving. tDCS is 
an appealing technique because it is inexpensive, easy to administer, non-invasive, and 
painless. Future research should evaluate the therapeutic potential of tDCS for 
eliminating problematic overeating and binge-eating behaviours by analysing the effects 
of repeated DLPFC stimulation. The inter-individual differences we detected in a 
participant’s susceptibility to the anti-craving effects of stimulation suggest that, if 
developed into a treatment for compulsive overeating, tDCS might be less effective for 
patients with poorer intertemporal decision-making abilities (e.g., those with clinical 
eating disorders; Davis et al., 2010). It may be possible to teach these individuals more 
adaptive strategies to prepare them for a tDCS intervention. 
 
In summary, our data contribute to the growing body of literature demonstrating that a 
single session of active tDCS to the DLPFC can temporarily suppress food craving. Our 
results support those of Fregni et al. (2008) and Goldman et al. (2011), and extend them 
by suggesting that tDCS has a stronger inhibitory effect on craving for sweet foods than 
on craving for savoury foods. We have also shown that individuals who exert more 
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reflective choice behaviours are more susceptible to the anti-craving effects of tDCS 
than are those who display more impulsive choice behaviours. The potential for DLPFC 
neuromodulation to transiently alter intertemporal choice behaviour was not supported 
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Objective: There is evidence that people with eating disorders display altered 
intertemporal choice behaviour (the degree of preference for immediate rewards over 
delayed rewards). Compared to healthy controls (HC), individuals with anorexia 
nervosa and binge-eating disorder show decreased and increased rates of temporal 
discounting (TD; the devaluation of delayed rewards), respectively. This is the first 
study to investigate TD in people with bulimia nervosa (BN).  
Method: Thirty-nine individuals with BN (2 men) and 53 HC (9 men) completed a 
hypothetical monetary TD task. Over 80 binary choices, participants chose whether they 
would prefer to receive a smaller amount of money available immediately or a larger 
amount available in 3 months. Self-reported ability to delay gratification (the 
behavioural opposite of TD) was also measured. 
Results: Individuals with BN showed greater TD (i.e., a preference for smaller-sooner 
rewards) and a decreased self-reported capacity to delay gratification relative to HC. 
Experimental groups did not differ in age, gender ratio, or BMI.  
Discussion: Increased rates of TD may contribute to some of the core symptoms of BN 
that appear to involve making choices between immediate and delayed rewards (i.e., 
binge-eating and compensatory behaviours). Altered intertemporal choice behaviour 





The pathophysiology of bulimia nervosa (BN) is poorly understood and strong evidence 
to guide treatment is lacking (Guillaume et al., 2010). Exploration of neurocognition in 
BN has the potential to elucidate mechanisms underpinning associated behavioural 
abnormalities, and to promote the development of tailored therapeutic interventions.  
 
Several neuropsychological difficulties have been observed in BN (Van den Eynde et al., 
2011). For example, individuals with BN, as well as other eating disorders (EDs; anorexia 
nervosa [AN] and binge-eating disorder [BED]), have an increased preference for risky 
and disadvantageous choices in a context of uncertainty (Guillaume et al., 2015). There 
is also evidence that patients with EDs make maladaptive intertemporal choices. A reward 
arriving sooner is often more appealing than one arriving later, even when the later reward 
is larger. Thus, individuals discount the value of delayed outcomes – a phenomenon 
known as temporal discounting (TD). This tendency to devalue future rewards appears to 
be accentuated in BED (increased TD) (Mole et al., 2015) and diminished in AN 
(decreased TD) (Steinglass et al., 2012), which may underlie the disinhibited and 
restrictive eating that characterise these disorders. This study investigated whether 
individuals with BN display altered rates of TD and differences in the self-reported 
capacity to delay gratification relative to healthy controls (HC).  
 
4.3 MATERIAL AND METHODS 
4.3.1 Participants 
Participants were men and women ≥18 years with BN or no current/previous diagnosis 
of any psychiatric disorder (HC): their data were pooled from two larger studies 
conducted by our group (currently in preparation for publication). Patients with BN were 
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recruited via online advertisements on the King’s College London (KCL) and Beat™ 
research recruitment webpages and through the South London and Maudsley NHS 
Foundation Trust ED Outpatient Service, while HC responded to online and poster 
advertisements at KCL. Group classification was established via self-report and checked 
over email/telephone: DSM-5 BN diagnosis was confirmed using an edited version of the 
Eating Disorder Diagnostic Scale (EDDS) (Stice, Telch, & Rizvi, 2000), and the absence 
of a psychiatric disorder in HC was confirmed using the EDDS and the Structured Clinical 
Interview for DSM-IV Axis I Disorders Screening Module (First, Spitzer, Gibbon, & 
Williams, 2002). 
 
One hundred and thirty participants (BN = 55; HC = 75) completed the screening and 122 
(BN = 52; HC = 70) were eligible for inclusion. Of these, 92 (BN = 39; HC = 53) 
completed the study and were included in the analyses.  
 
The two larger studies were approved by the KCL Psychiatry, Nursing and Midwifery 
Research Ethics Subcommittee and the London City Road & Hampstead Research Ethics 
Committee. Participants gave informed consent prior to taking part and were 
compensated for their time.  
 
4.3.2 Procedure 
All participants attended a testing session at the Institute of Psychiatry, Psychology & 
Neuroscience, KCL. Study procedures undertaken prior to the TD task were comparable 
between the two studies (Figures 4.1 and 4.2): both involved providing written consent 
and completing several identical questionnaires, including the Depression Anxiety and 
Stress Scales (DASS-21) (Lovibond & Lovibond, 1995) and the Delaying Gratification 
Inventory (DGI) (Hoerger, Quirk, & Weed, 2011). Additionally, in both cases the TD 
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task was done on a laptop with an experimenter present. Data were collected between 
May 2014 and September 2015.  
 
 
Figure 4.1 Flow chart showing the measures completed prior to the temporal 
discounting task in Study 1 (“Transcranial direct current stimulation improves 






Figure 4.2 Flow chart showing the measures completed prior to the temporal 
discounting task in Study 2 (“The impact of acute food restriction and distractor 
relevance on inhibitory control in healthy adults”). 
 
4.3.3 Further description of the two larger studies 
The two studies had unrelated aims: Study 1 was a crossover randomised controlled trial 
assessing the effects of transcranial direct current stimulation (tDCS) in bulimia 
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nervosa, and Study 2 explored the impact of acute food restriction and distractor 
relevance on inhibitory control in healthy controls. Whereas these studies assessed 
within-subject differences in temporal discounting due to tDCS treatment and acute 
fasting, respectively, the present research combined their baseline temporal discounting 
and delaying gratification data to evaluate between-group differences in intertemporal 
choice behaviour.   
 
4.3.4 Temporal discounting task 
TD was assessed using a computerised hypothetical monetary choice task, modelled on 
an established paradigm11 (Steinglass et al., 2012). On each of 80 trials, participants had 
an unrestricted amount of time to indicate whether they would prefer to receive a smaller 
amount of money immediately (smaller-sooner reward) or a larger amount after 3 months 
(larger-later reward). Two types of decision framing were employed: ‘Accelerate’ (larger-
later reward remained at £100, smaller-sooner reward increased from £20 to £98 in £2 
increments) and ‘Delay’ (smaller-sooner reward remained at £50, larger-later reward 
increased from £52 to £130 in £2 increments) (40 trials for each). The trials were pseudo-
randomly interleaved, so that the two decision frames were intermixed.  
 
TD was quantified by determining participants’ discount factor (DF) – the magnitude of 
reduction in the present value of a future reward – for each choice set using a two-step 
procedure (Steinglass et al., 2012). First, the ‘indifference point’ was established. This is 
                                                 
11 It was suspected that the TD task employed in the study presented in chapter 3 lacked sensitivity due to 
the sole use of ‘Accelerate’ decision framing (see section 3.5). A novel TD task containing both 
‘Accelerate’ and ‘Delay’ framing was therefore developed by our team for use in this study and in the 
study presented in chapter 5.  
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the amount of money that the participant judged as equivalent to the fixed reward – i.e., 
the value of the variable reward when the participant switched from larger-later to 
smaller-sooner in the Accelerate set and from smaller-sooner to larger-later in the Delay 
set (Steinglass et al., 2012). Second, a mathematical formula was fitted to the indifference 
point: δ = (x1/x2)(1/(t2−t1)), where x1 is the smaller-sooner reward, x2 is the larger-later 
reward, and t2-t1 is the delay to reward presentation (in years), which in this case was 0.25 
(Steinglass et al., 2012; Weber et al., 2007). This procedure is a sensitive measure of 
temporal discounting that is independent of hyperbolic modelling and area under the 
curve analyses (Steinglass et al., 2012; Weber et al., 2007). Global DF was calculated as 
the mean of the two DFs, and was used as the primary outcome variable in this study. The 
value obtained can range from 0 to 1, with smaller numbers indicating greater TD (i.e., a 
greater tendency to choose the smaller-sooner reward). 
 
4.3.5 Delaying Gratification Inventory 
Self-reported ability to delay gratification was measured with the DGI, which requires 
respondents to rate the extent to which they agree with 35 statements on a 5-point Likert 
scale. Scores are generated for five domains of delay behaviour (Food, Physical Pleasures, 
Social Interactions, Money, and Achievement) and a total score (Global DGI score) is 
calculated. This was used as the outcome variable here. Higher values indicate a greater 
capacity to delay gratification. 
 
4.3 RESULTS 
Statistical analyses were performed using SPSS® (tests were two-tailed, α = 0.05). Key 
sample characteristics and raw intertemporal choice data are provided in Table 4.1. TD 
data were positively skewed, therefore square-root transformations were applied and 
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transformed values were used in all subsequent analyses. Global DFs and Global DGI 
scores were correlated in the sample as a whole [r = 0.33, p = .002] (i.e., the higher the 
rate of TD, the lower the ability to delay gratification).  
  
Table 4.1 Sample characteristics and raw intertemporal choice data. 
  HC (n = 53) BN (n = 39)   
  M [n] SD [%] M [n] SD [%] p 
Age 25.55 7.33 25.85 6.62 .442c 
Gender - - - - .083d 
Female [44] [83.02] [37] [94.87] - 
Male [9] [16.98] [2] [5.13] - 
BMIa 21.71 2.17 21.65 3.20 .420c 
DASS-21 depression 2.68 2.96 20.62 10.39 < .000c 
DASS-21 anxiety 2.57 3.60 15.23 11.65 < .000c 
DASS-21 stress 6.64 5.24 21.97 10.19 < .000e 
EDE-Q global - - 4.21 1.06 - 
Illness duration (months) - - 110.87 95.62 - 
Binge-eating frequencyb - - 22.23 31.66 - 
Vomiting frequencyb - - 50.87 169.5 - 
Laxative use frequencyb - - 4.69 17.28 - 
Excessive exercise frequencyb - - 7.21 9.99 - 
DF Accelerate 0.45 0.35 0.32 0.34 .046c 
DF Delay 0.42 0.31 0.27 0.04 .012c 
DF Global 0.44 0.31 0.30 0.29 .020c 
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DGI global 140.79 12.86 121.85 15.24 < .000e 
HC, healthy controls; BN, bulimia nervosa; DF, discount factor (from temporal discounting task); DGI, 
Delaying Gratification Inventory; M, mean; SD, standard deviation; BMI, body mass index. 
a weight(kg)/(height(m))2  
b Number of times in the previous 28 days 
c Mann-Whitney U test 
d Pearson chi-squared test 
e Independent samples t-test 
 
A one-way multivariate ANOVA showed that individuals with BN had lower Global DFs 
(indicating an increased rate of TD) [F(1, 90) = 5.72, p = .019] and Global DGI scores 
(indicating a reduced capacity to delay gratification) [F(1, 90) = 41.65, p < .001] than 
HC. To examine whether these group differences persisted after controlling for other 
possible determinants, age, gender, BMI, and DASS-21 depression, anxiety, and stress 
scores were entered into the model as covariates. This revealed a significant effect of 
group on Global DF [F(1, 84) = 5.52, p = .021] but not Global DGI score [F(1, 84) = 
2.24, p = .138], due to the inclusion of DASS-21 stress scores [F(1, 84) = 5.25, p = .024]. 
An exploratory mixed ANOVA revealed no significant main effect of framing 
(Accelerate vs. Delay) or framing x group interaction on DFs [both p ≥ .654]. 
 
Bivariate correlations were used to explore relationships between Global DFs, Global 
DGI scores, clinical outcomes (DASS-21 and EDE-Q scores, illness duration, and 
frequency of binge-eating, vomiting, laxative use, and excessive exercise), and BMI. 
Pearson’s r and Spearman’s rho correlation coefficients were employed. In the BN group, 
Global DFs were not significantly related to any clinical variables [all p > .109], and 
Global DGI scores were also not significantly correlated with any clinical variables [all p 
≥ .278] except for DASS-21 depression [r = -0.34, p = .036] and stress [r = -0.39, p = 
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.013] scores. Neither Global DFs nor Global DGI scores were associated with BMI when 
the BN and HC groups were considered separately or together [all p ≥ .233].  
 
4.4 DISCUSSION 
This is the first study to assess intertemporal choice behaviour in BN. Individuals with 
BN displayed steeper rates of TD (i.e., an increased preference for smaller-sooner 
rewards) and a reduced self-reported capacity to delay gratification compared to HC. 
This is consistent with observations of disadvantageous monetary decision-making in 
BN (Guillaume et al., 2015) and with TD findings in BED (Mole et al., 2015), but 
contrasts with the lower rates of TD reported in AN (which reflect an increased 
preference for larger-later rewards) (Steinglass et al., 2012).  
 
Group differences in TD remained significant after controlling for variables reported to 
influence discounting rates (age, gender, BMI, depression, anxiety, and stress). TD did 
not correlate with illness duration, symptom severity, general psychopathology, or BMI 
among individuals with BN, suggesting that elevated TD reflects a stable 
neurocognitive feature of BN. It may also be that our sample was too small or had 
insufficient variability to detect what might have been a weak correlation between TD 
and clinical variables. Indeed, unpublished data from our team demonstrate weak but 
significant correlations between TD and binge-eating among 432 participants with or 
without a clinical eating disorder. As our study only included acutely ill individuals, we 
cannot determine whether TD is a trait- or state-based marker of illness. Interestingly, a 
recent study reported that reduced TD in AN normalised after weight restoration 
(Decker, Figner, & Steinglass, 2015); thus, studies should explore whether increased 




In contrast to TD rates, group differences in DGI scores disappeared after controlling 
for stress, and a decreased self-reported capacity to delay reward was associated with 
greater stress and depression in the BN group. Stress may therefore influence the 
perception of one’s tendencies to delay gratification, but not the behaviour itself. We 
did not replicate the finding that people discount future rewards more when they are 
asked to delay consumption than when they are offered the chance to accelerate 
consumption (Steinglass et al., 2012; Weber et al., 2007), which may be due to 
differences in the TD task administered.  
 
A reduced capacity to delay reward may underpin some of the core symptoms of BN. 
For example, greater TD is proposed to reflect choice impulsivity and poor reward-
related inhibitory control (Bari & Robbins, 2013), and these neurocognitive difficulties 
are implicated in binge-eating and compensatory behaviours. Furthermore, binge-eating 
can be regarded as a manifestation of the tendency to act in pursuit of immediate 
pleasure-driven desires, as people with BN have heightened reward sensitivity to food 
cues (Brooks et al., 2011) and report that binge-eating relieves negative affect (De 
Young, Zander, & Anderson, 2014). Altered intertemporal choice behaviour could 
therefore be a relevant target for intervention in this patient group.  
 
Excessive TD is not exclusive to BN and BED: it relates to a broader set of psychiatric 
conditions, including addictions and schizophrenia, and to a number of behavioural 
maladies, such as unsafe sex and poor health practices (Bickel, Jarmolowicz, Mueller, 
Koffarnus, & Gatchalian, 2012). It has therefore been proposed to function as a trans-
disease process, potentially underscored by a neurobiological imbalance between the 
‘impulsive’ and ‘executive’ decision systems, which are embodied in parts of the 
limbic/paralimbic brain regions and prefrontal cortices, respectively (Bickel et al., 
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2012). In this view, effective interventions will be those that restore regulatory balance 
to these competing systems (Koffarnus, Jarmolowicz, Mueller, & Bickel, 2013). Indeed, 
we recently found that direct manipulation of the executive system with transcranial 
magnetic stimulation concurrently altered TD and improved symptoms in AN 
(McClelland et al., 2016). 
 
This study has some limitations. Firstly, most participants were women, which may 
have introduced a gender bias (Weller, Cook, Avsar, & Cox, 2008); however, the male-
to-female ratio did not differ between groups and a predominantly female sample 
reflects the higher prevalence of BN in women than in men. Secondly, we were unable 
to explore between-group differences in income, education, or IQ, which may influence 
the subjective evaluation of monetary rewards (de Wit, Flory, Acheson, McCloskey, & 
Manuck, 2007; Green, Myerson, Lichtman, Rosen, & Fry, 1996). Finally, although the 
paradigm included more trials than most TD tasks, our findings are restricted to choices 
between immediate rewards and those delayed by three months: future studies should 
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Chapter 5. Transcranial direct current 
stimulation improves symptoms, mood, and 
self-regulatory control in bulimia nervosa: A 
randomised controlled trial 
______________________________________________________________________ 
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Background: Evidence suggests that pathological eating behaviours in bulimia nervosa 
(BN) are underpinned by alterations in reward processing and self-regulatory control, 
and by functional changes in neurocircuitry encompassing the dorsolateral prefrontal 
cortex (DLPFC). Manipulation of this region with transcranial direct current stimulation 
(tDCS) may therefore alleviate symptoms of the disorder. 
Objective: This double-blind sham-controlled proof-of-principle trial investigated the 
effects of bilateral tDCS over the DLPFC in adults with BN.  
Methods: Thirty-nine participants (two males) received three sessions of tDCS in a 
randomised and counterbalanced order: anode right/cathode left (AR/CL), anode 
left/cathode right (AL/CR), and sham. A battery of psychological/neurocognitive 
measures was completed before and after each session and the frequency of bulimic 
behaviours during the following 24-hours was recorded.    
Results: AR/CL tDCS reduced eating disorder cognitions (indexed by the Mizes Eating 
Disorder Cognitions Questionnaire-Revised) when compared to AL/CR and sham 
tDCS. Both active conditions suppressed the self-reported urge to binge-eat and 
increased self-regulatory control during a temporal discounting task. Compared to sham 
stimulation, mood (assessed with the Profile of Mood States) improved after AR/CL but 
not AL/CR tDCS. Lastly, the three tDCS sessions had comparable effects on the 
wanting/liking of food and on bulimic behaviours during the 24 hours post-stimulation. 
Conclusions: These data suggest that single-session tDCS transiently improves 
symptoms of BN. They also help to elucidate possible mechanisms of action and 
highlight the importance of selecting the optimal electrode montage. Multi-session trials 






Bulimia nervosa (BN) is characterised by recurrent episodes of binge-eating and 
inappropriate compensatory behaviours. It typically emerges during adolescence and is 
associated with substantial functional impairment, suicidality (Stice, Marti, & Rohde, 
2013), and an increased risk of mortality (Arcelus, Mitchell, Wales, & Nielsen, 2011; 
Smink, van Hoeken, & Hoek, 2012). Furthermore, BN has high rates of comorbidity 
with major mood, anxiety, impulse control, and substance use disorders (Hudson, 
Hiripi, Pope Jr, & Kessler, 2007). Lifetime prevalence estimates for young women are 
7% when subthreshold cases are considered (Stice et al., 2013). Cognitive behavioural 
therapy is regarded as the gold-standard treatment (National Institute for Health and 
Care Excellence, 2004), yet most patients remain symptomatic following therapy 
(Poulsen et al., 2014) and attrition rates are as high as 50% (Penas-Lledo et al., 2013).  
 
Development of novel therapies for BN relies on identifying factors that contribute to 
pathogenesis. Evidence indicates that alterations in reward processing may play a 
central role; for example, patients with BN rate pictures of food as more 
interesting/arousing than healthy controls (Mauler, Hamm, Weike, & Tuschen-Caffier, 
2006) and bulimic symptoms correlate positively with reward sensitivity (Farmer, Nash, 
& Field, 2001; Loxton & Dawe, 2001). Neuroimaging data support the importance of 
reward systems in BN: both hyper- and hypo-responsivity have been observed in the 
neural networks that subserve anticipatory (wanting) and consummatory (liking) food 
reward processing (Friederich, Wu, Simon, & Herzog, 2013; Garcia-Garcia et al., 2013; 
Wierenga et al., 2014). Individuals with BN also appear to have deficient self-regulatory 
control, thus increasing instability and erratic responding to rewarding stimuli 
(Wierenga et al., 2014). For example, BN (Wu et al., 2016) and binge-eating more 
generally (Bartholdy, Dalton, O’Daly, Campbell, & Schmidt, 2016) are associated with 
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impaired reactive response inhibition, and our group recently observed an increased 
propensity to devalue delayed rewards (a concept known as temporal discounting; TD) 
in patients with BN relative to healthy controls (Kekic et al., 2016a). Neuroimaging 
studies suggest these difficulties are related to hypoactivity in circuitry that supports 
self-regulatory capacities (Marsh et al., 2011; Marsh et al., 2009). It has therefore been 
proposed that disturbed eating in BN is underpinned by problems in reward processing 
and self-regulatory control, which correspond to aberrations within ventral limbic and 
dorsal cognitive frontostriatal neural networks, respectively (Berner & Marsh, 2014; 
Friederich et al., 2013; Wierenga et al., 2014). Negative mood may trigger binge-eating 
by altering the reward value of food (Bohon & Stice, 2012; Wagner, Boswell, Kelley, & 
Heatherton, 2012) and by diminishing self-regulatory processes (Heatherton & Wagner, 
2011).  
 
Non-invasive brain stimulation (NIBS) enables targeted manipulation of cortical 
excitability, and may be useful for ‘normalising’ altered neural circuit activity in BN. 
The most common NIBS modalities are repetitive transcranial magnetic stimulation 
(rTMS) and transcranial direct current stimulation (tDCS). rTMS uses a coil to generate 
a magnetic field, which penetrates the skull and induces an electrical current, whereas 
tDCS delivers a low-amplitude direct current via two surface electrodes (anode and 
cathode). Although both methods are well-tolerated and have minimal side effects, 
tDCS has several practical advantages over rTMS: it is portable, inexpensive, has a 
more favourable safety-feasibility profile, and can be applied bilaterally.  
 
Evidence for the usefulness of NIBS in psychiatry is accumulating, and the dorsolateral 
prefrontal cortex (DLPFC) has been the targeted site in most studies. This region is part 
of the dorsal cognitive frontostriatal circuitry – representing the major neural structure 
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involved in executive functions, including self-regulatory control (Hare, Camerer, & 
Rangel, 2009) – and is also implicated in reward processing due to its 
anatomical/functional connections with ventral limbic circuitry (Diana, 2011). Given 
the aetiological relevance of these neurocognitive capacities in BN, manipulating the 
DLPFC with NIBS might alleviate symptoms of the disorder (McClelland, Bozhilova, 
Campbell, & Schmidt, 2013). Indeed, our group found that one session of real versus 
sham rTMS over the left DLPFC was associated with a decreased urge to eat and fewer 
binge-eating episodes during the 24-hour follow-up period in 38 participants with a 
bulimic disorder (Van den Eynde et al., 2010), and Hausmann et al. (2004) observed 
complete remission of binge/purge symptoms following 10 sessions of left DLPFC 
rTMS in a patient with refractory BN. Modulation of the DLPFC with tDCS has 
produced therapeutic effects in food cravers (Kekic et al., 2014), obese individuals 
(Gluck et al., 2015), and patients with various psychiatric disorders including anorexia 
nervosa and binge-eating disorder (Burgess et al., 2016; Kekic, Boysen, Campbell, & 
Schmidt, 2016b; Khedr, Elfetoh, Ali, & Noamany, 2014); however, its utility in BN has 
not been explored. 
 
This proof-of-principle clinical trial investigated the effects of two single sessions of 
sham-controlled tDCS administered bilaterally over the DLPFC (anode right/cathode 
left [AR/CL] and anode left/cathode right [AL/CR]) in patients with BN. The aims were 
to establish whether these sessions would temporarily: (i) suppress core symptoms of 
BN (urge to binge-eat, eating disorder [ED]-related cognitions, frequency of binge-
eating and compensatory behaviours); (ii) reduce TD behaviour (an indicator of poor 
self-regulatory control); (iii) alter the wanting/liking of high- and low-calorie sweet and 




5.3 MATERIAL AND METHODS 
5.3.1 Participants 
Male and female volunteers (≥ 18 years) with BN were recruited from the King’s 
College London, Beat, Call for Participants, and Experimatch websites, and from the 
South London and Maudsley NHS Foundation Trust ED outpatient service.12 
Respondents were screened by phone and a DSM-5 diagnosis of BN was confirmed 
with an adapted version of the Eating Disorder Diagnostic Scale (EDDS; Stice, Telch, 
& Rizvi, 2000). Exclusion criteria were: (i) contraindications to tDCS (Brunoni et al., 
2012; details available on request); (ii) significant health problems in the previous six 
months; and (iii) pregnancy. Ongoing parallel treatment was permitted since inter-
session intervals were short (M = 9.10 days, SD = 9.39 days) and each participant 
served as their own control. Fifty-seven people (4 males) completed the telephone 
screen and 53 fulfilled the eligibility criteria (Figure 5.1). Of these, 39 (2 males) 
completed all 3 study sessions (the dropout rate was 0%) and 35 (2 males) completed all 
3 follow-up questionnaires.  
 
The study was conducted at the Institute of Psychiatry, Psychology & Neuroscience 
(London, UK). Ethical approval was obtained from the London City Road & 
Hampstead National Research Ethics Service committee (10th February 2014, 
14/LO/0025). All participants provided written informed consent and were debriefed at 
                                                 
12 A two-way 2 x 3 repeated measures ANOVA sample size calculation (incorporating interaction effects) 
was conducted using G*Power, with a two-sided significance of 0.05 and a power of 0.95 (number of 
groups = 3; number of measurements = 6). This indicated that 36 participants were needed to detect a 




the end of the experiment. £50 was given to each participant as compensation for their 
time. The trial was registered at www.controlled-trials.com (29th April 2014, 
ISRCTN70396934). Participants were recruited between 1st May 2014 and 17th August 
2015, and data were collected between 20th May 2014 and 9th September 2015.  
 
 
Figure 5.1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram of 
the progress through the phases of this randomised controlled trial. 
 
5.3.2 Design and procedure 
A double-blind sham-controlled crossover design was employed in which all 
participants received three sessions of tDCS: (i) AR/CL; (ii) AL/CR; and (iii) sham. In 
an effort to minimise any potential learning effects, order of stimulation was 
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randomised and counterbalanced across participants by a third party using the block 
method (block size: 6). Electrode polarity for sham sessions was determined with a 
random number generator (0 or 1). Due to the inclusion of two electrode montages, it 
was not possible for the tDCS technician to be blinded; however, the patient and the 
researcher administering the experimental measures remained blind throughout. An 
intersession interval (≥ 2 days; M = 9.10, SD = 9.39) was used to avoid any carryover 
effects of stimulation and, for each participant, all three sessions were held at the same 
time of day.  
 
At the first appointment, participants completed several baseline assessments: 
demographic questionnaire, Eating Disorder Examination Questionnaire (EDE-Q; 
Fairburn & Beglin, 2008), and Depression Anxiety and Stress Scales (DASS-21; 
Lovibond & Lovibond, 1995). The following pre-tDCS measures were completed 
during each study session13: (i) TD task; (ii) Profile of Mood States (POMS; McNair et 
al., 1971); (iii) Positive and Negative Affect Schedule (PANAS; Watson et al., 1988); 
(iv) Food Challenge Task (FCT); (v) urge to binge-eat visual analogue scale (VAS); (vi) 
Mizes Eating Disorder Cognition Questionnaire-Revised (MEDCQ-R; Mizes et al., 
2000); and (vi) blood pressure/pulse. Participants then received a 20-minute session of 
tDCS (AR/CL, AL/CR, or sham). Immediately post-tDCS, they repeated the pre-tDCS 
measures in the same order, followed by a VAS measuring the tolerability of tDCS. A 
follow-up questionnaire was completed 24 hours later. At the end of the third 
appointment, intervention acceptability and blinding success were evaluated. A 
schematic representation of the study procedure is provided in Figure 5.2.  
                                                 
13 Previous studies have demonstrated good short-term test retest reliability for TD tasks (Weafer, 
Baggott, & de Wit, 2013) as well as for the POMS (McNair, Lorr, & Droppleman, 1971), PANAS 





Figure 5.2 Schematic representation of study procedure. 
 
5.3.3 Transcranial direct current stimulation 
tDCS was delivered using a neuroConn® DC-STIMULATOR (20 mins, 2 mA, 10-
second ramp on/off) via two 25cm2 surface sponge electrodes soaked in 0.9% sodium 
chloride. In the AR/CL condition, the anode and cathode were placed over the right (F4) 
and left DLPFC (F3), respectively. This montage was reversed for AL/CR tDCS. The 
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sites of stimulation were located using the Beam F3 Location System (Beam, Borckardt, 
Reeves, & George, 2009), which is based on the International 10-20 system. For sham 
tDCS, electrode placement corresponded to one of the active conditions (see Design and 
procedure). To mimic real stimulation, the device’s sham setting was used: a current 
was applied for the first 30 seconds of the session, after which it stopped automatically. 
Participants therefore experienced the initial tingling sensation but received no 
stimulation for the remaining 19.5 minutes. Our group has shown that this sham 
treatment cannot be distinguished from real tDCS (Kekic et al., 2014).  
 
5.3.4 Measures 
Measures are described in the order in which they were administered. The primary 
outcome variable was urge to binge-eat; all other outcomes were secondary.  
 
5.3.4.1 Urge to binge-eat visual analogue scale 
Participants rated their urge to binge-eat on a computerised VAS administered via 
Adaptive Visual Analog Scales software (Marsh-Richard, Hatzis, Mathias, Venditti, & 
Dougherty, 2009), which was anchored with “no urge to binge-eat” and “extreme urge 
to binge-eat”.  
 
5.3.4.2 Mizes Eating Disorder Cognition Questionnaire-Revised 
The MEDCQ-R (formerly the Mizes Anorectic Cognitions Questionnaire-Revised; 
Mizes et al., 2000) is a 24-item self-report inventory which assesses cognitions in EDs. 
Responses are made on a Likert scale ranging from 1 (strongly disagree) to 5 (strongly 
agree), yielding a global score and a score for three subscales: self-control and self-
esteem, rigid weight regulation and fear of weight gain, and weight and approval. 
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Interpretation of the scores involves converting raw scores into T-scores using the 
following formula: (obtained raw score – mean)/standard deviation x 10 + 50. 
Appropriate normative data are published elsewhere (Peak, Mizes, & Guillard Jr, 2012). 
Global MEDCQ-R T-score was used as the outcome variable for this measure.  
 
5.3.4.3 Food Challenge Task 
The FCT – which involves exposure to a food video, the presentation of real food, and a 
series of VASs – was initially developed by our group to induce and assess food 
cravings, and has been administered in our laboratory in variable formats (Kekic et al., 
2014; McClelland et al., 2016a; Uher et al., 2005; Van den Eynde et al., 2010; Van den 
Eynde, Guillaume, Broadbent, Campbell, & Schmidt, 2013). Based on recent literature 
(Cowdrey, Finlayson, & Park, 2013) and on feedback from participants in earlier studies 
(Kekic et al., 2014; McClelland et al., 2016a), several adaptations were made to the 
FCT for the present trial. Firstly, a new food video was created (5 mins) using clips 
from television advertisements. This video was piloted in 40 adults (9 males), who rated 
the foods shown as highly appetising (mean rating: 73.38/100) and whose hunger was 
significantly increased by the footage [t(39) = -6.37, p < .001, r = 0.71]. Secondly, the 
real foods presented were altered to cover four categories: high-calorie sweet 
(chocolate, sweets), high-calorie savoury (crisps, nuts), low-calorie sweet (orange, 
apple), and low-calorie savoury (table water crackers, rice cakes). Lastly, the VASs – 
which were computerised and administered via Adaptive Visual Analog Scales software 
– were modified so that both the wanting (craving) and the perceived liking of each real 
food were measured. For wanting, participants were asked “How much do you want 
some of the [food] right now?” and, for liking, they were asked “How pleasant would it 
be to experience the taste of the [food]?”. These questions have been used previously to 




5.3.4.4 Temporal discounting task 
TD was assessed with a hypothetical monetary choice task, modelled on an established 
paradigm (Steinglass et al., 2012; Weber et al., 2007). Eighty binary choices were 
administered in a random order: for each one participants chose between a smaller 
amount of money available immediately (smaller-sooner [SS] reward) and a larger 
amount available in 3 months (larger-later [LL] reward). Two types of decision framing 
were employed: Accelerate and Delay (40 binary choices in each set). In the Accelerate 
set, the LL reward remained at £100 and the SS reward increased from £20 to £98 in £2 
increments. In the Delay set, the SS reward was fixed at £50 while the LL reward 
increased from £52 to £130 in £2 increments. TD was quantified by determining 
participants’ discount factor – the magnitude of reduction in the present value of a 
future reward – for each choice set using a two-step procedure described elsewhere 
(Read, 2001; Steinglass et al., 2012; Weber et al., 2007). The value obtained ranges 
from 0 to 1, with smaller numbers indicating greater TD and thus a greater tendency to 
choose the immediate reward. The global discount factor was calculated as the mean of 
the Accelerate and Delay discount factors, and used as the outcome variable. 
 
5.3.4.5 Profile of Mood States 
The POMS (McNair et al., 1971) is a self-report measure containing 65 adjectives 
which respondents rate on a Likert scale ranging from 0 (not at all) to 4 (extremely). 
Participants answered in relation to how they were feeling at the time of responding 
(“right now”).  The scale includes six factors (tension, depression, anger, vigour, 
fatigue, and confusion). A total mood disturbance score can also be calculated (global 




5.3.4.6 Positive and Negative Affect Schedule 
The PANAS (Watson et al., 1988) consists of two 10-item self-report scales which 
measure positive and negative affect. On a Likert scale ranging from 0 (very slightly or 
not at all) to 4 (extremely), participants rate the extent to which they have experienced 
each of the 20 descriptors within a particular time frame (“right now” in the current 
study). Two scores are generated: positive (PANAS-positive) and negative (PANAS-
negative) affect.  
 
5.3.4.7 Tolerability, acceptability, and blinding of transcranial direct current 
stimulation 
Tolerability was assessed with a 10cm paper-based VAS measuring level of discomfort 
experienced during the tDCS. Acceptability was determined by asking participants 
whether they would consider taking part in a therapeutic trial of tDCS (involving ~20 
sessions), if it were available. The validity of the sham treatment was judged by asking 
participants and researchers who administered the experimental measures to identify the 
placebo session, and to rate their confidence in their answer on a 10cm paper-based 
VAS. 
 
5.3.4.8 Follow-up questionnaire 
The follow-up questionnaire was administered online (the URL was shared by email). 
Participants were required to state how many episodes of binge-eating, vomiting, 
laxative/diuretic use, and excessive exercise they had engaged in during the 24-hour 




5.3.5 Data analysis 
Statistical analyses were performed on IBM® SPSS® (version 21) using a two-sided 
significance of 0.05. A series of boxplots indicated that there were no obvious outliers 
in the data. For variables with normally distributed data, effects of tDCS were evaluated 
using two-way 3 (stimulation: AR/CL vs. AL/CR vs. sham) x 2 (timepoint: pre-tDCS 
vs. post-tDCS) repeated measures ANOVAs, whereby significant stimulation x 
timepoint interactions indicated that the effects of stimulation varied across conditions 
(simple effects analyses were used to determine which conditions differed). Where data 
were not normally distributed, Wilcoxon signed-rank tests were used to compare pre- 
and post-tDCS scores for each condition separately. Friedman’s one-way ANOVAs and 
one-way repeated measures ANOVAs were used to explore the effect of stimulation 
type (AR/CL vs. AL/CR vs. sham) on symptoms during the 24-hour follow-up period 
and on the discomfort experienced during tDCS, respectively. Blinding success was 
appraised using Pearson’s chi-square goodness-of-fit tests. Where relevant, effect sizes 
(r) are reported. Since this was a proof-of-principle study, an exploratory analysis of 
multiple outcomes was used in an attempt to identify hypotheses that could be subject to 
more rigorous future examination. To avoid being too conservative and making Type II 
errors, we did not correct for multiple comparisons.  
 
5.4 RESULTS 
5.4.1 Demographic and clinical characteristics 
The sample comprised 37 females and 2 males aged 18-48 (M = 25.85, SD = 6.62) with 
a mean BMI of 21.65 (SD = 3.20). The majority were right-handed (87.2%), described 
their ethnicity as “white” (74.4%), and had an annual personal income < £20,000 
(61.5%). All participants were educated to A Level standard or higher (a qualification 
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offered to students completing secondary or pre-university education in the UK). The 
mean global EDE-Q score was 4.21 (SD = 1.06) – with 61.5% of scores above the 
clinically relevant cut-off (≥ 4; Rø, Reas, & Rosenvinge, 2012) – and severe or 
extremely severe levels of depression (≥ 21), anxiety (≥ 15), and stress (≥ 26; indexed 
by the DASS-21) were reported by 56.4%, 43.6%, and 35.9% of participants, 




Table 5.1 Clinical characteristics of the study sample. 
  M (n) SD (%) Range 
Duration of illness (months) 110.87 95.62 4.00-528.00 
Time spent in treatment (months) 22.97 42.29 0.00-183.60 
Current treatment       
Psychotherapy (13) (33.3) - 
Pharmacotherapy (4) (10.3) - 
None (22) (56.4) - 
Been an inpatient?    
Yes (10) (25.6) - 
No (29) (74.4) - 
Bulimic behaviours per weeka    
Binge-eating 8.08 13.80 1.00-87.50 
Self-induced vomiting 8.10 14.25 0.00-88.00 
Laxative/diuretic abuse 1.15 3.06 0.00-14.00 
Fasting 2.44 2.44 0.00-10.00 
Excessive exercise 2.16 2.57 0.00-10.00 
EDE-Qb       
Restraint 3.92 1.21 0.60-6.00 
Eating concern 3.86 1.14 1.40-6.00 
Shape concern 4.68 1.24 0.75-6.00 
Weight concern 4.38 1.33 1.40-6.00 
Global 4.21 1.06 1.65-6.00 
DASS-21c       
Depression 20.62 10.39 0.00-38.00 
Anxiety 15.23 11.65 0.00-42.00 
Stress 21.97 10.19 2.00-42.00 
M, mean; SD, standard deviation; EDE-Q, Eating Disorder Examination Questionnaire; DASS-21, 
Depression Anxiety and Stress Scales. 
a Self-reported during the telephone screen. 
b Subscale and global scores can range from 0-6. 




5.4.2 Effects of transcranial direct current stimulation 
5.4.2.1 Eating disorder symptoms 
Three Wilcoxon signed-rank tests demonstrated that urge to binge-eat VAS scores were 
reduced following active [AR/CL: Z = -2.42, p = .016, r = -0.27, AL/CR: Z = -2.52, p = 
.012, r = -0.28] but not sham stimulation [Z = -1.26, p = .207, r = -0.14] (Figure 5.3). 
For global MEDCQ-R T-score, a repeated measures ANOVA revealed a significant 
main effect of timepoint [F(1, 38) = 11.92, p = .001], but not stimulation [F(2, 76) = 
0.30, p = .744], and a significant stimulation x timepoint interaction (with a Huynh-
Feldt correction) [F(1.63, 62.02) = 3.83, p = .035] (Figure 5.4). Simple effects analyses 
showed that AR/CL stimulation reduced global MEDCQ-R T-scores significantly more 
than both AL/CR [F(1, 38) = 4.42, p = .042, r = 0.32] and sham stimulation [F(1, 38) = 
5.17, p = .029, r = 0.35], and that AL/CR and sham tDCS exerted equivalent effects 
[F(1, 38) = 0.22, p = .643, r = 0.08]. Several Friedman’s ANOVAs showed that the 
frequency of binge-eating, vomiting, laxative/diuretic use, and excessive exercise during 





Figure 5.3 Mean urge to binge-eat visual analogue scale scores pre and post anode 
right/cathode left, anode left/cathode right, and sham transcranial direct current 
stimulation (tDCS).  
VAS, visual analogue scale; AR/CL, anode right/cathode left; AL/CR, anode left/cathode right; tDCS, 
transcranial direct current stimulation.  
* p < .05.  


































Figure 5.4 Mean global Mize’s Eating Disorder Cognition Questionnaire-Revised T-
scores pre and post anode right/cathode left, anode left/cathode right, and sham 
transcranial direct current stimulation (tDCS).  
MEDCQ-R, Mize’s Eating Disorder Cognition Questionnaire-Revised; AR/CL, anode right/cathode left; 
AL/CR, anode left/cathode right; tDCS, transcranial direct current stimulation.  
Note: pre-tDCS scores across the three conditions were not significantly different [F(2, 76) = 2.05, p = 
.136]. 
 
5.4.2.2 Wanting and liking of food 
Repeated measures ANOVAs were conducted to assess the effects of tDCS on the 
wanting and liking of each food separately, all foods together, sweet foods, savoury 
foods, high-calorie foods, low-calorie foods, sweet high-calorie foods, sweet low-
calorie foods, savoury high-calorie foods, and savoury low-calorie foods. There was a 
































variables [all p ≥ .091]. Non-significant main effects of stimulation [all p ≥ .123] and 
stimulation x timepoint interactions were observed for all wanting/liking outcomes [all 
p ≥ .100]. 
 
5.4.2.3 Temporal discounting behaviour 
Wilcoxon signed-rank tests showed that post-tDCS global discount factors were 
significantly higher (indicating increased self-regulatory control) than pre-tDCS scores 
following AR/CL [Z = -2.91, p = .004, r = -0.33] and AL/CR [Z = -3.04, p = .002, r = -
0.34] tDCS, but not sham tDCS [Z = -1.74, p = .083, r = -0.20] (Figure 5.5). 
 
 
Figure 5.5 Mean global discount factors pre and post anode right/cathode left, anode 






























AR/CL, anode right/cathode left; AL/CR, anode left/cathode right; tDCS, transcranial direct current 
stimulation.  
** p < .01.  
Note: pre-tDCS scores across the three conditions were not significantly different [X2(2) = 1.61, p = .446]. 
 
5.4.2.4 Mood 
A repeated measures ANOVA showed a significant main effect of timepoint [F(1, 35) = 
21.73, p = < .001], no main effect of stimulation [F(1.47, 51.44) = 2.19, p = .135], and a 
trend towards a significant stimulation x timepoint interaction for global POMS score 
[F(2, 70) = 2.92, p = .060]. Simple effects analyses demonstrated that AR/CL tDCS 
lowered global POMS scores significantly more than sham stimulation [F(1, 35) = 5.15, 
p = .030, r = 0.36]. In addition, although the two active conditions exerted similar 
effects on global POMS scores [F(1, 35) = 0.82, p = .371, r = 0.15], AL/CR tDCS was 
not significantly superior to sham stimulation [F(1, 35) = 2.32, p = .137, r = 0.25].  Two 
further repeated measures ANOVAs revealed a significant main effect of timepoint for 
PANAS-negative [F(1, 38) = 16.72, p < .001] but not PANAS-positive [F(1, 38) = 0.62, 
p = .435] score, and non-significant main effects of stimulation [all p ≥ .395] and 
interaction terms [all p ≥ .516] for both variables.   
 
5.4.3 Success of the blinding procedure 
Neither participants [41.0% correct; χ2(1) = 1.04, p = .308] nor researchers who 
administered the experimental measures [40.5% correct; χ2(1) = 0.87, p = .352] 
distinguished real from sham tDCS at a rate better than chance. Both parties expressed 
little confidence in their identification of the placebo session (10cm VAS, participants: 




5.4.4 Safety, tolerability and acceptability of transcranial direct 
current stimulation 
Three repeated measures ANOVAs revealed no effect of stimulation type on blood 
pressure or pulse [all p ≥ .104]. An additional repeated measures ANOVA revealed a 
main effect of stimulation on discomfort ratings [F(2, 76) = 5.82, p = .004]. Simple 
effects analyses showed that both real conditions were rated as more uncomfortable than 
sham tDCS [AR/CL: F(1, 38) = 7.14, p = .011, r = 0.40, AL/CR: F(1, 38) = 10.05, p = 
.003, r = 0.46]. Nevertheless, all sessions were associated with low levels of discomfort 
(10cm VAS, AR/CL: M = 2.82, SD = 2.40, AL/CR: M = 2.88, SD = 2.23, sham: M = 
1.72, SD = 1.54). Thirty-eight of 39 participants indicated that they would consider 
taking part in a therapeutic trial of tDCS (the remaining participant was unsure).  
 
5.5 DISCUSSION 
This is the first study to investigate the effects of tDCS in BN. The results provide 
positive proof-of-principle for the clinical utility of bilateral tDCS applied to the 
DLPFC in this patient population. Specifically, AR/CL tDCS transiently reduced the 
severity of ED-related cognitions (indexed by the MEDCQ-R) when compared with 
AL/CR and sham tDCS. In addition, both AR/CL and AL/CR suppressed the urge to 
binge-eat and increased the level of self-regulatory control exercised during a TD task. 
Compared to sham stimulation, mood (assessed with the POMS) improved after AR/CL 
but not AL/CR tDCS. Lastly, the three tDCS sessions exerted equivalent effects on the 





The decrease in symptoms of BN is consistent with emerging evidence demonstrating 
that modulation of the DLPFC with NIBS can induce therapeutic effects in EDs 
(Burgess et al., 2016; Khedr et al., 2014; McClelland et al., 2013; McClelland et al., 
2016a; McClelland, Kekic, Campbell, & Schmidt, 2016b). Though only modest 
improvements were recorded and no effects on actual bulimic behaviours were 
observed, cortical excitability changes generated by a single session of tDCS are slight 
(~20%) and appear to diminish approximately 1-2 hours post-stimulation (Alonzo, 
Brassil, Taylor, Martin, & Loo, 2012; Monte-Silva et al., 2013). Conversely, tDCS 
interventions comprising multiple sessions have been shown to produce consolidative 
and cumulative excitatory effects (Alonzo et al., 2012), and to elicit long-lasting clinical 
gains in several psychiatric disorders (Kekic et al., 2016b), including anorexia nervosa 
(Khedr et al., 2014). The results of this study therefore provide a strong rationale for 
conducting a tDCS treatment trial in BN.  
 
Our finding that active but not sham tDCS reduced TD behaviour contributes to 
research showing that this presumed stable personality trait can be altered acutely by 
experimental manipulation (Gray & MacKillop, 2015; Koffarnus, Jarmolowicz, 
Mueller, & Bickel, 2013; McClelland et al., 2016a), and suggests that the absence of 
change previously documented by our group (Kekic et al., 2014) might be attributable 
to differences in the TD task/measurement of discounting. It also supports a key role for 
the DLPFC in self-regulatory control, and provides some insight into the neurocognitive 
mechanisms through which tDCS might exert its therapeutic effects. Further 
mechanistic inferences can be drawn from our finding that real versus sham tDCS 
reduced total mood disturbance (though only at trend level), which corresponds to data 
from the depression literature (Meron, Hedger, Garner, & Baldwin, 2015). As negative 
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affect is generally elevated prior to binge-eating and purging (Berg et al., 2013), 
improvements in mood are likely to facilitate improvements in clinical symptoms.  
 
In this study, real versus sham stimulation had no impact on the wanting or liking of a 
selection of sweet and savoury high- and low-calorie foods, which contradicts the anti-
craving effects of tDCS reported previously (Fregni et al., 2008; Goldman et al., 2011; 
Kekic et al., 2014). Nevertheless, these prior studies were conducted in healthy 
individuals, whose cravings may have been less intense and more modifiable. It may 
also be that our method of assessment lacked sensitivity, since the craving index in our 
earlier study (Kekic et al., 2014) incorporated ratings of the sensory properties of the 
foods presented (i.e., smell, taste, and appearance), and cravings are known to represent 
desire for particular sensory stimulation (Weingarten & Elston, 1990). Alternatively, 
motivational tendencies towards food might be best captured with tasks assessing 
implicit as opposed to explicit wanting, such as those measuring reaction time 
(Cowdrey et al., 2013) or saccadic eye movement (Fregni et al., 2008). Another 
explanation for the lack of effect of tDCS on food wanting and liking relates to the 
neural bases of these constructs. Food reward processing is supported by ventral limbic 
frontostriatal circuits and, whilst DLPFC modulation has the potential to impact these 
pathways via their overlap with dorsal cognitive networks (Haber, 2016), they were not 
directly targeted by tDCS in this trial.  
 
The polarity effect identified in the present study – which favoured AR/CL over AL/CR 
tDCS – is in agreement with data from individuals with frequent food cravings (Fregni 
et al., 2008), and suggests that ED cognitions and mood disturbance may be 
hemispherically lateralised in BN. Indeed, cortical asymmetry has been reported in 
relation to a number of ED symptoms; for example, overeating and decision-making 
249 
 
impairments have been associated with reduced function in the right prefrontal cortex 
(Alonso-Alonso & Pascual-Leone, 2007), while disinhibition and appetitive 
responsivity have been linked to greater left-sided prefrontal activation (Ochner, Green, 
van Steenburgh, Kounios, & Lowe, 2009). These findings support the therapeutic 
potential of anodal (excitatory) and cathodal (inhibitory) modulation of the right and left 
DLPFC, respectively, but do not explain why AL/CR tDCS (and excitatory rTMS to the 
left DLPFC; Van den Eynde et al., 2010) too produces beneficial effects. It is also 
unclear why AL/CR stimulation failed to improve mood in this study, when this tDCS 
montage has been successfully used to treat major depression (Meron et al., 2015). 
Additional neuroimaging data may foster a greater understanding of brain laterality in 
BN.  
 
This study has several limitations. Firstly, by chance, there was a trend for pre-tDCS 
urge to binge-eat scores to differ across the conditions: slightly lower values were 
obtained before sham tDCS than before AR/CL and AL/CR tDCS (Figure 5.3), 
allowing less scope for improvement in the sham session. Similarly, pre-tDCS 
MEDCQ-R scores appeared to be highest before AR/CL tDCS (Figure 5.4), although 
this difference did not approach significance. Secondly, due to the high levels of 
psychiatric comorbidity associated with BN (O'Brien & Vincent, 2003), we did not 
exclude individuals with co-occurring mental disorders. While it seems unlikely, it is 
not possible to state whether an effect of tDCS on comorbid psychiatric symptoms 
contributed to the findings (Sauvaget et al., 2015). Thirdly, we included both left- and 
right-handed participants, and handedness influences the effects of rTMS in BN (Van 
den Eynde et al., 2012). Fourthly, although the researcher administering the 
experimental measures was blind to the stimulation condition, we cannot rule out the 
possibility that participants were influenced by interaction with the unblinded tDCS 
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technician. Lastly, data on ED symptoms immediately after stimulation were gathered 
using self-report psychological measures. This limits the clinical applicability of our 
findings since the principal goal of BN treatments is normalisation of eating behaviour.  
 
5.6 CONCLUSIONS 
The current research provides preliminary evidence that bilateral tDCS to the DLPFC 
has the potential to induce therapeutic effects in BN, at least temporarily. It also 
elucidates possible mechanisms of action and informs the design of future trials, 
particularly in relation to electrode montage selection. While only modest conclusions 
can be drawn regarding the clinical utility of tDCS in BN, our findings offer support 
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6.1 HYPOTHESES TESTED 
The overarching aim of this research was to investigate the therapeutic utility of 
transcranial direct current stimulation (tDCS) in bulimia nervosa (BN). Four major 
hypotheses were tested: 
(1) Exiting literature demonstrates that tDCS induces beneficial clinical effects 
in several psychiatric disorders, and may therefore have therapeutic potential 
in BN (chapter 2). 
(2) A single session of real versus sham tDCS applied to the bilateral 
dorsolateral prefrontal cortex (DLPFC) will temporarily reduce food craving 
and temporal discounting (a marker of low self-regulatory control denoting a 
preference towards more immediate rewards) in healthy women with 
frequent food cravings – again, suggesting tDCS may have therapeutic 
potential in BN (chapter 3).  
(3) Individuals with BN will display increased temporal discounting (i.e., poor 
self-regulatory control) relative to healthy comparison participants (chapter 
4). 
(4) A single session of real versus sham tDCS applied to the bilateral DLPFC 
will temporarily reduce symptoms, improve mood, alter food wanting/liking, 
and decrease temporal discounting (i.e., improve self-regulatory control) in 
individuals with BN (chapter 5). 
 
6.2 SUMMARY OF THE FINDINGS 
The first hypothesis was tested in a systematic review of the clinical efficacy of tDCS 
across all psychiatric disorders (chapter 2). Sixty-six studies were appraised in total and, 
overall, data suggested that tDCS interventions comprising multiple sessions can 
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ameliorate symptoms of major depression, schizophrenia, and substance use disorders, 
both acutely and in the long-term. Limited support for the therapeutic potential of tDCS 
in obsessive compulsive disorder, generalised anxiety disorder, and anorexia nervosa 
(AN) was also obtained. Although a considerable proportion of the evidence was 
derived from case studies/series, and several methodological and ethical issues were 
identified, this review supports hypothesis one and provides a rationale for research 
investigating the clinical utility of tDCS in individuals with BN.  
 
A randomised controlled trial (RCT) in 17 healthy women with frequent food cravings 
was conducted to test hypothesis two (chapter 3). Results showed that a single session 
of real versus sham tDCS applied to the bilateral DLPFC (anode right/cathode left) 
transiently reduced cue-induced craving for sweet but not savoury food, and had no 
effect on temporal discounting or actual food consumption during a free-eating task. In 
addition, participants who exhibited lower rates of temporal discounting (i.e., greater 
self-regulatory control) were more susceptible to the anti-craving effects of stimulation 
than those who displayed higher rates of temporal discounting (i.e., poorer self-
regulatory control). Lastly, the blinding procedure employed was effective and tDCS 
was shown to be a safe and tolerable intervention. Since tDCS temporarily altered 
anticipatory food reward processing but had no effect on self-regulatory control, these 
findings provide partial support for hypothesis two and for the application of tDCS in 
BN.  
 
The third hypothesis was tested in a cross-sectional study examining temporal 
discounting behaviour in 39 patients with BN as compared with 53 healthy controls 
(chapter 4). Consistent with expectations, the BN group showed greater temporal 
discounting (i.e., poorer self-regulatory control) during a computerised task – even after 
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controlling for several confounding variables – as well as a decreased self-reported 
capacity to delay gratification (the reverse of temporal discounting). Temporal 
discounting was not significantly correlated with body mass index or with any clinical 
outcomes (i.e., general/eating disorder [ED] psychopathology and illness 
duration/severity) among individuals with BN, whilst delaying gratification was 
negatively related to anxiety and stress only. Given the between-group differences 
observed, findings from this study substantiate the idea that altered self-regulatory 
control could be a relevant target for intervention among individuals with BN, and thus 
offer support for the testing of hypothesis four.  
 
To test the fourth major hypothesis, an RCT of single-session tDCS applied to the 
bilateral DLPFC was carried out in 39 patients with BN14 (chapter 5). The design of this 
study was informed by the preliminary RCT discussed above: several changes were 
made to the food-exposure task (see section 5.3.4.3), a new temporal discounting task 
was created that was considered more sensitive, and a third tDCS condition was added 
to the protocol (anode left/cathode right). Results revealed that, firstly, anode 
right/cathode left tDCS reduced ED cognitions when compared to anode left/cathode 
right and sham tDCS. Secondly, both active conditions suppressed the self-reported 
urge to binge-eat and increased self-regulatory control during the temporal discounting 
task. Thirdly, compared to sham stimulation, mood improved after anode right/cathode 
left but not anode left/cathode right tDCS. Fourthly, the three tDCS sessions had 
comparable effects on the wanting/liking of food and on bulimic behaviours during the 
24 hours post-stimulation. Lastly, the intervention demonstrated safety and high 
tolerability/acceptability among participants. Since tDCS transiently improved 
                                                 
14 These patients were the same ones who took part in the study presented in chapter 4.   
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symptoms, mood, and self-regulatory control but had no impact upon food 
wanting/liking, the findings from this experiment partially support hypothesis four.  
 
6.3 IMPLICATIONS 
6.3.1 Treatment of bulimia nervosa 
The results of studies presented in this thesis suggest that tDCS may have potential for 
development as a treatment for adult BN. This is an exciting prospect given the sizeable 
proportion of patients (~23%; Steinhausen & Weber, 2009) who do not respond to 
available psychological and pharmacological therapies for the disorder. Nevertheless, 
despite considerable data supporting the clinical utility of tDCS in major depression and 
schizophrenia (see chapter 2), neither the US Food and Drug Administration Agency 
nor the UK National Institute for Health and Care Excellence have approved the use of 
this neuromodulation tool for these conditions. Therefore, even if evidence of efficacy 
in BN accumulates, it will probably be many years before tDCS is used to treat 
individuals with this ED.  
 
6.3.2 Neurobiology of bulimia nervosa 
The ability of tDCS to transiently ameliorate symptoms of BN – reported in chapter 5 of 
this thesis – provides evidence that the condition has a neural basis. Furthermore, the 
concurrent reduction in temporal discounting offers indirect support for the self-
regulation neurocircuit model of BN (see section 1.2.5.1), and for the involvement of 
the DLPFC and wider dorsal cognitive circuitry in the pathogenesis of the disorder. 
Improvements in symptoms were not accompanied by alterations in the wanting or 
liking of food, hence the food reward processing neurocircuit model of BN (see section 
1.2.5.2) was not substantiated. Nevertheless, the ventral frontostriatal circuits implicated 
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in this model were not directly targeted by tDCS. Alternatively, the observation that 
food craving was reduced by DLPFC tDCS among healthy ‘food cravers’ raises the 
possibility that the null result in BN was related to differences in the task administered 
(see section 5.5).  
 
Figure 6.1 shows the neurobiological model of BN, initially presented in section 1.2.8, 
amended to incorporate findings from the current research. According to this model, 
dysregulated overlapping dorsal cognitive and ventral limbic frontostriatal neurocircuits 
contribute to impaired self-regulatory control and food reward processing, respectively. 
The combination of these behavioural maladies leads to binge-eating, which is made 
more likely by negative affect. Compensatory behaviours, intended to prevent weight 
gain, ensue due to an over-concern with body weight and shape. This cycle is repeated 
and maintained as a result of altered habit learning processes caused by disturbances in 





Figure 6.1 Neurobiological model of bulimia nervosa incorporating findings reported in 
this thesis.  
Components influenced by transcranial direct current stimulation (tDCS) are shown in 
yellow. tDCS applied to the bilateral dorsolateral prefrontal cortex (part of the dorsal 
frontostriatal circuitry) was found to lower food craving (i.e., alter food reward 
processing) in healthy participants with frequent food cravings. It was also shown to 
decrease temporal discounting (i.e., improve self-regulatory control), and to reduce 
negative affect, the urge to binge-eat, and eating disorder cognitions (e.g., over-concern 
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with weight and shape15) in individuals with bulimia nervosa. Compensatory 
behaviours, habit learning, and reward-based learning were not assessed in either of 
the tDCS studies presented in this thesis. 
 
6.4 STRENGTHS 
The main strengths associated with the studies presented in this thesis relate to the 
novelty of the research conducted. Most notably, the paper that forms chapter 4 is the 
first to examine temporal discounting behaviour in people with BN, and chapter 5 
reports on the first known investigation of tDCS in this patient population. The latter 
study was also innovative because, in addition to assessing the clinical efficacy of 
tDCS, it explored the impact of electrode polarity manipulation and probed the 
neurocognitive mechanisms driving the therapeutic response to stimulation. Although 
tDCS had been administered to ‘frequent food cravers’ prior to the experiment 
discussed in chapter 3, this was the first time the moderating role of self-regulatory 
control was considered. Finally, chapter 2 comprises the first published systematic 
review of tDCS across all psychiatric disorders to incorporate a standardised quality 
assessment. 
 
                                                 
15 Eating disorder cognitions were assessed with the Mize’s Eating Disorder Cognitions Questionnaire-
Revised (MEDCQ-R). Although this questionnaire measures eating disorder cognitions in general, 16 of 




6.5.1 Methodological limitations 
The major methodological limitations associated with the studies included in this thesis 
are outlined in the discussion sections of chapters 3-5. Overall, this research is primarily 
compromised by the assessment (or lack of assessment) of actual eating behaviour 
immediately following tDCS. Although food intake post-stimulation was measured 
among frequent food cravers, the task administered (see section 3.3.9) lacked ecological 
validity, which may explain why participants were found to eat equal amounts 
following real and sham stimulation. Indeed, a single session of tDCS applied to the 
bilateral DLPFC has previously been shown to reduce caloric ingestion in healthy 
individuals with frequent food cravings (Fregni et al., 2008). Due to validity concerns, 
and because laboratory eating paradigms are likely to elicit high levels of anxiety 
among individuals with EDs, the free-eating task was omitted from the BN tDCS study. 
Therefore, while the intervention significantly lowered the self-reported urge to binge-
eat, whether this would have translated into an immediate reduction in actual binge-
eating behaviour is unknown.  
 
Additional shortcomings of the present research relate to the study samples. Firstly, due 
to safety concerns surrounding the delivery of tDCS in children (Kessler et al., 2013), 
only individuals over the age of 18 were eligible to participate. Since BN commonly 
begins in adolescence, and focus on the early pre-syndromal stages of illness may be 
associated with better outcomes in EDs (Currin & Schmidt, 2005), restricting tDCS 
interventions to adults with BN may reduce their probability of success. Secondly, of 
the 56 people who took part in the tDCS research, only 2 were male. Although BN 
affects more women than men, this ratio of male-to-female participants (1:27) far 
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exceeds sex ratio estimates for the disorder (see section 1.1.3.3). Thirdly, all 56 
participants were educated to A-Level standard or higher, which to some extent may 
limit the generalisability of the findings. Nevertheless, while educational attainment 
among participants was higher than in the general population (in 2015 in England, 
63.4% of 19-64-year-olds held a qualification at this level or above; Department for 
Education, 2017), being female and having BN have been associated with increased 
education (Kessler et al., 2014). Finally, the tDCS studies conducted are likely to have 
attracted an unrepresentative subgroup of patients with BN – i.e., those who have failed 
previous treatments and are thus interested in trying novel strategies – though this is an 
issue in most neuromodulation research that causes little concern since these brain-
directed techniques are currently considered potential second-line therapies for 
psychiatric disorders.  
 
6.5.2 Theoretical limitations 
The rationale behind the present research stems partly from neurocircuit models of BN 
that implicate dysregulated dorsal and ventral frontostriatal pathways in the 
development of the disorder (see section 1.2.5). Whilst these models have provided 
valuable new insights into the pathophysiology of EDs, they fail to address cortical 
laterality and there are considerable inconsistencies and contradictions within the 
literature on which they are based. For example, functional magnetic resonance imaging 
investigations of reward system function in BN have observed hypo-activation 
(Radeloff et al., 2014), hyper-activation (Bohon & Stice, 2011), and ‘normal’ activation 
(Van den Eynde et al., 2013) in patients responding to food reward. Similarly, in 
comparison to healthy controls, individuals with BN have demonstrated both increased 
(Lock, Garrett, Beenhakker, & Reiss, 2011) and decreased (Marsh et al., 2009) 
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frontostriatal activation during neuropsychological tasks that engage self-regulatory 
control processes.  
 
Inconsistencies in behavioural data also exist: although there is evidence that people 
with BN perform poorly on laboratory self-regulation tasks – including temporal 
discounting (see chapter 4) – many studies fail to replicate this finding (for reviews see 
Bartholdy, Dalton, O'Daly, Campbell, & Schmidt, 2016; Wu et al., 2016; Wu, 
Hartmann, Skunde, Herzog, & Friederich, 2013). Furthermore, ‘controlled’ dietary 
restraint may be just as central to BN as ‘impulsive’ binge-eating, and a relatively large 
proportion of individuals with the disorder have previously suffered from AN (Eddy et 
al., 2008), which is thought to involve excessive self-regulatory control (Steinglass et 
al., 2012). These poorly understood behavioural and neurobiological disparities thwart 
our understanding of the aetiology of BN and undermine the theoretical background to 
this research.  
 
6.6 DIRECTIONS FOR FUTURE RESEARCH 
6.6.1 Multi-session trials 
Whilst the present research provides an important first step in elucidating the 
therapeutic utility of tDCS in BN, multi-session trials are needed to determine whether 
this neuromodulatory technique has potential for development as a treatment for the 
disorder. Indeed, the majority of tDCS clinical efficacy studies conducted in psychiatric 
populations have administered repeated sessions of stimulation (see chapter 2), which 
are presumed to have cumulative effects associated with greater magnitude and duration 
of behavioural responses, due to the induction of neuroplasticity (Brunoni et al., 2012; 




Empirical evidence for dose-dependent additivity in tDCS was reported by Monte-Silva 
and colleagues (2010), who found that performing a second stimulation session during 
the after-effects of a first led to a prolongation and enhancement of tDCS-induced 
effects. Furthermore, Boggio et al. (2007) observed enduring motor function 
improvement in stroke patients following five consecutive daily sessions of tDCS, but 
not after four weekly sessions. Although the optimal repetition rate and duration to 
promote tDCS-induced plasticity remains to be determined, long-lasting effects are 
undoubtedly crucial for clinical purposes (Brunoni et al., 2012), thus investigations of 
multi-session tDCS in BN are essential.  
 
6.6.2 Accessibility considerations 
The therapeutic utility of tDCS must be established through trials that are sufficiently 
powered and which include an adequate number of stimulation sessions (Charvet et al., 
2015). As noted in section 2.5.3, additional evidence of efficacy from large-scale RCTs 
is necessary to permit the transition of this neuromodulatory technique from bench to 
bedside. Given that the effects of tDCS are cumulative, treatment protocols require 
multiple consecutive sessions spanning several weeks or months, which places a 
significant burden on patients and their caregivers, and often leads to high attrition rates 
(Charvet et al., 2015). Such demanding treatment regimens are likely to be problematic 
for individuals with BN, who are typically engaged in full- or part-time employment. 
Furthermore, these labour-intensive study designs are time-consuming and costly for the 
providers, particularly with increased sample sizes (Charvet et al., 2015).  
 
In light of these difficulties, neuromodulation manufacturers have developed tDCS 
devices that enable controlled remote application and are specifically designed for 
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home-based use. While there has not yet been a clinical trial involving remotely-
supervised tDCS in patients with a psychiatric disorder, protocols for those in 
neurological conditions are emerging (Kasschau et al., 2015; O’Neill, Sacco, & 
Nurmikko, 2015), and the safety and efficacy of a self-administered tDCS programme 
were recently established among patients with mal de debarquement syndrome (a 
neurological condition characterised by a persistent rocking or swaying sensation; Cha, 
Urbano, & Pariseau, 2016). Despite obvious limitations associated with self- or proxy-
administered tDCS away from the clinic, the implementation of home-based tDCS in 
psychiatric research has the potential to dramatically accelerate progress in the field.  
 
6.6.3 Transcranial direct current stimulation and cognitive training 
Extensive data indicate that tDCS can enhance cognitive performance among people 
with mental disorders across a range of domains, including self-regulatory control (see 
chapter 5), working memory, attention, and processing speed (for a review see Tortella 
et al., 2015). There has therefore been growing interest in examining the potential 
synergistic effects of tDCS in combination with cognitive training (interventions 
designed to improve targeted cognitive abilities). For example, Saunders et al. (2015) 
treated a pilot group of patients suffering from post-traumatic stress disorder and poor 
working memory with computerised cognitive training and tDCS, and observed both 
behavioural and neuropsychological improvements in all four participants. Moreover, in 
individuals with major depression, the co-administration of cognitive control training 
and tDCS has been found to induce a greater reduction in symptoms than administration 
of either treatment in isolation (Brunoni et al., 2014; Segrave, Arnold, Hoy, & 
Fitzgerald, 2014). Since BN is associated with difficulties in various aspects of 
cognition (Van den Eynde et al., 2011; see chapter 4), and the therapeutic effects of 
tDCS in BN may be underpinned in part by alterations in self-regulatory control 
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processes (see chapter 5), the efficacy of combined tDCS and cognitive training in 
treating individuals with this condition certainly warrants investigation. Cognitive 
training methods that could be helpful here include attention bias modification, which 
targets cognitive biases such as those towards food cues, and mindfulness-based 
interventions, which work on building a present-focused attentional state that 
emphasises observing and experiencing. Both have shown promise in reducing binge-
eating and other ED symptoms (Brockmeyer, Hahn, Reetz, Schmidt, & Friederich, 
2015; Godfrey, Gallo, & Afari, 2015).  
 
6.6.4 Transcranial direct current stimulation and neuroimaging 
Despite numerous clinical applications in large numbers of patients suffering from 
psychiatric disorders, how tDCS influences the mentally affected human brain is not 
fully understood (Baeken, Brunelin, Duprat, & Vanderhasselt, 2016; see section 1.3.3). 
Indeed, the notion that the therapeutic effects of stimulation reported in the present 
research are underscored by changes in frontostriatal circuitry is speculative. Given that 
tDCS has poor spatial focality (Nitsche et al., 2007), it is possible that alterations within 
neighbouring circuits contributed to the responses observed.  
 
In recent years, the simultaneous application of neuromodulation and neuroimaging 
methods has answered questions about the relationship between the physiological 
impact of tDCS and its behavioural consequences (Bestmann & Feredoes, 2013); 
however, so far, neuroimaging evidence of the distributed network modulatory effects 
of tDCS is largely limited to the motor system (Baeken et al., 2016). Future studies in 
psychiatric populations should use electroencephalography-recorded event related 
potentials to provide a fast indication of whether the neuronal network of interest has 
been targeted, while the co-registration of functional magnetic resonance imaging and 
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tDCS may help to elucidate spatial connectivity patterns following stimulation (Baeken 
et al., 2016). Finally, clinical trials that use neuroimaging to examine brain structure and 
function before and after multi-session tDCS interventions in BN and other mental 
disorders are merited.  
 
6.6.5 Transcranial direct current stimulation and genetic testing 
Data suggest that the individual genetic profile may modulate both the clinical (see 
section 2.5.1.1) and cognitive effects of tDCS. Of particular relevance to this research, a 
polymorphism of the catechol-O-methyltransferase (COMT) gene (Val158Met) – which 
regulates prefrontal dopamine – appears to predict the effect of tDCS to the left DLPFC 
on executive functions in healthy participants (Nieratschker, Kiefer, Giel, Krüger, & 
Plewnia, 2015; Plewnia et al., 2013). Specifically, COMT Met allele homozygosity (the 
high dopamine-activity genotype) has been associated with a deterioration of set-
shifting ability (a measure of cognitive flexibility) following anodal tDCS (Plewnia et 
al., 2013), while Val homozygosity (the low dopamine-activity genotype) has been 
linked to a cathodal tDCS-induced impairment in response inhibition (a facet of self-
regulatory control; Nieratschker et al., 2015). These findings have important 
implications for tDCS as a treatment for BN, since a therapeutic response in patients 
with the disorder may be dependent on improvements in self-regulatory control 
processes (see chapter 5). Importantly, there is evidence that homozygosity for the Val 
allele of the COMT Val158Met polymorphism increases the risk of having BN, and that 
patients with this genotype score higher on measures of ineffectiveness, drive for 
thinness, and perfectionism than those homozygous for the Met allele (Mikołajczyk, 
Grzywacz, & Samochowiec, 2010). Future research may benefit from accounting for 
genetic variability in the design and analysis of therapeutic tDCS applications 
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(Nieratschker et al., 2015), although the widespread implementation of this approach is 
unlikely to be economically or practically feasible.  
 
6.6.6 Dimensional approaches to psychiatric disorders 
The present research relies on a categorical diagnostic approach to BN, which considers 
the illness as being either present or absent. Although this model of classification has 
facilitated reliable clinical diagnosis and research in psychiatry for many years, it is 
increasingly being recognised as problematic for a number of reasons. For example, 
diagnostic categories based upon presenting signs and symptoms fail to align with 
findings emerging from clinical neuroscience and genetics, and the boundaries of these 
categories have not been predictive of treatment response (Insel et al., 2010). Moreover, 
this method of classification may fail to capture fundamental underlying mechanisms of 
dysfunction (Insel et al., 2010).  
 
To address the need for a new approach to classifying mental disorders, the US National 
Institute of Mental Health (NIMH) launched the Research Domain Criteria (RDoC) 
project – a framework for organising research which incorporates an explicitly 
dimensional approach to psychopathology, and which will ultimately inform future 
taxonomic schemes (Cuthbert & Insel, 2013; Morris & Cuthbert, 2012). The RDoC 
framework is currently conceived as a two-dimensional matrix: the rows represent 
domains of functioning (e.g., cognitive systems) and the columns denote different levels 
of analysis (e.g, circuits) (Insel et al., 2010; National Institute of Mental Health, n.d.).  
 
This approach is likely to guide the development of novel brain-directed treatments – 
like tDCS and other forms of neuromodulation – because it will make it possible to 
recruit participants to clinical trials based on a relevant neurobiological mechanism of 
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dysfunction, rather than simply enrolling individuals with a particular ‘disorder’. This 
may result in studies with samples spanning multiple Diagnostic and Statistical Manual 
of Mental Disorders (DSM) diagnoses. Indeed, the dysregulated frontostriatal circuits 
targeted in the present research have been implicated not only in BN, but also in several 
other conditions including AN, binge-eating disorder, and substance use disorders (see 
sections 1.2.6 and 1.2.7). Although RDoC is by no means a short-term project, it can be 




The research presented in this thesis is based on the empirically supported premise that 
BN is underpinned by impairments in self-regulatory control and food reward 
processing, which are encoded in dorsal cognitive and ventral limbic frontostriatal 
circuits, respectively. According to this neurobiological model of BN, non-invasive 
brain stimulation techniques, such as tDCS, capable of enhancing frontostriatal function 
may hold promise as treatments for the disorder.  
 
Taken together, the findings reported in chapters 2-5 provide preliminary support for the 
therapeutic utility of tDCS in BN. Firstly, the systematic review shows that this 
neuromodulatory tool has produced significant clinical benefits in a range of psychiatric 
disorders. Secondly, the RCT in healthy volunteers reveals that stimulation of the 
DLPFC with tDCS can reduce food craving (i.e., alter food reward processing). Thirdly, 
the cross-sectional study confirms the presence of self-regulatory control difficulties in 
patients with BN. Lastly, the RCT in BN demonstrates the ability of tDCS over the 
DLPFC to reduce symptoms, improve mood, and increase self-regulatory control 
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among individuals with the condition. Overall, this thesis paves the way for future 
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APPENDIX B: ETHICAL APPROVAL 
Appendix B.1 Ethical approval for study of tDCS in healthy individuals 
with frequent food cravings 
Maria Kekic 
50 Azalea Walk 
Pinner  
Middlesex HA5 2EH  
 
27 March 2013 
 
Dear Maria  
 
PNM/12/13-112 An investigation into the effects of transcranial direct current stimulation 
(tDCS) on food cravings and self-regulation in healthy women. 
 
Review Outcome: Full Approval 
 
Thank you for submitting an application to the PNM RESC which was reviewed on 19 March 
2013.  I am pleased to inform you that these meet the requirements of the PNM RESC and 
therefore that full approval is now granted with the following provisos: 
1. Section 2.8: Please complete this section.  Please email your response to Rebecca 
Cowper: Rebecca.cowper@kcl.ac.uk, quoting your reference number on all 
correspondence. 
2. Consent Form: Please use tick boxes for all of the statements, permitting participants to 
consent to each clause. 




Note that you should submit a response to the above provisos where specified; it is a condition of 
the approval granted by the PNM RESC that the provisos are carried out prior to the study 
commencing.  If the provisos are not adhered to, the approval granted by the PNM RESC would 
no longer be valid. Should you have any queries on this please do not hesitate to contact the 
Research Ethics Office. 
 
Please ensure that you follow all relevant guidance as laid out in the King's College London 
Guidelines on Good Practice in Academic Research 
(http://www.kcl.ac.uk/college/policyzone/index.php?id=247). 
 
For your information ethical approval is granted until 19 March 2014. If you need approval 
beyond this point you will need to apply for an extension to approval at least two weeks prior to 
this explaining why the extension is needed, (please note however that a full re-application will 
not be necessary unless the protocol has changed). You should also note that if your approval is 
for one year, you will not be sent a reminder when it is due to lapse. 
 
Ethical approval is required to cover the duration of the research study, up to the conclusion of 
the research. The conclusion of the research is defined as the final date or event detailed in the 
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study description section of your approved application form (usually the end of data collection 
when all work with human participants will have been completed), not the completion of data 
analysis or publication of the results. For projects that only involve the further analysis of pre-
existing data, approval must cover any period during which the researcher will be accessing or 
evaluating individual sensitive and/or un-anonymised records. Note that after the point at which 
ethical approval for your study is no longer required due to the study being complete (as per the 
above definitions), you will still need to ensure all research data/records management and 
storage procedures agreed to as part of your application are adhered to and carried out 
accordingly. 
 
If you do not start the project within three months of this letter please contact the Research Ethics 
Office.  
 
Should you wish to make a modification to the project or request an extension to approval you will 
need approval for this and should follow the guidance relating to modifying approved applications: 
http://www.kcl.ac.uk/innovation/research/support/ethics/applications/modifications.aspx   
The circumstances where modification requests are required include the addition/removal of 
participant groups, additions/removal/changes to research methods, asking for additional data 
from participants, extensions to the ethical approval period. Any proposed modifications should 
only be carried out once full approval for the modification request has been granted. 
 
Any unforeseen ethical problems arising during the course of the project should be reported to 
the approving committee/panel. In the event of an untoward event or an adverse reaction a full 
report must be made to the Chair of the approving committee/review panel within one week of the 
incident. 
 
Please would you also note that we may, for the purposes of audit, contact you from time to time 
to ascertain the status of your research.  
 
If you have any query about any aspect of this ethical approval, please contact your 
panel/committee administrator in the first instance 
(http://www.kcl.ac.uk/innovation/research/support/ethics/contact.aspx). We wish you every 
success with this work. 
 






Rebecca Cowper  
Research Support Assistant  
For and on behalf of 
Mrs Joyce Epstein, Vice-Chair  
Psychiatry, Nursing and Midwifery Research Ethics Subcommittee (PNM RESC)  
 
 





























                                                 








APPENDIX C: RECRUITMENT DOCUMENTS 
Appendix C.1 Recruitment documents for study of tDCS in healthy 
individuals with frequent food cravings 
Appendix C.1.1 Poster 
 
Appendix C.1.2 King’s College London (KCL) recruitment email 
Transcranial direct current stimulation (tDCS) in food cravings and decision 
making – advertisement 
 
Advertisement for use for recruitment of volunteers for study ref: PNM/12/13-112, 
approved by the Psychiatry, Nursing and Midwifery Research Ethics Subcommittee 
(PNM RESC). This project contributes to the College's role in conducting research, and 
teaching research methods. You are under no obligation to reply to this email, however 
if you choose to, participation in this research is voluntary and you may withdraw at 
anytime. 
 
Research shows that the frontal areas of the brain play a role in the control of eating, 
and that variation in activity in these areas might explain why some people get food 
cravings and others do not. The same areas might also be involved in decision making 
processes. This study aims to find out whether a single session of tDCS (a technique 
used to stimulate specific areas of the brain) has any short-term effects on food 




To take part you must be a female aged between 18 and 60 who has frequent food 
cravings (your eligibility will be confirmed over a 20 minute telephone call). If you 
choose to participate you will be required to attend two sessions (48 hours apart) at the 
Institute of Psychiatry, lasting 1.5-2 hours each. The sessions will involve completing a 
series of questionnaires, a neuropsychological task (brain puzzle), and a food task. 
You will also receive a 20-minute tDCS session and have saliva samples collected to 
measure cortisol levels (a stress hormone). You will be reimbursed £30 for your time 
plus travel expenses (up to £5).  
 
If you are interested in taking part or would like further information please email 
maria.kekic@kcl.ac.uk or call 07814798727. Full details of the study will be available 
on the participant information sheet that will be sent to you upon response to this 
advertisement. Pease note that contacting us for further information does not mean you 
are obliged to take part in the study.  
 




Appendix C.2 Recruitment documents for study of tDCS in patients with 
BN 





Appendix C.2.2 Text for KCL and Experimatch recruitment webpage advertisements 
TREAT - Transcranial direct current stimulation (tDCS) in eating disorders  
 
We are investigating the effects of a non-invasive brain stimulation technique 
called transcranial direct current stimulation (tDCS) on eating disorder 
symptoms in people with bulimia nervosa.  
 
Advertisement for use for recruitment of volunteers for study ref: 14/LO/0025, approved 
by the City Road and Hampstead Ethics Committee. This project contributes to the 
college's role in conducting research, and teaching research methods. You are under 
no obligation to reply to this email, however if you choose to, participation in this 
research is voluntary and you may withdraw at anytime. 
 
Psychological therapies are often ineffective for people with bulimia nervosa (BN); 
therefore there is an ongoing need for the development of new treatments. Research 
shows that the frontal areas of the brain play a role in the development and 
maintenance of eating disorders, including BN. Stimulating these brain areas to alter 
their functioning is therefore believed to have the potential to reduce eating disorder 
symptoms. A technique that is capable of stimulating specific brain areas is called 
transcranial direct current stimulation (tDCS). This involves the delivery of a low 
electrical current via small electrodes placed on the scalp. This procedure is widely 
used in research and is being applied in clinical settings.  
 
This study aims to investigate the short-term effects of a single session of tDCS in 
individuals who suffer from BN. In particular, we are interested in its effects on thought 
processes and emotions relating to food, eating, weight, and body shape. In the long 
term, this may help us to develop improved treatments for BN. 
 
To take part you must be a male or female aged between 18 and 70 who has a current 
diagnosis of BN or a related disorder (your eligibility will be confirmed over a 20-minute 
telephone call). If you choose to participate you will be required to attend three 
sessions at the Institute of Psychiatry, lasting approximately 1.5 hours each. The 
sessions will involve completing a series of questionnaires, a neuropsychological task 
(brain puzzle), and a food task (you will not be asked to eat any food). You will also 
receive a 20-minute tDCS session. You will be reimbursed £50 for your time.  
 
If you are interested in taking part or would like further information please email 
maria.kekic@kcl.ac.uk or call 02078480183. Full details of the study will be available 
on the participant information sheet that will be sent to you upon response to this 
advertisement. Please note that contacting us for further information does not mean 
you are obliged to take part in the study.  
 





Appendix C.2.3 Text for Beat recruitment webpage advertisement 




Psychological therapies are often ineffective for people with bulimia nervosa (BN); 
therefore there is an ongoing need for the development of new treatments. Research 
shows that the frontal areas of the brain play a role in the development and maintenance 
of eating disorders, including BN. Stimulating these brain areas to alter their functioning is 
therefore believed to have the potential to reduce eating disorder symptoms. A technique 
that is capable of stimulating specific brain areas is called transcranial direct current 
stimulation (tDCS). This involves the delivery of a low electrical current via small 




This study aims to investigate the short-term effects of a single session of tDCS in 
individuals who suffer from BN. In particular, we are interested in its effects on thought 
processes and emotions relating to food, eating, weight, and body shape. In the long term, 
this may help us to develop improved treatments for BN. 
 
What’s involved? 
If you choose to participate you will be required to attend three sessions at the Institute of 
Psychiatry (Denmark Hill), lasting 1.5-2 hours each. The sessions will involve completing a 
series of questionnaires, a neuropsychological task (brain puzzle), and a food task (you 
will not be asked to eat any food). You will also receive a 20-minute session of tDCS. After 
the third session you will be reimbursed £50 for your time and effort.  
 
Can I take part? 
We are looking for males and females aged between 18 and 70 who have a current 
diagnosis of BN or a related disorder (your eligibility will be confirmed over a 20-minute 
telephone call). Taking part in this study will not influence the timing of any treatment you 
are currently receiving for your eating disorder. 
 
If you are interested in taking part or would like further information please contact 
Maria Kekic (maria.kekic@kcl.ac.uk, 02078480183). Please note that contacting us 
for further information does not mean you are obliged to take part in the study. 
Participation in this research is voluntary and if you decide to take part you may 









Appendix C.3 Recruitment documents for study of temporal discounting in 
healthy individuals 
Appendix C.3.1 Poster 
 
 
Appendix C.2.2 Text for KCL recruitment webpage advertisement 
Exploring the effects of motivational stimuli on response inhibition - advertisement. 
 
Synopsis:  
We are interested in seeing how fasting and food cues affect self control in healthy 
individuals to get an idea of how this may be involved in the atypical behavioural control 
seen in eating disorders. 
 
Advertisement for use in the recruitment of volunteers for study ref: PNM/13/14-147 
approved by the King’s College London (KCL) College Research Ethics Committee (CREC). 
This project contributes to the College's role in conducting research, and teaching research 
methods. You are under no obligation to reply to this email, however if you choose to, 
participation in this research is voluntary and you may withdraw at any time. 
 
Eating disorders (ED) are associated with atypical control over one’s behaviour. However, 
it is not yet clear whether all types of behavioural control is different in EDs compared to 
healthy individuals. Our team are trying to build a comprehensive picture of what types of 
behavioural control is atypical across the ED spectrum. To do this, we first need to pilot 
some new behavioural paradigms in healthy people without eating disorders (or any other 
major psychiatric disorder). In addition, we are interested in seeing how fasting affects 
your self control to get an idea of how this may be involved in the atypical behavioural 
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control seen in ED patients. We are also interested in seeing how food cues affect your 
ability to inhibit your responses, and how this effect differs in the fed and fasted state. 
 
We are looking for volunteers to participate in our study. To take part, you must be a male 
or female over 18 years old with no history of or current psychiatric or neurological 
illness. If you choose to participate, you will be asked to meet with the researcher on two 
separate occasions. Each session will last approximately 1 to 1.5 hours. On both 
sessions, you will be asked to complete a series of questionnaires, followed by several 
computer-based tasks. Your weight and height will be measured, and you will have a small 
blood sample taken by a finger prick. This sample is to monitor your blood glucose. On one 
of the sessions, you will be asked to avoid eating or drinking anything in the morning of 
the study. This will be your ‘fasted’ session. Both sessions will take place in the morning 
before noon, so that in your fasted session you will only be asked to skip breakfast.  
 
Appointments take place at the Institute of Psychiatry at 103 Denmark Hill.We are offering 
£20 as a token of thanks (£10 per session), and up to £5 travel compensation per visit upon 
proof of receipt. 
 
If you are interested in participating, or would like further information, please send an 
email to savani.bartholdy@kcl.ac.uk with your contact details or call 0207 848 0367. 
Full details will be available on the participant information sheet that you will be sent if 
you respond to this email. Please note that contacting us does not mean you have to take 
part in the study. 
 
Thank you for taking the time to read this message. I look forward to hearing from you. 
 
Kind regards, 






APPENDIX D: PARTICIPANT INFORMATION SHEETS 
Appendix D.1 Information sheet for study of tDCS in healthy individuals 
with frequent food cravings 
INFORMATION SHEET FOR PARTICIPANTS 
 
REC Reference Number: PNM/12/13-112 
 
YOU WILL BE GIVEN A COPY OF THIS INFORMATION SHEET 
 
An investigation into the effects of transcranial direct current stimulation 
(tDCS) on food cravings and self-regulation in healthy women 
 
We would like to invite you to participate in this postgraduate research project. You 
should only participate if you want to; choosing not to take part will not disadvantage 
you in any way. Before you decide whether you want to take part, it is important for you 
to understand why the research is being done and what your participation will involve.  
Please take time to read the following information carefully and discuss it with others if 
you wish.  Ask us if there is anything that is not clear or if you would like more 
information. 
 
Aims of the research and possible benefits 
Research shows that the frontal areas of the brain play a role in the control of eating, 
and that variation in activity in these areas might explain why some people get food 
cravings and others do not. The same areas might also be involved in decision making 
processes. Stimulating these areas to alter their functioning is therefore believed to 
have the potential to reduce food cravings and to affect decision making. A technique 
that is capable of stimulating specific brain areas is called transcranial direct current 
stimulation (tDCS). This involves the delivery of low currents via small electrodes 
placed on the scalp. This procedure is widely used in research and is being applied in 
clinical settings. This study, funded by King’s College London, aims to find out whether 
a single session of tDCS has any short-term effects on food cravings and decision 
making in healthy women. In the long term, this may help us to develop strategies to 
help people control their food cravings.  
 
Who can participate? 
You are invited to participate if you are a female aged between 18 and 60 who 
experiences frequent food cravings. We will be recruiting 20 participants in total.  
 
Unfortunately you cannot participate if you: 
- Take anti-convulsive medication 
- Take antipsychotic medication 
- Are on a dose of any psychotropic medication that has not been stable for at least 14 
days prior to participation 
- Are pregnant 
- Smoke more than 10 cigarettes per day 
- Have a current major psychiatric disorder needing treatment 
- Have a food allergy (including to chocolate, biscuits, potato crisps, or nuts, or to any 
of the ingredients these foods contain e.g. milk) 
- Have had a seizure 
- Have someone in your family who has epilepsy  
- Have had a stroke 
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- Have any metal in your head (outside the mouth) 
- Suffer from severe or frequent headaches 
- Have had a serious head injury or any brain-related condition 
- Have any implanted devices (e.g. cardiac pacemakers, medical pumps) 
 
What will happen if you agree to take part? 
You do not have to take part in this experiment; it is your choice. If you decide you want 
to participate you will firstly be asked to engage in a telephone conversation with the 
experimenter (lasting approximately 20 minutes) to confirm that you are eligible to take 
part. If you are, you will be invited to the Institute of Psychiatry on a day that is 
convenient for both you and the researchers, in either the morning or the afternoon. 
You will be asked to return two days later at the same time. Upon arrival to your first 
visit you will be asked to sign a consent form to confirm that you want to participate.  
 
Each visit will take 1.5-2 hours and will involve completing a series of questionnaires 
(assessing mood and eating habits), a neuropsychological task (brain puzzle), and a 
food task for which you will be asked to rate different foods. You will be given the 
opportunity to eat some of these foods if you wish to. You will also receive a 20-minute 
tDCS session, and have saliva samples collected to measure cortisol levels (a stress 
hormone). During the tDCS session you will sit on a comfortable chair and wear a 
plastic headband to keep the electrodes in place. The researcher will turn the machine 
on which will deliver the currents. There is no need for any special preparation before 
the visits.  
 
If you decide to take part you will be free to withdraw from the study at any time without 
giving a reason. You may also withdraw any data or information you have already 
provided up until it is transcribed for use in the final report (30/06/13). 
 
Are there any risks involved? 
There are no risks involved in taking part in this study; however, you may find the 
procedure slightly uncomfortable. This is because a number of sensations can occur 
beneath the electrodes during stimulation including tingling, pain, itching, and burning. 
Not everyone feels these sensations or finds them uncomfortable, but if you do 
remember you are free to stop the study at any point without giving an explanation.  
 
Will you benefit from taking part?  
This study is not intended to help any individual participant, but the information we get 
may help us to develop strategies to help people control their food cravings. Upon 
completion of your second visit you will be reimbursed £30 (plus travel expenses up to 
£5) for your time and effort.  
 
What will happen to the data collected? 
Your personal information and the data we collect from you will remain confidential at 
all times. It will also remain anonymous to everyone apart from the primary 
researchers. You will be offered the opportunity to be informed about your individual 
results once the data for all participants has been collected. If you want written 
feedback of the study’s findings you can contact the researcher (contact details below) 
for a summary. The results will be included in an examined postgraduate report, 
presented as part of a postgraduate presentation, and sent to a medical journal for 
publication. Your participation in the study will not be disclosed.  
 
What to do if you have more questions 
If you have any questions or require more information about this study, please contact 
the researcher using the following contact details:  
 
Maria Kekic (maria.kekic@kcl.ac.uk) 




103 Denmark Hill (1st floor) 
SE5 8AZ 
 
If this study has harmed you in any way you can contact King's College London using 
the following details for further advice and information:  
 
Ulrike Schmidt (ulrike.schmidt@kcl.ac.uk) 
Department of Psychological Medicine 
Eating Disorders 




Appendix D.2 Information sheet for study of tDCS in patients with BN  
PARTICIPANT INFORMATION SHEET 
 
An investigation into the effects of transcranial direct current 
stimulation (tDCS) in bulimia nervosa 
 
Research Ethics Committee reference number: 14/LO/0025 
 
We would like to invite you to participate in this postgraduate research project. You 
should only participate if you want to; choosing not to take part will not disadvantage you 
in any way. Before you decide whether you want to take part, it is important for you to 
understand why the research is being done and what your participation will involve.  
Please take time to read the following information carefully and discuss it with others if 
you wish.  Part 1 tells you the purpose of this study and what will happen to you if you 
take part. Part 2 gives you more detailed information about the conduct of the study.  





What is the purpose of the study? 
Psychological therapies are often ineffective for people with bulimia nervosa (BN); 
therefore there is an ongoing need for the development of new treatments. Research 
shows that the frontal areas of the brain play a role in the development and maintenance 
of eating disorders, including BN. Stimulating these brain areas to alter their 
functioning is therefore believed to have the potential to reduce eating disorder 
symptoms. A technique that is capable of stimulating specific brain areas is called 
transcranial direct current stimulation (tDCS). This involves the delivery of a low electrical 
current via small electrodes placed on the scalp. This procedure is widely used in research 
and is being applied in clinical settings.  
 
This study aims to investigate the short-term effects of a single session of tDCS in 
individuals who suffer from BN. In particular, we are interested in its effects on thought 
processes and emotions relating to food, eating, weight, and body shape. In the long term, 




Why have I been invited? 
You are invited to participate if you are a male or female aged between 18 and 70 who has 
a current diagnosis of bulimia nervosa (BN) or eating disorder not otherwise specified-
bulimia type (EDNOS-BN). We will be recruiting 36 participants in total.  
 
Do I have to take part? 
You do not have to take part in this experiment; it is your choice.  If you decide to take part 
you will be asked to sign a consent form. You will be free to withdraw from the study at 
any time without giving a reason. You may also withdraw any data or information you 
have already provided up until it is analysed for use in the final report. Whether you 
decide to take part or not will in no way influence your care or the timing of your 
treatment.  
 
What will happen to me if I take part and what will I have to do? 
If you decide you want to participate you will firstly be asked to engage in a telephone 
conversation with the experimenter (lasting approximately 20 minutes) to confirm that 
you are eligible to take part. If you are, you will be invited to the Institute of Psychiatry on 
a day that is convenient for both you and the researchers, in either the morning or the 
afternoon. You will be asked to return to the laboratory two more times, leaving a gap of at 
least 48 hours between each session. There is no need for any special preparation before 
the visits.  Upon arrival to your first visit you will be asked to sign a consent form to 
confirm that you want to participate.  
 
Each visit will take 1.5-2 hours and will involve completing a 
series of questionnaires (assessing mood and eating habits), a 
neuropsychological task (brain puzzle), and a food task for 
which you will be asked to rate different foods. You will not 
be required to eat any of these foods. You will also receive a 
20-minute tDCS session, and have your blood pressure and 
pulse measured before and after. During the tDCS session you 
will sit on a comfortable chair and wear a plastic headband to 
keep the two electrodes in place (shown in the diagram on 
the right). The electrodes will be placed in small sponges 
soaked in a salt water solution, so they might feel a bit wet 
against your head. The researcher will turn the machine on which will deliver the 
currents. Two of the tDCS sessions you receive will be real and one will be a placebo (a 
fake session). The placebo session will be the same as the real sessions, but on this 
occasion the tDCS machine won’t deliver any electrical current. Most people can’t tell the 
difference between real and placebo tDCS sessions.  
 
24 hours after each tDCS session the researcher will email you a short questionnaire to 
complete at your earliest convenience. This can be done over the telephone if you prefer.  
 
Expenses and payments 
Upon completion of your third visit you will be reimbursed £50 for your time and effort. 
This payment should be declared for tax and/or benefit purposes. Unfortunately we are 
not able to cover travel expenses except in exceptional circumstances.  
 
What are the possible disadvantages and risks of taking part? What are the side 
effects? 
There are no disadvantages or risks involved in taking part in this study; however, you 
may find the procedure slightly uncomfortable. This is because a number of sensations can 
occur beneath the electrodes during stimulation including tingling, pain, itching, and 
burning. Not everyone feels these sensations or finds them uncomfortable, but if you do 
remember you are free to stop the study at any point without giving an explanation. In 
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some rarer cases tDCS has been known to cause a headache, but this can be treated with 
mild painkillers (e.g. paracetamol). 
 
What are the possible benefits of taking part? 
Unfortunately there are no direct benefits to taking part in this study, but the information 
we get may help us to improve the treatment of BN in the future.  
 
What happens when the research study stops? 
When the research study stops no further tDCS sessions will be available.  
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. Detailed information on this is given in Part 2. 
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled 
in confidence. The details are included in Part 2. 
 
If the information in Part 1 has interested you and you are considering participation, 





What if relevant and new information becomes available? 
Sometimes we get new information about the treatment being studied. This is not 
expected to occur given the very short time frame of participation (3 sessions over 5 
days); however, if any new and relevant information becomes available during this time 
we will inform you immediately. You can then decide whether you wish to continue in the 
study.  
 
What will happen if I don’t want to carry on with the study? 
If you decide to withdraw from the study there will be no adverse consequences. You may 
also withdraw any data or information you have already provided up until it is transcribed 
for use in the final report.  
 
What if there is a problem? 
If you have a concern about any aspect of the study, please ask the researchers 
(maria.kekic@kcl.ac.uk, 0207 848 0183) who will do their best to answer your questions. 
If you remain unhappy and wish to complain formally please contact Dr Gill Dale (director 
of research quality/head of joint South London and Maudsley NHS Foundation Trust and 
Institute of Psychiatry R&D Office) at Institute of Psychiatry P005, 16 De Crespigny Park, 
London, SE5 8AF. Should you wish to speak to someone outside of the university, the 
eating disorders charity Beat provides helplines for adults and young people which offer 
support and information to sufferers, carers and professionals. Further information can be 
found on their website (www.b-eat.co.uk). 
 
Will my taking part in the study be kept confidential? 
Your personal information and the data we collect from you will remain confidential at all 
times. It will also remain anonymous to everyone apart from the primary researchers. 
Manual files will be locked securely in a filing cabinet, which will be kept in a locked office, 
and all electronic files will be password protected. Your personal data will be destroyed 12 
months after the study has ended. 
 
Involvement of the General Practitioner (GP) 
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It is not necessary that we notify your GP of your participation in the study; however, you 
will be asked by the researcher whether you consent to us doing do. If you agree to this, 
you will be asked to provide us with your GP’s contact details so that we can send them a 
letter with details of the research.   
 
Involvement of the insurance company 
If you have private medical insurance you should inform your insurance company that you 
are taking part in this study.  
 
Will any genetic tests be done? 
No.  
 
What will happen to the results of the research study? 
You will be offered the opportunity to be informed about your individual results once the 
data for all participants has been collected. If you want written feedback of the study’s 
findings you can contact the researcher (maria.kekic@kcl.ac.uk) for a lay summary. The 
results will be included in an examined postgraduate report, presented as part of a 
postgraduate presentation, and sent to a medical journal for publication. Your 
participation in the study will not be disclosed. 
 
Who is organising and funding the research? 
This study is being funded by King’s College London.  
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been reviewed and given 
favourable opinion by City Road and Hampstead Ethics Committee. 
 
Further information and contact details 
If you have any questions or require more information about this study, please contact the 
researcher using the following contact details:  
 
Maria Kekic (maria.kekic@kcl.ac.uk) 
Department of Psychological Medicine 
Section of Eating Disorders 
Institute of Psychiatry, P059 
16 De Crespigny Park 
London, SE5 8AF 
 
0207 848 0183 
 
 
Appendix D.3 Information sheet for study of temporal discounting in 
healthy individuals 
PARTICIPANT INFORMATION SHEET 
 
Exploring the effects of motivational stimuli on proactive and 




Research Ethics Committee reference number: PNM/13/14-147 
 
We would like to invite you to take part in this postgraduate research project. You should 
only participate if you want to; choosing not to take part will not disadvantage you in any 
way. Before you decide whether you want to take part, it is important for you to 
understand why the research is being done and what your participation will involve.  
Please take time to read the following information carefully and discuss it with others if 
you wish.  Part 1 tells you the purpose of this study and what will happen to you if you 
take part. Part 2 gives you more detailed information about the conduct of the study.  





What is the purpose of the study? 
There is a growing interest in psychiatry surrounding how humans control their 
behaviour. In particular, a lot of research is being done on two aspects of behavioural 
control: (1) delayed gratification (i.e., choosing between receiving a greater reward later 
compared to a smaller reward sooner), and (2) response inhibition. We are particularly 
interested in behavioural control in relation to eating disorders, as eating disorders are 
typically thought to lie along a continuum of atypical self-regulation. For example, people 
with Anorexia may have excessive behavioural control, whereas people with more 
impulsive eating behaviours such as binge-eating may have poor behavioural control. 
 
While most studies of behavioural control have focused on reactive inhibition (i.e., 
cancelling a response following a “go” stimulus when one sees a latter “stop” cue), there 
has been little research into proactive inhibition (i.e. the process which generally 
suppresses responses until we are certain of the need to response. This proactive 
mechanism may be particularly important in the context of eating disorders, where cues 
predicting food-availability may trigger this process in an attempt to control food intake 
and food-related thoughts. While numerous studies have shown altered reactive inhibition 
in eating disorders, proactive inhibition has not yet been formally tested in this patient 
sample. 
 
We are trying to develop an experiment that can be used to study proactive inhibition in 
eating disorders. Importantly, we first need to explore proactive inhibition in healthy 
people who do not have an eating disorder (or any other major psychiatric disorder).  
 
In addition, we are interested in seeing how starvation affects your self control to get an 
idea of how this may be involved in the atypical behavioural control seen in eating 
disorders. We are also interested in seeing how food cues affect your ability to inhibit your 
responses. Food is a primary reward and generates a motivated emotional state. When 
you are hungry, food-related stimuli become even more motivationally-relevant. We are 
interested in seeing whether (a) motivational stimuli influence your ability to proactively 
or reactively inhibit behavioural responses, and (b) whether your motivational state 
affects the influence of these food-related stimuli. More specifically, we are exploring 
whether your performance is affected by food images when you are hungry (fasted state) 
compared to when you are not hungry (fed state). 
 
Why have I been invited? 
We have invited males and females to take part in this research who: (1) are aged over 18 
years; (2) are of a healthy body weight (Body Mass Index (BMI) (kg/m2): 18.5-24.9); and (3) 




Who must we exclude? 
Unfortunately, we must ask you to not participate if you: (1) have a significant medical 
condition (e.g., a cardiovascular, neurological, or blood disorder); (2) are currently using 
illicit drugs; (3) are currently taking any psychotropic medication (e.g., antidepressants); 
(4) have a visual impairment that cannot be corrected (e.g., by glasses or contact lenses); 
(5) are pregnant, and (6) have insufficient knowledge of the English language, as this may 
compromise your understanding our assessments and questionnaires, which are not 
designed for people who might need extra help understanding what we are asking. Finally, 
(7) if you regularly consume a considerable amount of caffeine (i.e. tea, coffee, caffeinated 
soft-drinks) as you will be asked to refrain from consuming caffeine on the morning of the 
study and heavy consumers may experience some mild withdrawal symptoms. 
 
The taking of drugs or medication may alter your behavioural responses, for example any 
drugs with sedative effects or caffeinated drinks, or medications whose effects may differ 
when you are fed compared to fasted and may interfere with what this study aims to 
measure. Lastly, because we require you not to eat on the morning of one of your visits, we 
ask that you have no serious medical condition and that you are not pregnant or 
breastfeeding for the purpose of your own safety. 
 
Do I have to participate? 
You do not have to take part in this study.  It is up to you to decide whether you wish to 
participate or not. We will describe the study and go through this information sheet, which 
we will then give to you. If you decide to participate, we will then ask you to sign up to three 
copies of a consent form to show that you have agreed to take part: one for you to keep, one 
for us to keep, and one that will be sent to your GP (if you would like your GP to know of 
your involvement in the study). 
 
If you do take part, you must agree that we can decide how to use the data. You are free to 
withdraw at any time, without giving a reason. If you withdraw from the study, you can tell 
us to destroy any information about you. It is of importance for you to know that, your 
treatment and care will not be affected, whether you decide to take part or not. 
 
If you agree to take part you will be asked whether you are happy to be contacted about 
participation in future studies. Your participation in this study will not be affected should 
you choose not to be-recontacted. 
 
If you do decide to take part you will be given this information sheet to keep and be asked 
to sign a consent form.  
 
What will I have to do if I take part? 
You will be asked to meet with the researcher on two separate occasions. Each session will 
last approximately 1 to 1.5 hours. During the first session, the researcher will explain the 
study to you and the instructions, and you will be given the opportunity to ask questions. If 
you are happy to continue, you will be asked to sign two copies of a consent form (one for 
you to keep).  
 
On both sessions, you will be asked to complete a series of questionnaires pertaining to 
mood, personality and eating behaviours, followed by several computer-based tasks. Your 
weight, height and temperature will be measured, and you will have a small blood sample 
taken by a finger prick. This sample is to monitor your blood glucose.  
 
On one of the sessions, you will be asked to avoid eating or drinking anything in the morning 
of the study. This will be your ‘fasted’ session. Both sessions will take place in the morning 
before noon, so that in your fasted session you will only be asked to skip breakfast. 
 
Expenses and payments 
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You will receive £10 in compensation for each assessment day you complete (total £20) 
and can be reimbursed up to £5 for travel. 
 
What is expected from you? 
Apart from avoiding eating food on one visit, the expectations on you are minimal. We will 
ask that you avoid drinking alcohol the previous evening, and that you abstain from coffee 
on the morning of the scan, as caffeine, the active component in coffee, can influence your 
alertness and task performance. The tasks we are exploring are all relatively simple and 
are designed to measure your reaction times in different contexts. 
 
What are the possible disadvantages and risks of participating in this study? 
It is very unlikely that you will experience any discomfort from taking part in this research. 
You may find the finger prick slightly uncomfortable. This is a widely used procedure for 
obtaining blood samples. It takes only a second and we will only take a drop of blood from 
your index finger on your non-dominant hand. There is a small chance that you may find 
answering questions about mental health difficulties to be upsetting. However, you should 
remember that you do not have to answer any questions or give a blood sample if you do 
not want to and can withdraw from the study at any point without giving any explanation. 
 
If you are pregnant you will not be able to participate in this study due to the effects of 
fasting on unborn children. You will be requested to inform the researcher of this 
information. 
 
What are the possible benefits of taking part? 
Taking part in this study will probably not benefit you directly. In the future, though, this 
research will help to develop tests and hypotheses for research in psychiatric and 
neurological disorders. If you want to have written feedback of the study findings, you can 
contact the researcher (contact details below) for a summary.  
 
What if there is a problem? 
Any concern or complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed.  
 
Will my participation be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled 
in confidence. The details are included in Part 2. 
 
If the information in Part 1 has interested you and you are considering participation, 




What if relevant and new information becomes available? 
This is highly unlikely to occur within the time frame of this study however if it does, you 
will be informed immediately.  
 
What will happen if I don’t want to carry on with the study? 
If you withdraw from the study we will ask your permission to use any data collected up to 
the time of your withdrawal. You will be able to withdraw until data collection for this 
study is complete. 
 
Will my participation be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled 
in confidence. The data from this study will be anonymised and coded. These electronic 
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data will be stored on University computers, which are all password protected. Paper data 
will be stored in locked cupboards at the Eating Disorders Unit at the Institute of 
Psychiatry. Only researchers involved in this study and regulatory authorities will have 
access to the data. All information which is collected during the course of the research will 
be kept strictly confidential according to the Data Protection Act 1998. 
 
We will only use your personal information to contact you if you have agreed to be contacted 
for participation in follow-up or future studies. 
 
We will keep information about your identity secure for at least 10 years. Your data will be 
stored and analysed for as long as it can be used in research. Our data storage and analysis 
meets both current ethical guidelines and the conditions listed on the consent form.  
 
What will happen to any samples I give? 
We will collect blood samples on both days to monitor blood glucose levels. The samples 
will provide instant results and will be destroyed immediately after the reading is 
obtained. In the very unlikely event that an unusually high or low value was observed, we 
would inform you and advise you to contact your GP.  
 
Will any genetic tests be done? 
No, genetic tests will not be done. Blood samples are collected for monitoring blood 
glucose levels only. 
 
What will happen to the results of the research study? 
You will be offered the opportunity to be informed about your individual results once the 
data for all participants have been collected. The results of the study will be sent to an 
academic journal for publication, but you will not be identifiable. Your participation in the 
study will, of course, not be disclosed.  
 
Who is organising and funding this research? 
This study is being organised by a team of researchers at the Institute of Psychiatry, King’s 
College London. It is being conducted as part of Ms Savani Bartholdy’s (the principal 
investigator) 3 year postgraduate PhD programme and a dissertation project for a student 
on the MSc Neuroscience course. This project is funded by King’s College London. The 
researchers in the study will not be paid for including you in this study.  
 
Who has reviewed this study? 
This study has been reviewed and approved by the Psychiatry, Nursing and Midwifery 
(PNM) Research Ethics Subcommittee (RESC) at King’s College London. 
 
Further information about the study and contact details: 
General information about this research project can be obtained from Miss Savani 
Bartholdy, Section of Eating Disorders, Institute of Psychiatry, King’s College London (Tel: 
0207 848 0367 or Email: savani.bartholdy@kcl.ac.uk). If you have a concern about any 
aspects of the study, please contact Savani using the above contact details. 
If this study has harmed you in any way or if you wish to make a complaint about the 
conduct of the study you can contact King’s College London using the details below for 
further advice and information: 
 
Dr Owen O’Daly  
Centre for Neuroimaging Sciences,  
Institute of Psychiatry,  
De Crespigny Park,  
London,  
SE5 8AF  
Email: o.o’daly@kcl.ac.uk  
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Tel: 0203228 3057, 
 
General enquiries: 
Savani Bartholdy (savani.bartholdy@kcl.ac.uk) 
Department of Psychological Medicine 
Section of Eating Disorders 
Institute of Psychiatry, P059 
16 De Crespigny Park 
London, SE5 8AF 
 





APPENDIX E: CONSENT FORMS 
Appendix E.1 Consent form for study of tDCS in healthy individuals with 
frequent food cravings 
CONSENT FORM FOR PARTICIPANTS IN RESEARCH STUDIES 
 
Please complete this form after you have read the 
Information Sheet and/or listened to an explanation about 
the research. 
 
Title of Study: An investigation into the effects of transcranial direct current stimulation 
(tDCS) on food cravings and self-regulation in healthy women 
 
King’s College Research Ethics Committee Ref: PNM/12/13-112 
 
Thank you for considering taking part in this research. The person organising 
the research must explain the project to you before you agree to take part.  If 
you have any questions arising from the Information Sheet or explanation 
already given to you, please ask the researcher before you decide whether to 




 I understand that if I decide at any time during the research that I no 
longer wish to participate in this project, I can notify the researchers 
involved and withdraw from it immediately without giving any reason. 
Furthermore, I understand that I will be able to withdraw my data up until it is 
transcribed for use in the final report (30/06/13). 
 
 I consent to the processing of my personal information for the purposes 
explained to me.  I understand that such information will be handled in 
accordance with the terms of the UK Data Protection Act 1998. 
__________________________________________________________ 
 
 I have read and understood the information sheet provided. 
 I agree to be contacted in the future by King’s College London 
researchers who would like to invite me to participate in follow up 
studies to this project, or in future studies of a similar nature. 
 I understand that confidentiality and anonymity will be maintained and it 
will not be possible to identify me in any publications 
 I understand that I must not take part if I have any of the conditions 








agree that the research project named above has been explained to me to my 
satisfaction and I agree to take part in the study. I have read both the notes 
written above and the Information Sheet about the project, and understand what 
the research study involves. 
 




Confirm that I have carefully explained the nature, demands and any foreseeable 
risks (where applicable) of the proposed research to the participant. 
Signed    Date 
 
 
Appendix E.2 Consent form for study of tDCS in patients with BN  
CONSENT FORM FOR PARTICIPANTS IN RESEARCH STUDIES 
 
Please complete this form after you have read the information 
sheet and listened to an explanation about the research. 
 
Title of Study: An investigation into the effects of transcranial 
direct current stimulation (tDCS) in anorexia nervosa and bulimia nervosa 
 
Research Ethics Committee reference number: 14/LO/0025 
 
Thank you for considering taking part in this research. The person organising the 
research must explain the project to you before you agree to take part.  If you 
have any questions arising from the information sheet or explanation already 
given to you, please ask the researcher before you decide whether to join in. You 
will be given a copy of this consent form to keep and refer to at any time. 
________________________________________________________________________________________ 
 
 I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving a reason, without my medical care or 
legal rights being affected.  I understand that I will be able to withdraw my 
data up until it is analysed for use in the final report. 
 
 I consent to the processing of my personal information for the purposes 
explained to me.  I understand that such information will be handled in 
accordance with the terms of the UK Data Protection Act 1998. I understand 
that confidentiality and anonymity will be maintained and it will not be possible 
to identify me in any publications 
 
 I have read and understood the information sheet provided. I have had the 
opportunity to consider the information and ask questions.  
 
 I understand that I must not take part if I have any of the conditions listed in 





 I agree to my GP being informed of my participation in this study 
 






agree that the research project named above has been explained to me to my satisfaction 
and I agree to take part in the study. I have read both the notes written above and the 
Information Sheet about the project, and understand what the research study involves. 
 





Confirm that I have carefully explained the nature, demands and any foreseeable risks 
(where applicable) of the proposed research to the participant. 
 
Signed                                          Date 
 
 
Appendix E.3 Consent form for study of temporal discounting in healthy 
individuals 
CONSENT FORM FOR PARTICIPANTS IN RESEARCH STUDIES 
 
Please complete this form after you have read the information 
sheet and listened to an explanation about the research. 
 
Title of Study: Exploring the effects of motivational stimuli on 
proactive and reactive response inhibition. 
 
Research Ethics Committee reference number: PNM/13/14-147 
 
Thank you for considering taking part in this research. The person organising the 
research must explain the project to you before you agree to take part.  If you 
have any questions arising from the information sheet or explanation already 
given to you, please ask the researcher before you decide whether to join in. You 
will be given a copy of this consent form to keep and refer to at any time. 
________________________________________________________________________________________ 
 
 I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving a reason, without my legal rights 
being affected.  I understand that I will be able to withdraw my data up 
until it is transcribed for use in the final report. 
 
 I have read and understood the information sheet provided. I have had the 





 I understand that my data will be handled in accordance with the terms of 
the UK Data Protection Act 1998. I understand that confidentiality and 
anonymity will be maintained and it will not be possible to identify me in 
any publications. 
 
 I agree that the research team may use my data for future research and 
understand that any such use of identifiable data would be reviewed and 
approved by a research ethics committee.  (In such cases, as with this 
project, data would not be identifiable in any report). 
 
 I understand that I must not take part if I have any of the conditions listed 
in the exclusion criteria. 
 
 I agree that the investigators will take a sample of my blood. I understand 
that these samples will be used to assess glucose level. I understand that I 
may not receive any information about my individual results.  
 
 I know that if I would like to, I can contact the research team and request a 
written summary of findings of the study. 
 
 I consent/do not consent to be contacted in the future by King’s College 
London researchers who would like to invite me to participate in follow up 
studies to this project, or in future studies of a similar nature. 
 






I _____________________________________________________________________ agree that the research 
project named above has been explained to me to my satisfaction and I agree to take part 
in the study. I have read both the notes written above and the Information Sheet about the 
project, and understand what the research study involves. 
 




I ______________________________________________________________________ confirm that I have carefully 
explained the nature, demands and any foreseeable risks (where applicable) of the proposed 
research to the participant. 
 




P059, Section of Eating Disorders,  
Institute of Psychiatry,  
De Crespigny Park,  
London, SE5 8AF,  
 




APPENDIX F: SCREENING MEASURES 
Appendix F.1 Inclusion/exclusion criteria for study of tDCS in healthy 
individuals with frequent food cravings 
 
Do you have frequent food cravings?  
 
 
                  Yes                         No 
 
 












Have you been diagnosed with an eating 




                  Yes                         No 
 
Have you been diagnosed with another 
psychiatric disorder (e.g. depression, 
anxiety, schizophrenia, panic disorder)? If 
yes, which one and when? 
 
 





Have you had any significant health 
problems in the past 6 months (e.g. 
diabetes, asthma, chronic pain, heart 
problems)? If yes, provide more details 
 
 
                  Yes                         No  
 
Have you had any blood tests in the past 
month?  
 
If yes, were there any abnormal results? 
 
 
                  Yes                         No  
 
 
                  Yes                         No  
 
 
Do you have any food allergies? 
 
If yes, provide details 
 
 
                  Yes                         No  
 
 




                  Yes                         No  
 
 
Do you drink alcohol? 
 
 
If yes, how much? 
 
 
                  Yes                         No  
 
 




Do you take drugs? 
 





Do you have a current GP? 
 
If yes, are you happy for us to contact 
them in an emergency? 
 
If yes, provide name of GP and GP 
practice  
 
                  Yes                         No  
 
 
                  Yes                         No  
 
 
Are you pregnant? 
 
 
                  Yes                         No  
 
 
Do you take the contraceptive pill?  
 
If yes, which one? 
 
 
                  Yes                         No  
 
 

















Appendix F.2 Inclusion/exclusion criteria for study of tDCS in patients 
with BN 
 















Have you been diagnosed with another 
psychiatric disorder (e.g. depression, anxiety, 
schizophrenia, panic disorder)? If yes, which 




          Yes                         No 
 
 
Have you had any significant health problems 
in the past 6 months (e.g. diabetes, asthma, 









Have you had any blood tests in the past 
month?  
 
If yes, were there any abnormal results? 
 
          Yes                         No  
 
           
          Yes                         No  
 
 




          Yes                         No  
 
 
Do you drink alcohol? 
 
 
If yes, how much? 
 
 
          Yes                         No  
 
 
 _____ days per week       
 _____ drinks per day 
 
 
Do you take drugs? 
 
 
          Yes                         No  
 
 
Do you have a current GP? 
 
If yes, are you happy for us to contact them? 
 
If yes, provide name of GP and GP practice  
 
          Yes                         No  
 
 





Are you pregnant? 
 
 
          Yes                         No  
 
 
Do you take the contraceptive pill?  
 
 
          Yes                         No  
 
 


















Appendix F.3 Inclusion/exclusion criteria for study of temporal 
discounting in healthy individuals 









….. if YES please provide more details? (eg diabetes, asthma, 
chronic pain, cardiovascular/heart problems?) 
 
3. Have you ever had any neurological disease (eg stroke), 
brain or eye injury or any brain surgery? 





4. Do you experience regular headaches, migraines, dizzy 
or fainting spells, double or blurred vision, numbness or 
tingling, or problems with balance?  





5. Have you had blood tests done in the past month? 





6. Do you smoke more than 5 cigarettes/day? 
 
YES NO 
7. How much caffeine do you drink?  
….. if YES what type? (eg. coffee, tea, coke) 
 
 
……..days/wk      
……..drinks/day 
7. How much alcohol do you drink?  




How many units do you drink per week? (NB. 1 unit = 25ml 
spirits or half a pint of beer, 1.5units = 125ml wine) 











9. Are you currently taking any medication? 














13. Are you pregnant? 
YES NO 
14. Are you currently on a diet?  










Meal Never Rarely Some 
days 
Most days Everyday 
Breakfast      
Describe:  
Mid morning snack      
Describe:  
Lunch      
Describe:  
Afternoon snack      
Describe:  
Dinner      
Describe:  




Appendix F.4 Structured Clinical Interview for Diagnostic and Statistical 
Manual Disorders (SCID) 
 
1. Was there ever a period in your life when 
you drank too much and: 
a) alcohol caused problems for you 
(probe controlling drinking, work, 
family, friends, financially) or; 
b) someone else objected to your 









If yes to a) or b) circle yes on E.1 
and assess for alcohol problems 
  
 




2. Have you ever regularly or frequently used 
street drugs and: 
a) street drugs caused problems for you 
(probe controlling drug use, work, 
family, friends, financially) or; 
b) someone else objected to you taking 
street drugs or thought they were a 
problem for you? 
 





If yes to a) or b) circle yes on E.10 
and assess for substance abuse 
 
3. In the last 6 months have you been 
particularly nervous or anxious? Do you worry 
a lot about bad things that might happen? 
During the last 6 months would you say that 
you have been worrying more days than not? 
 
 




If yes circle yes on F.31 and assess 
for GAD 
 
4. Have you ever had periods of time when 
you were feeling depressed or down most of 
the day nearly every day? Or periods of time 




        1                  2                  3 
 
 
If yes circle yes on A.1 and assess 
for major depressive episode 
(current then past) 
 
5. Have you ever felt so bad you thought 
about hurting yourself? Or had times when 
you’ve thought about death or even wished 
you were dead? 
 
 
        1                  2                  3 
 
 
Screener only - if yes assess risk to 
self/others 
 
6. Have you ever had a panic attack when 
you suddenly felt frightened or anxious, or 




        1                  2                  3 
 
 
If yes circle yes on F.1 and assess 
for panic disorder 
 
7. Were you ever afraid of going out of the 
house alone, being in crowds, standing in a 
line, or travelling on buses or trains? 
 
 
        1                  2                  3 
 
If yes circle yes on F.7 and assess 
for agoraphobia 
 
8. Is there anything that you have been afraid 
to do or felt uncomfortable doing in front of 
other people like speaking, eating, or writing? 
 
        1                  2                  3 
 
If yes circle yes on F.11 and assess 
for social anxiety 
 
9. Are there any other things that you have 
been especially afraid of like flying, seeing 
blood, injections, heights, closed places, or 
certain kinds of animals or insects? 
 
 
        1                  2                  3 
 
If yes circle yes on F.16 and assess 
for specific phobias 
 
10. Have you ever been bothered by thoughts 
that didn’t make any sense and kept coming 
back to you even when you tried not to have 
 





them? If not sure what is meant – thoughts 
like hurting someone even though you really 
didn’t want to or being contaminated by 
germs or dirt 
 
 
If yes circle yes on F.20 and assess 
for obsession 
 
11. Was there ever anything that you had to 
do over and over again and couldn’t resist 
doing like washing your hands again and 
again, counting up to a certain number, or 
checking something several times to make 
sure that you’d done it right? 
 
 




If yes circle yes on F.21 and assess 
for compulsions 
 
12. Have you ever felt so good or high or 
hyper that other people thought you were not 
your normal self? 
 
 
        1                  2                  3 
 
If yes circle yes on A.18 and assess 
for manic episodes (current then 
past) 
 
13. Sometimes things happen to people that 
are extremely upsetting: things like being in a 
life threatening situation like a major disaster, 
very serious accident or fire; being physically 
assaulted or raped; seeing another person 
killed, dead, or badly hurt; or hearing about 
something horrible that has happened to 
someone you are close to. At any time during 
your life have any of these kinds of things 
happened to you? 
 






Sometimes after experiencing very upsetting 
events like these, people have psychological 
or emotional reactions such as nightmares, 
thoughts they can’t get out of their heads, or 
trying to avoid anything that reminds them of 
the event. Did you ever have any reactions 











2. Yes, but not in the past 12 
months 








        




2. Yes, but not in the past 12 
months 
3. Yes, in the past 12 months  
 
14. Have you ever had a time when you 
weighed much less than other people thought 




        1                  2                  3 
 
 
15. Have you often had times when your 
eating was out of control? 
 
 






16. Some people are very bothered by the 
way that they look. Aside from your weight 
and shape has this ever been a problem for 
you? 
 
              1                  2                  
3 
 
If yes circle yes on G.13 and assess 
for BDD 
 
17. Has it ever seemed like people were 
talking about you or taking special notice of 
you? Or have you ever heard things that other 
people could not hear, or seen things that 
other people could not see? 
 
 





Screener only - if yes assess risk to 
self/others 
 
Appendix F.5 tDCS safety screen 
Have you ever:  
 
Had an adverse reaction to tDCS?       
 
Had a seizure?         
 
Had an electroencephalogram (EEG)?      
 
Had a stroke?         
 
Had a serious head injury (include neurosurgery)?     
 
Had any brain-related condition?      
 
Had any illness that caused brain injury?     
 
 
Do you have any metal in your head (outside the 
mouth) such as shrapnel, surgical clips, or fragments    
from welding or metalwork?    
 
Do you have any implanted devices such as cardiac  
pacemakers, medical pumps, or intracardiac lines?    
  
Do you suffer from frequent or severe headaches?    
 
Are you taking any medications?       
 
If you are a woman of childbearing age, are you sexually  
active, and if so, are you not using a reliable method of 
birth control?         
 
Does anyone in your family have epilepsy?      
 
Do you need further explanation of tDCS and its  






If you answered yes to any of the above, please provide details: 
 
 
Appendix F.6 Eating Disorder Diagnostic Scale (EDDS) 
During the past 3 months... 
 
  Not at all   Slightly   Moderately   Extremely 
1 Have you felt fat? 0 1 2 3 4 5 6 
2 
Have you had a 
definite fear that you 
might gain weight or 
become fat? 
0 1 2 3 4 5 6 
3 
Has your weight 
influenced how you 
think about/judge 
yourself as a person? 
0 1 2 3 4 5 6 
4 
Has your shape 
influenced how you 
think about/judge 
yourself as a person? 
0 1 2 3 4 5 6 
 
5. During the past 6 months have there been times when you felt you have eaten what 
other people would regard as an unusually large amount of food (e.g. a tub of ice 
cream) given the circumstances?  
 
YES  NO 
 
6. During the times when you ate an unusually large amount of food, did you 
experience a loss of control (feel you couldn't stop eating or control what or how much 
you were eating)? 
 
YES  NO 
 
7. How many DAYS per week on average over the past 6 MONTHS have you eaten 
an unusually large amount of food and experienced a loss of control? 
 
________ (0 – 7)  
 
8. How many TIMES per week on average over the past 3 MONTHS have you eaten 




During these episodes of overeating and loss of control did you… 
 




10. Eat until you felt uncomfortably full?           YES         NO 
 
11. Eat large amounts of food when you didn't feel physically hungry?   YES         NO 
 
12. Eat alone because you were embarrassed by how much you  
were eating?               YES         NO 
 
13. Feel disgusted with yourself, depressed, or very guilty after  
overeating?               YES         NO 
 
14. Feel very upset about your uncontrollable overeating or resulting  




15. How many times per week on average over the past 3 months have you made 




16. How many times per week on average over the past 3 months have you used 




17. How many times per week on average over the past 3 months have you fasted 





18. How many times per week on average over the past 3 months have you engaged 















21. Over the past 3 months, how many menstrual periods have you missed?  
 
________ (0 – 3) 
 
22. Have you been taking birth control pills during the past 3 months? 
 








APPENDIX G: EXPERIMENTAL MEASURES 
Appendix G.1 Demographic questionnaire for study of tDCS in healthy 



























Highest level of education 
completed (please circle) 
 
 




Marital status (please circle) 
 
 




Ethnicity (please circle) 
 
 






















































£19,999 or less          £20,000 - £39,999       £40,000 - 59,999    
 
£60,000 - £79,999       £80,000 - £99,999     £100,000 or more 
 
 
Highest level of education 
completed (please circle) 
 
 
GCSE    AS Level     A Level   Bach. degree    Masters     PhD 
 
 
Marital status (please circle) 
 
 
Single     Married     Divorced     Engaged     Widowed    Other 
 
 
Ethnicity (please circle) 
 
 
White     Mixed     Asian       Black      Chinese     Arab    Other 
 
 







Right handed                 Left handed 
 
Diet (please circle) 
 
 
Vegetarian         Vegan         Neither 
 
Number of meals/snacks per day 
 
 
Meals__________          Snacks__________ 
 
Do you take any medications? 
 
If yes, which ones and what for? 
 
 
Yes       No  
 
 
Do you have a current GP? 
 
If yes, would you like us to 
inform them of your 
participation in this study? 
 
If yes, provide contact details.  
 
 
Yes       No  
 
 





Do you have a current 
psychological therapist? 
 
If yes, would you like us to 
inform them of your 
participation in this study? 
 
If yes, provide contact details.  
 
 
Yes       No  
 
 






Appendix G.3 Demographic questionnaire for study of temporal 
discounting in healthy individuals 
1. Name……………………………………………….  
          
 
2. Address…………………………………………………………………………………………… 
        
 






5. Age…………….  6. D.O.B……………….   
 
 









12. Marital Status……………………………………… 
 
 
13. No. of children (if any)……………………………. 
 
 
Appendix G.4 Eating Disorder Examination-Questionnaire (EDE-Q) 
The following questions are concerned with the past four weeks (28 days) only. Please 
read each question carefully. Please answer all the questions.  
 
Questions 1 to 12: Please circle the appropriate number on the right. Remember that 
the questions only refer to the past four weeks (28 days) only. 
 
  

















Have you been deliberately 
trying to limit the amount of 
food you eat to influence 
your shape or weight 
(whether or not you have 
succeeded)? 




Have you gone for long 
periods of time (8 waking 
hours or more) without 
eating anything at all in order 
to influence your shape or 
weight? 
0 1 2 3 4 5 6 
3 
Have you tried to exclude 
from your diet any foods that 
you like in order to influence 
your shape or weight 
(whether or not you have 
succeeded)? 
0 1 2 3 4 5 6 
4 
Have you tried to follow 
definite rules regarding your 
eating (for example, a calorie 
limit) in order to influence 
your shape or weight 
(whether or not you have 
succeeded)? 
0 1 2 3 4 5 6 
5 
Have you had a definite 
desire to have an empty 
stomach with the aim of 
influencing your shape or 
weight? 
0 1 2 3 4 5 6 
6 
Have you had a definite 
desire to have a totally flat 
stomach? 
0 1 2 3 4 5 6 
7 
Has thinking about food, 
eating or calories made it 
very difficult to concentrate 
on things you are interested 
in (for example, working, 
following a conversation, or 
reading)? 
0 1 2 3 4 5 6 
8 
Has thinking about shape or 
weight made it very difficult 
to concentrate on things you 
are interested in (for 
example, working, following 
a conversation, or reading)? 
0 1 2 3 4 5 6 
9 Have you had a definite fear 
of losing control over eating? 
0 1 2 3 4 5 6 
10 Have you had a definite fear 
that you might gain weight? 
0 1 2 3 4 5 6 
11 Have you felt fat? 0 1 2 3 4 5 6 
12 Have you had a strong 
desire to lose weight? 
0 1 2 3 4 5 6 
 
Questions 13-18: Please fill in the appropriate number in the boxes on the 
right. Remember that the questions only refer to the past four weeks (28 days). 
 
13 
Over the past 28 days, how many times have you eaten what other people 
would regard as an unusually large amount of food (given the 
circumstances)?   
14 
… On how many of these times did you have a sense of having lost control 





Over the past 28 days, on how many DAYS have such episodes of 
overeating occurred (i.e. you have eaten an unusually large amount of food 
and have had a sense of loss of control at the time)? 
  
16 
Over the past 28 days, how many times have you made yourself sick (vomit) 
as a means of controlling your shape or weight? 
  
17 
Over the past 28 days, how many times have you taken laxatives as a 
means of controlling your shape or weight? 
  
18 
Over the past 28 days, how many times have you exercised in a “driven” or 
“compulsive” way as a means of controlling your weight, shape or amount of 
fat, or to burn off calories? 
  
 
Questions 19 to 21: Please circle the appropriate number. Please note that for 
these questions the term “binge eating” means eating what others would regard 
as an unusually large amount of food for the circumstances, accompanied by a 


















Over the past 28 
days, on how many 
days have you 
eaten in secret (ie, 
furtively)? … Do 
not count episodes 
of binge eating. 






















On what proportion 
of the times that 
you have eaten 
have you felt guilty 
(felt that you’ve 
done wrong) 
because of its 
effect on your 
shape or weight? 
… Do not count 
episodes of binge 
eating. 




  Slightly   Moderately   Markedly 
21 
Over the past 28 
days, how 
concerned have 
you been about 
other people 
seeing you eat? … 
Do not count 
episodes of binge 
eating. 
0 1 2 3 4 5 6 
 
 
Questions 22 to 28: Please circle the appropriate number on the right. 









  Slightly   Moderately   Markedly 
22 
Has your weight 
influenced how 
you think about 
(judge) yourself 
as a person? 
0 1 2 3 4 5 6 
23 
Has your shape 
influenced how 
you think about 
(judge) yourself 
as a person? 
0 1 2 3 4 5 6 
24 
How much 
would it have 
upset you if you 
had been asked 
to weigh 
yourself once a 
week (no more, 
or less, often) 
for the next four 
weeks? 
0 1 2 3 4 5 6 
25 
How dissatisfied 
have you been 
with your 
weight? 
0 1 2 3 4 5 6 
26 
How dissatisfied 
have you been 
with your 
shape? 








your shape in 




taking a bath or 
shower)? 




have you felt 
about others 
seeing your 
shape or figure 




or wearing tight 
clothes)? 






Appendix G.5 Depression Anxiety and Stress Scales (DASS-21) 
DAS S 21                     
Please read each statement and circle a number 0, 1, 2 or 3 which indicates how much the 
statement applied to you over the past week.  There are no right or wrong answers.  Do not 
spend too much time on any statement. 
The rating scale is as follows: 
0  Did not apply to me at all 
1  Applied to me to some degree, or some of the time 
2  Applied to me to a considerable degree, or a good part of time 
3  Applied to me very much, or most of the time 
 
1 I found it hard to wind down 0      1      2      3 
2 I was aware of dryness of my mouth 0      1      2      3 
3 I couldn't seem to experience any positive feeling at all 0      1      2      3 
4 I experienced breathing difficulty (eg, excessively rapid breathing, 
breathlessness in the absence of physical exertion) 
0      1      2      3 
5 I found it difficult to work up the initiative to do things 0      1      2      3 
6 I tended to over-react to situations 0      1      2      3 
7 I experienced trembling (eg, in the hands) 0      1      2      3 
8 I felt that I was using a lot of nervous energy 0      1      2      3 
9 I was worried about situations in which I might panic and make 
a fool of myself 
0      1      2      3 
10 I felt that I had nothing to look forward to 0      1      2      3 
11 I found myself getting agitated 0      1      2      3 
12 I found it difficult to relax 0      1      2      3 
13 I felt down-hearted and blue 0      1      2      3 
14 I was intolerant of anything that kept me from getting on with 
what I was doing 
0      1      2      3 
15 I felt I was close to panic 0      1      2      3 
16 I was unable to become enthusiastic about anything 0      1      2      3 
17 I felt I wasn't worth much as a person 0      1      2      3 
18 I felt that I was rather touchy 0      1      2      3 
19 I was aware of the action of my heart in the absence of physical 
exertion (eg, sense of heart rate increase, heart missing a beat) 
0      1      2      3 
20 I felt scared without any good reason 0      1      2      3 





Appendix G.6 Food Craving Questionnaire-Trait (FCQ-T) 
Below is a list of comments made by people about their eating habits.  In the space to 
the left, please write the number indicating how frequently these comments would be 
true for you in general. Please respond to each item as honestly as possible. 
 
Never or not applicable     Rarely    Sometimes         Often        Usually         Always 
              (1)            (2)          (3)          (4)     (5)              (6) 
 
____  1. Being with someone who is eating often makes me hungry.        
____  2. When I crave something, I know I won't be able to stop eating once I start. 
____  3. If I eat what I am craving, I often lose control and eat too much. 
____  4. I hate it when I give into cravings.  
____  5. Food cravings invariably make me think of ways to get what I want to eat. 
____  6. I feel like I have food on my mind all the time. 
____  7. I often feel guilty for craving certain foods. 
____  8. I find myself preoccupied with food. 
____  9. I eat to feel better.  
____  10. Sometimes, eating makes things seem just perfect. 
____  11. Thinking about my favorite foods makes my mouth water. 
____  12. I crave foods when my stomach is empty. 
____  13. I feel as if my body asks me for certain foods. 
____  14. I get so hungry that my stomach seems like a bottomless pit.  
____  15. Eating what I crave makes me feel better. 
____  16. When I satisfy a craving I feel less depressed. 
____  17. When I eat what I am craving I feel guilty about myself. 
____  18. Whenever I have cravings, I find myself making plans to eat. 
____  19. Eating calms me down. 
____  20. I crave foods when I feel bored, angry, or sad.  
____  21. I feel less anxious after I eat. 
____  22. If I get what I am craving I cannot stop myself from eating it.  
____  23. When I crave certain foods, I usually try to eat them as soon as I can. 
____  24. When I eat what I crave I feel great. 
____  25. I have no will power to resist my food crave. 
____  26. Once I start eating, I have trouble stopping. 
____  27. I can't stop thinking about eating no matter how hard I try.  
____  28. I spend a lot of time thinking about whatever it is I will eat next.  
____  29. If I give in to a food craving, all control is lost. 
____ 30. When I’m stressed out, I crave food. 
____  31. I daydream about food. 
____  32. Whenever I have a food craving, I keep on thinking about eating until I 
actually eat the food.  
____  33. If I am craving something, thoughts of eating it consume me.  
____  34. My emotions often make me want to eat. 
____  35. Whenever I go to a buffet I end up eating more that what I needed. 
____  36. It is hard for me to resist the temptation to eat appetizing foods that are in 
my reach. 
____  37. When I am with someone who is overeating, I usually overeat too.  
____  38. When I eat food, I feel comforted. 





Appendix G.7 Food Craving Questionnaire-State (FCQ-S) 
Below is a list of comments made by people about their eating habits.  In the space to 
the left, please write the number indicating how much you agree with the comment right 
now, at this very moment. Notice that some questions refer to foods in general while 
others refer to one or more specific foods. Please respond to each item as honestly as 
possible. 
 
Strongly disagree   Disagree          Neutral            Agree  Strongly agree 
            (1)        (2)        (3)       (4)            (5) 
  
 
____  1. I have an intense desire to eat [one or more specific foods]. 
____  2. I'm craving [one or more specific foods].  
____  3. I have an urge for [one or more specific foods].                   
____  4. Eating [one or more specific foods] would make things seem just perfect. 
____  5. If I were to eat what I am craving, I am sure my mood would improve.  
____  6. Eating [one or more specific foods] would feel wonderful. 
____  7. If I ate something I wouldn't feel so sluggish and lethargic. 
____  8. Satisfying my craving would make me feel less grouchy and irritable. 
____  9. I would feel more alert if I could satisfy my craving. 
____  10. If I had [one or more specific foods], I could not stop eating it.  
____  11. My desire to eat [one or more specific foods] seems overpowering. 
____  12. I know I'm going to keep on thinking about [one or more specific foods] until I  
actually have it. 
____  13. I am hungry. 
____  14. If I ate right now, my stomach wouldn't feel as empty. 




Appendix G.8 Food Challenge Task (FCT) for study of tDCS in healthy 
individuals with frequent food cravings 
1. Please mark the following lines at the point that most accurately reflects the way that 

















Not appetising at 
all 
Smell: 
Not appetising at 
all 
Taste: 


















2. Please mark the following lines at the point that most accurately reflects the way that 

























3. Please mark the following lines at the point that most accurately reflects the way that 




















Urge to eat: 
Would like to eat 
them very much 
Would not 
like to eat 
them at all 
Appearance: 
Not appetising at 
all 
Smell: 
Not appetising at 
all 
Taste: 
Not tasty at all 
Urge to eat: 
Would like to eat 








like to eat 
them at all 
Appearance: 
Not appetising at 
all 
Smell: 
Not appetising at 
all 
Taste: 
Not tasty at all 
Urge to eat: 
Would like to eat 








like to eat 





4. Please mark the following lines at the point that most accurately reflects the way that 


























5. Please mark the following line at the point that most accurately reflects your current 






6. Looking at the foods in front of you, please mark the following line at the point that 







7. Please mark the following line at the point that most accurately reflects your current 























Extremely low Extremely 
high 
Appearance: 
Not appetising at 
all 
Smell: 
Not appetising at 
all 
Taste: 
Not tasty at all 
Urge to eat: 
Would like to eat 








like to eat 











10. Please mark the following line at the point that most accurately reflects your current 







11. Please mark the following line at the point that most accurately reflects your current 







Appendix G.9 Delaying Gratification Inventory (DGI) 
Please rate the extent to which you agree with each of the following statements, using 
the scale provided. Please circle an answer according to what really reflects your 















I can resist junk 
food when I want 
to. 
1 2 3 4 5 
2 
I am able to 
control my 
physical desires. 
1 2 3 4 5 
3 
I hate having to 
take turns with 
other people. 
1 2 3 4 5 
4 
When I am able 
to, I try to save 
away a little 
money in case an 
emergency should 
arise. 
1 2 3 4 5 
5 
I worked hard in 
school to improve 
myself as a 
person. 
1 2 3 4 5 




No urge to eat 
at all 
Extremely 
strong urge to 
eat 
No urge to 
binge at all 
Extremely 





I would have a 
hard time sticking 
with a special, 
healthy diet. 
1 2 3 4 5 
7 
I like to get to 
know someone 
before having a 
physical 
relationship. 
1 2 3 4 5 
8 
Usually I try to 
consider how my 
actions affect 
others. 
1 2 3 4 5 
9 
It is hard for me to 
resist buying 
things I cannot 
afford. 
1 2 3 4 5 
10 
I have tried to 
work hard in 
school so that I 
could have a 
better future. 
1 2 3 4 5 
11 
If my favourite 
food were in front 
of me, I would 
have a difficult 
time waiting to eat 
it. 
1 2 3 4 5 
12 
My habit of 
focusing on what 
“feels good” has 
cost me in the 
long run. 
1 2 3 4 5 
13 
I think that helping 
each other 
benefits society. 
1 2 3 4 5 
14 
I try to spend my 
money wisely. 
1 2 3 4 5 
15 
In school, I tried to 
take the easy way 
out. 
1 2 3 4 5 
16 
It is easy for me to 
resist candy and 
bowls of snack 
foods. 
1 2 3 4 5 
17 
I have given up 
physical pleasure 
or comfort to 
reach my goals. 
1 2 3 4 5 
18 
I try to consider 
how my actions 
will affect other 
people in the 
long-term. 
1 2 3 4 5 
19 
I cannot be 
trusted with 
money. 
1 2 3 4 5 
20 
I am capable of 
working hard to 
get ahead in life. 




Sometimes I eat 
until I make 
myself sick. 
1 2 3 4 5 
22 
I prefer to explore 




1 2 3 4 5 
23 
I do not consider 
how my behaviour 
affects other 
people. 
1 2 3 4 5 
24 
When someone 
gives me money, I 
prefer to spend it 
right away. 
1 2 3 4 5 
25 




1 2 3 4 5 
26 
I have always 
tried to eat 
healthy because it 
pays off in the 
long run. 
1 2 3 4 5 
27 
When faced with 
a physically 
demanding chore, 
I always tried to 
put off doing it. 
1 2 3 4 5 
28 
I value the needs 
of other people 
around me. 
1 2 3 4 5 
29 
I manage my 
money well. 
1 2 3 4 5 
30 
I have always felt 
like my hard work 
would pay off in 
the end. 
1 2 3 4 5 
31 
Even if I am 
hungry, I can wait 
until it is meal 
time before eating 
something. 
1 2 3 4 5 
32 
I have lied or 
made excuses in 
order to go do 
something more 
pleasurable. 
1 2 3 4 5 
33 
There is no point 
in considering 
how my decisions 
affect other 
people. 
1 2 3 4 5 
34 
I enjoy spending 
money the 
moment I get it. 
1 2 3 4 5 
35 
I would rather 
take the easy 
road in life than 
get ahead. 





Appendix G.10 Profile of Mood States (POMS) 
Please describe how you feel RIGHT NOW, using the scale provided. Please circle an 
answer that reflects how you really feel, rather than how you think you should feel.   
 
  
Feeling Not at all   Moderately   Extremely 
1 Friendly 0 1 2 3 4 
2 Tense 0 1 2 3 4 
3 Angry 0 1 2 3 4 
4 Worn out 0 1 2 3 4 
5 Unhappy 0 1 2 3 4 
6 Clear-headed 0 1 2 3 4 
7 Lively 0 1 2 3 4 
8 Confused 0 1 2 3 4 
9 Sorry for things done 0 1 2 3 4 
10 Shaky 0 1 2 3 4 
11 
Listless (impassive, lack 
of energy) 




0 1 2 3 4 
13 Considerate 0 1 2 3 4 
14 Sad 0 1 2 3 4 
15 Active 0 1 2 3 4 
16 On edge 0 1 2 3 4 
17 Grouchy 0 1 2 3 4 
18 Blue 0 1 2 3 4 
19 Energetic 0 1 2 3 4 
20 Panicky 0 1 2 3 4 
21 Hopeless 0 1 2 3 4 
22 Relaxed 0 1 2 3 4 
23 Unworthy 0 1 2 3 4 
24 Spiteful 0 1 2 3 4 
25 Sympathetic 0 1 2 3 4 
26 Uneasy 0 1 2 3 4 
27 Restless 0 1 2 3 4 
28 Unable to concentrate 0 1 2 3 4 
29 Fatigued 0 1 2 3 4 
373 
 
30 Helpful 0 1 2 3 4 
31 Annoyed 0 1 2 3 4 
32 Discouraged 0 1 2 3 4 
33 Resentful 0 1 2 3 4 
34 Nervous 0 1 2 3 4 
35 Lonely 0 1 2 3 4 
36 Miserable 0 1 2 3 4 
37 Muddled 0 1 2 3 4 
38 Cheerful 0 1 2 3 4 
39 Bitter 0 1 2 3 4 
40 Exhausted 0 1 2 3 4 
41 Anxious 0 1 2 3 4 
42 Ready to fight 0 1 2 3 4 
43 Good-natured 0 1 2 3 4 
44 Gloomy 0 1 2 3 4 
45 Desperate 0 1 2 3 4 
46 Sluggish 0 1 2 3 4 
47 Rebellious 0 1 2 3 4 
48 Helpless 0 1 2 3 4 
49 Weary 0 1 2 3 4 
50 Bewildered 0 1 2 3 4 
51 Alert 0 1 2 3 4 
52 Deceived 0 1 2 3 4 
53 Furious 0 1 2 3 4 
54 Efficient 0 1 2 3 4 
55 Trusting 0 1 2 3 4 
56 
Full of pep (full of 
energy, full of drive) 
0 1 2 3 4 
57 Bad-tempered 0 1 2 3 4 
58 Worthless 0 1 2 3 4 
59 Forgetful 0 1 2 3 4 
60 Carefree 0 1 2 3 4 
61 Terrified 0 1 2 3 4 
62 Guilty 0 1 2 3 4 
63 Vigorous 0 1 2 3 4 




Bushed (tired out, 
exhausted) 
0 1 2 3 4 
 
 
Appendix G.11 Positive and Negative Affect Schedule (PANAS) 
Please describe how you feel RIGHT NOW, using the scale provided. Please 
circle an answer that reflects how you really feel, rather than how you think you 





or not at all 




1 Interested 1 2 3 4 5 
2 Distressed 1 2 3 4 5 
3 Excited 1 2 3 4 5 
4 Upset 1 2 3 4 5 
5 Strong 1 2 3 4 5 
6 Guilty 1 2 3 4 5 
7 Scared 1 2 3 4 5 
8 Hostile 1 2 3 4 5 
9 Enthusiastic 1 2 3 4 5 
10 Proud 1 2 3 4 5 
11 Irritable 1 2 3 4 5 
12 Alert 1 2 3 4 5 
13 Ashamed 1 2 3 4 5 
14 Inspired 1 2 3 4 5 
15 Nervous 1 2 3 4 5 
16 Determined 1 2 3 4 5 
17 Attentive 1 2 3 4 5 
18 Jittery 1 2 3 4 5 
19 Active 1 2 3 4 5 





Appendix G.12 Mize’s Eating Disorder Examination Questionnaire-
Revised (MEDCQ-R) 
This is an inventory of beliefs and attitudes about eating and weight. There are a 
number of statements with which you may tend to agree or disagree. For each 
statement, please circle one of the numbers according to your own reaction to the item.  
 
It is not necessary to think over any item very long. Mark you answer quickly and go on 
to the next statement. 
 
Be sure to mark how you actually feel about the statement, not how you think you 
should feel. 
 
Try to avoid the neutral or “3” response as much as possible. Select this answer only if 

















I feel victorious over 
my hunger when I am 
able to refuse sweets. 
1 2 3 4 5 
2 
No matter how much I 
weigh, fats, sweets, 
breads, and cereals 
are bad food because 
they always turn into 
fat. 
1 2 3 4 5 
3 
No one likes fat 
people; therefore, I 
must remain thin to be 
liked by others. 
1 2 3 4 5 
4 
I am proud of myself 
when I control my urge 
to eat. 
1 2 3 4 5 
5 
When I eat desserts, I 
get fat. Therefore, I 
must never eat 
desserts so I won’t be 
fat. 
1 2 3 4 5 
6 
How much I weigh has 
little to do with how 
popular I am 
1 2 3 4 5 
7 
If I don’t establish a 
daily routine, 
everything will be 
chaotic and I won’t 
accomplish anything. 
1 2 3 4 5 
8 
My friends will like me 
regardless of how 
much I weigh. 




When I am overweight, 
I am not happy with my 
appearance. Gaining 
weight will take away 
the happiness I have 
with myself. 
1 2 3 4 5 
10 
People like you 
because of your 
personality, not 
whether you are 
overweight or not. 
1 2 3 4 5 
11 
When I eat something 
fattening, it doesn’t 
bother me that I have 
temporarily let myself 
eat something I’m not 
supposed to. 
1 2 3 4 5 
12 
If I eat a sweet, it will 
be converted instantly 
into stomach fat. 
1 2 3 4 5 
13 
If my weight goes up, 
my self-esteem goes 
down. 
1 2 3 4 5 
14 
I can’t enjoy anything 
because it will be 
taken away. 
1 2 3 4 5 
15 
It is more important to 
be a good person than 
it is to be thin. 
1 2 3 4 5 
16 
When I see someone 
who is overweight, I 
worry that I will be like 
him/her. 
1 2 3 4 5 
17 
All members of the 
opposite sex want a 
mate who has a 
perfect, thin body. 
1 2 3 4 5 
18 
Having a second 
serving of a high 
calorie food I really like 
doesn’t make me feel 
guilty. 
1 2 3 4 5 
19 
If I can cut out all 
carbohydrates, I will 
never be fat. 
1 2 3 4 5 
20 
When I overeat, it has 
no effect on whether or 
not I feel like a strong 
person. 
1 2 3 4 5 
21 
Members of the 
opposite sex are more 
interested in “who” you 
are rather than 
whether or not you are 
thin. 
1 2 3 4 5 
22 
If I gain one pound, I’ll 
go on and gain a 
hundred pounds, so I 
must keep precise 
control of my weight, 
food, and exercise. 




I rarely criticize myself 
if I have let my weight 
go up a few pounds. 
1 2 3 4 5 
24 
I try to attract members 
of the opposite sex 
through my personality 
rather than by being 
thin. 
1 2 3 4 5 
 
 
Appendix G.13 Tolerability questionnaire 
Please mark the following line at the point that most accurately reflects how much 








Appendix G.14 Acceptability questionnaire 
1. If a therapeutic trial of tDCS were available, would you be happy to take part? A 
therapeutic trial would typically involve 20 sessions of tDCS over 4 weeks. (Please 
circle) 
 
Yes   No 
 
 
2. If no, why would you not be happy to take part? (Please select all that apply). 
 
I found it too painful/uncomfortable □ 
I wouldn’t be able to commit to so many sessions □ 
I don’t think it would be helpful for me □ 
I think it would do more harm than good □ 
















Appendix G.15 Test of blinding 
1. One/two of your tDCS sessions was/were real and one was a placebo. Which 
session do you think was the placebo session? (Please circle) 
 
Session one   Session two   Session three17 
 
 








                                                 







APPENDIX H: OTHER 
Appendix H.1 Berner and Marsh (2014) neurobiological model of BN 
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